{
  "success": true,
  "data": {
    "id": 3524741,
    "url": "https://www.linkedin.com/company/grail-inc.",
    "hash": "1ddddf4c18cde73f716e0dee646d8cb2",
    "name": "GRAIL",
    "website": "http://www.grail.com",
    "size": "1,001-5,000 employees",
    "industry": "Biotechnology Research",
    "description": "Our mission is to detect cancer early, when it can be cured. We are working to change the trajectory of cancer mortality and bring stakeholders together to adopt innovative, safe, and effective technologies that can transform cancer care.\n\nWe are a healthcare company, pioneering new technologies to advance early cancer detection. We have built a multi-disciplinary organization of scientists, engineers, and physicians and we are using the power of next-generation sequencing (NGS), population-scale clinical studies, and state-of-the-art computer science and data science to overcome one of medicine\u2019s greatest challenges.\n\nGRAIL is headquartered in Menlo Park, California, with locations in Washington, D.C., North Carolina, and the United Kingdom. It is supported by leading global investors and pharmaceutical, technology, and healthcare companies. \n\nFor more information, please visit grail.com.\n\nCommunity Guidelines: https://bit.ly/3xigb24",
    "followers": 99497,
    "founded": 2016,
    "headquarters_city": null,
    "headquarters_country": null,
    "headquarters_state": null,
    "headquarters_street1": null,
    "headquarters_street2": null,
    "headquarters_zip": null,
    "logo_url": "https://media.licdn.com/dms/image/v2/C560BAQFnNuw0L2pjBQ/company-logo_200_200/company-logo_200_200/0/1656697463686/grail_inc_logo?e=2147483647&v=beta&t=zrJSGZq71WWcFuhyo9GXnDGlKjeet1vB_a5MSR5-l4A",
    "created": "2016-06-22 21:09:03",
    "last_updated": "2025-10-14 22:38:02",
    "last_response_code": 200,
    "type": "Privately Held",
    "headquarters_new_address": "Menlo Park, CA",
    "employees_count": 1104,
    "headquarters_country_restored": "United States",
    "headquarters_country_parsed": "United States",
    "company_shorthand_name": "grail-inc.",
    "company_shorthand_name_hash": "fa99ce62452b79597b1f1376f7c2f60f",
    "canonical_url": "https://www.linkedin.com/company/grail-inc.",
    "canonical_hash": "1ddddf4c18cde73f716e0dee646d8cb2",
    "canonical_shorthand_name": "grail-inc.",
    "canonical_shorthand_name_hash": "fa99ce62452b79597b1f1376f7c2f60f",
    "deleted": 0,
    "last_updated_ux": 1760481481,
    "source_id": 10399839,
    "company_affiliated_collection": [
      {
        "id": 6614355,
        "company_id": 3524741,
        "affiliated_company_url": "https://www.linkedin.com/showcase/galleritest",
        "affiliated_company_id": 56189030,
        "created": "2022-08-08 22:25:30",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 5508844,
        "company_id": 3524741,
        "affiliated_company_url": "https://www.linkedin.com/showcase/galleritest",
        "affiliated_company_id": 56189030,
        "created": "2021-10-12 12:34:47",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 4626079,
        "company_id": 3524741,
        "affiliated_company_url": "https://www.linkedin.com/showcase/galleritest",
        "affiliated_company_id": null,
        "created": "2021-09-02 17:30:11",
        "last_updated": "2021-10-12 12:34:47",
        "deleted": 1
      },
      {
        "id": 4017215,
        "company_id": 3524741,
        "affiliated_company_url": "https://www.linkedin.com/showcase/galleritest",
        "affiliated_company_id": null,
        "created": "2020-12-06 05:57:37",
        "last_updated": "2021-08-20 11:16:41",
        "deleted": 1
      }
    ],
    "company_also_viewed_collection": [
      {
        "id": 13139577,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/grail-research",
        "viewed_company_id": null,
        "created": "2016-06-22 21:09:03",
        "last_updated": "2019-08-03 22:45:13",
        "deleted": 1
      },
      {
        "id": 13139578,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/illumina",
        "viewed_company_id": null,
        "created": "2016-06-22 21:09:03",
        "last_updated": "2019-08-03 22:45:13",
        "deleted": 1
      },
      {
        "id": 39392914,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/my-helix",
        "viewed_company_id": null,
        "created": "2016-12-09 04:02:54",
        "last_updated": "2019-08-03 22:45:13",
        "deleted": 1
      },
      {
        "id": 39392915,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/guardant-health",
        "viewed_company_id": null,
        "created": "2016-12-09 04:02:54",
        "last_updated": "2019-08-03 22:45:13",
        "deleted": 1
      },
      {
        "id": 141192125,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/freenome",
        "viewed_company_id": null,
        "created": "2018-07-10 23:50:43",
        "last_updated": "2019-08-03 22:45:13",
        "deleted": 1
      },
      {
        "id": 141192127,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/verily-life-sciences",
        "viewed_company_id": null,
        "created": "2018-07-10 23:50:43",
        "last_updated": "2019-08-03 22:45:13",
        "deleted": 1
      },
      {
        "id": 39392916,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/natera",
        "viewed_company_id": null,
        "created": "2016-12-09 04:02:54",
        "last_updated": "2018-07-10 23:50:43",
        "deleted": 1
      },
      {
        "id": 87563956,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/genomic-health",
        "viewed_company_id": null,
        "created": "2017-03-05 20:52:25",
        "last_updated": "2018-07-10 23:50:43",
        "deleted": 1
      },
      {
        "id": 71646696,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/23andme",
        "viewed_company_id": null,
        "created": "2017-01-17 12:13:01",
        "last_updated": "2017-03-05 20:52:25",
        "deleted": 1
      },
      {
        "id": 13139579,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/grail-inc",
        "viewed_company_id": null,
        "created": "2016-06-22 21:09:03",
        "last_updated": "2017-01-17 12:13:02",
        "deleted": 1
      },
      {
        "id": 13139580,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/grail",
        "viewed_company_id": null,
        "created": "2016-06-22 21:09:03",
        "last_updated": "2016-12-09 04:02:54",
        "deleted": 1
      },
      {
        "id": 13139581,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/artthaus",
        "viewed_company_id": null,
        "created": "2016-06-22 21:09:03",
        "last_updated": "2016-12-09 04:02:54",
        "deleted": 1
      },
      {
        "id": 13139582,
        "company_id": 3524741,
        "viewed_company_url": "https://www.linkedin.com/company/ardelyx-inc-",
        "viewed_company_id": null,
        "created": "2016-06-22 21:09:03",
        "last_updated": "2016-12-09 04:02:54",
        "deleted": 1
      }
    ],
    "company_crunchbase_info_collection": [
      {
        "id": 63321,
        "company_id": 3524741,
        "cb_url": "https://www.crunchbase.com/organization/grail",
        "created": "2020-09-17 05:40:57",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 267179,
        "company_id": 3524741,
        "cb_url": "https://www.crunchbase.com/organization/grail",
        "created": "2023-02-06 16:23:18",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      }
    ],
    "company_featured_employees_collection": [
      {
        "id": 11869626,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/per-knudsgaard-27214",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2020-01-26 10:51:16",
        "deleted": 1
      },
      {
        "id": 11869627,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/cos-nicolaou",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 11869628,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/jeffhuber",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2021-08-20 11:16:41",
        "deleted": 1
      },
      {
        "id": 11869629,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/bennettandrew",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2021-07-13 05:57:15",
        "deleted": 1
      },
      {
        "id": 33598891,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/jenniferlturcotte",
        "created": "2020-01-26 10:51:16",
        "last_updated": "2020-07-14 02:39:17",
        "deleted": 1
      },
      {
        "id": 46949940,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/christina-clarke-dur-phd-mph-3831a1",
        "created": "2020-07-14 02:39:17",
        "last_updated": "2021-02-14 06:58:32",
        "deleted": 1
      },
      {
        "id": 60556325,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/arseni",
        "created": "2021-02-14 06:58:32",
        "last_updated": "2021-04-24 08:43:27",
        "deleted": 1
      },
      {
        "id": 64349848,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/evamok",
        "created": "2021-04-24 08:43:27",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 68580674,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/christina-clarke-dur-phd-mph-3831a1",
        "created": "2021-07-13 05:57:15",
        "last_updated": "2022-02-09 19:30:28",
        "deleted": 1
      },
      {
        "id": 71315058,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/candacebain",
        "created": "2021-08-20 11:16:41",
        "last_updated": "2021-09-02 17:30:11",
        "deleted": 1
      },
      {
        "id": 72256316,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/resultsfocussed",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 85519193,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/gailhouston",
        "created": "2022-02-09 19:30:28",
        "last_updated": "2022-06-27 08:40:35",
        "deleted": 1
      },
      {
        "id": 92714209,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/sam-an-66a15",
        "created": "2022-06-27 08:40:35",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 108172758,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/sam-an-66a15",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 108172759,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/cos-nicolaou",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 108172760,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/resultsfocussed",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 108172761,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/evamok",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 204474182,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/gailhouston",
        "created": "2024-04-11 03:33:53",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 212959203,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/christina-clarke-dur-phd-mph-3831a1",
        "created": "2024-09-19 14:58:02",
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 214029845,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/resultsfocussed",
        "created": "2024-10-15 14:46:42",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 224890744,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/in/christina-clarke-dur-phd-mph-3831a1",
        "created": "2025-05-06 15:25:51",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      }
    ],
    "company_featured_investors_collection": [],
    "company_funding_rounds_collection": [
      {
        "id": 97967,
        "last_round_investors_count": 0,
        "total_rounds_count": 4,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2020-09-17 05:40:57",
        "last_updated": "2020-10-27 22:01:08",
        "deleted": 1
      },
      {
        "id": 216792,
        "last_round_investors_count": 0,
        "total_rounds_count": 4,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2020-10-27 22:01:08",
        "last_updated": "2020-11-01 22:46:24",
        "deleted": 1
      },
      {
        "id": 245358,
        "last_round_investors_count": 0,
        "total_rounds_count": 4,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2020-11-01 22:46:24",
        "last_updated": "2020-12-06 05:57:37",
        "deleted": 1
      },
      {
        "id": 348512,
        "last_round_investors_count": 0,
        "total_rounds_count": 4,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2020-12-06 05:57:37",
        "last_updated": "2020-12-16 10:00:26",
        "deleted": 1
      },
      {
        "id": 397555,
        "last_round_investors_count": 0,
        "total_rounds_count": 4,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2020-12-16 10:00:26",
        "last_updated": "2021-01-11 13:56:01",
        "deleted": 1
      },
      {
        "id": 498321,
        "last_round_investors_count": 0,
        "total_rounds_count": 4,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-01-11 13:56:01",
        "last_updated": "2021-01-12 20:19:37",
        "deleted": 1
      },
      {
        "id": 511508,
        "last_round_investors_count": 0,
        "total_rounds_count": 4,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-01-12 20:19:37",
        "last_updated": "2021-02-14 06:58:32",
        "deleted": 1
      },
      {
        "id": 599448,
        "last_round_investors_count": 0,
        "total_rounds_count": 4,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-02-14 06:58:32",
        "last_updated": "2021-03-03 15:08:49",
        "deleted": 1
      },
      {
        "id": 649692,
        "last_round_investors_count": 0,
        "total_rounds_count": 4,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-03-03 15:08:49",
        "last_updated": "2021-04-24 08:43:27",
        "deleted": 1
      },
      {
        "id": 832957,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-04-24 08:43:27",
        "last_updated": "2021-05-11 04:15:59",
        "deleted": 1
      },
      {
        "id": 902200,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-05-11 04:15:59",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 1027008,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series unknown",
        "last_round_date": "2021-01-13 00:00:00",
        "last_round_money_raised": null,
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-unknown--3e5ae90e",
        "created": "2021-06-21 17:28:51",
        "last_updated": "2021-07-13 05:57:15",
        "deleted": 1
      },
      {
        "id": 1086676,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-07-13 05:57:15",
        "last_updated": "2021-07-15 14:57:58",
        "deleted": 1
      },
      {
        "id": 1109707,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-07-15 14:57:58",
        "last_updated": "2021-08-11 11:18:23",
        "deleted": 1
      },
      {
        "id": 1241827,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-08-11 11:18:23",
        "last_updated": "2021-08-20 11:16:41",
        "deleted": 1
      },
      {
        "id": 1292515,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-08-20 11:16:41",
        "last_updated": "2021-08-26 21:15:59",
        "deleted": 1
      },
      {
        "id": 1322133,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-08-26 21:15:59",
        "last_updated": "2021-09-02 17:30:11",
        "deleted": 1
      },
      {
        "id": 1359962,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2021-09-09 00:46:32",
        "deleted": 1
      },
      {
        "id": 1403601,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-09-09 00:46:32",
        "last_updated": "2021-09-15 05:51:46",
        "deleted": 1
      },
      {
        "id": 1461718,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-09-15 05:51:46",
        "last_updated": "2021-10-12 12:34:47",
        "deleted": 1
      },
      {
        "id": 1593441,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-10-12 12:34:47",
        "last_updated": "2021-10-12 17:16:21",
        "deleted": 1
      },
      {
        "id": 1598826,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-10-12 17:16:21",
        "last_updated": "2021-11-20 22:51:20",
        "deleted": 1
      },
      {
        "id": 1782317,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-11-20 22:51:20",
        "last_updated": "2021-11-22 15:23:49",
        "deleted": 1
      },
      {
        "id": 1802109,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-11-22 15:23:49",
        "last_updated": "2021-11-30 16:58:47",
        "deleted": 1
      },
      {
        "id": 1879400,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-11-30 16:58:47",
        "last_updated": "2021-12-29 05:17:15",
        "deleted": 1
      },
      {
        "id": 1994886,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2021-12-29 05:17:15",
        "last_updated": "2022-01-05 08:46:55",
        "deleted": 1
      },
      {
        "id": 2099219,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-01-05 08:46:55",
        "last_updated": "2022-01-19 15:40:40",
        "deleted": 1
      },
      {
        "id": 2157770,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-01-19 15:40:40",
        "last_updated": "2022-02-09 19:30:28",
        "deleted": 1
      },
      {
        "id": 2234391,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$\n                  390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-02-09 19:30:28",
        "last_updated": "2022-02-10 01:38:40",
        "deleted": 1
      },
      {
        "id": 2247378,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$\n                  390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-02-10 01:38:40",
        "last_updated": "2022-03-05 22:35:30",
        "deleted": 1
      },
      {
        "id": 2400847,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$\n                  390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-03-05 22:35:30",
        "last_updated": "2022-03-08 12:10:16",
        "deleted": 1
      },
      {
        "id": 2419755,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$\n                  390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-03-08 12:10:16",
        "last_updated": "2022-04-03 03:22:00",
        "deleted": 1
      },
      {
        "id": 2539722,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$\n                  390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-04-03 03:22:00",
        "last_updated": "2022-04-08 12:01:11",
        "deleted": 1
      },
      {
        "id": 2604983,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$\n                  390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-04-08 12:01:11",
        "last_updated": "2022-05-09 19:02:12",
        "deleted": 1
      },
      {
        "id": 2704186,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$\n                  390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-05-09 19:02:12",
        "last_updated": "2022-05-19 03:58:27",
        "deleted": 1
      },
      {
        "id": 2810601,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$\n                  390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-05-19 03:58:27",
        "last_updated": "2022-06-27 08:40:35",
        "deleted": 1
      },
      {
        "id": 2932912,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-05-06 00:00:00",
        "last_round_money_raised": "US$\n                  390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-06-27 08:40:35",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 3048188,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2022-08-08 22:25:30",
        "deleted": 1
      },
      {
        "id": 3172890,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-08-08 22:25:30",
        "last_updated": "2022-08-09 17:08:47",
        "deleted": 1
      },
      {
        "id": 3187308,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-08-09 17:08:47",
        "last_updated": "2022-09-17 21:43:58",
        "deleted": 1
      },
      {
        "id": 3352550,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-09-17 21:43:58",
        "last_updated": "2022-10-21 09:16:46",
        "deleted": 1
      },
      {
        "id": 3513462,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-10-21 09:16:46",
        "last_updated": "2022-11-20 12:09:53",
        "deleted": 1
      },
      {
        "id": 3608367,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-11-20 12:09:53",
        "last_updated": "2022-12-25 03:00:05",
        "deleted": 1
      },
      {
        "id": 3790029,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2022-12-25 03:00:05",
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 3898518,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-01-16 16:24:39",
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 3961434,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-01-24 12:15:21",
        "last_updated": "2023-01-24 12:15:23",
        "deleted": 1
      },
      {
        "id": 3961436,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-01-24 12:15:23",
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 3988705,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-02-06 16:23:18",
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 4053979,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-02-12 09:18:52",
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 4159387,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-03-02 14:01:45",
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 4327759,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-04-09 07:08:22",
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 4443746,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-04-26 11:37:25",
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 4561644,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-05-11 23:23:03",
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 4912047,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-06-20 19:18:55",
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 5144200,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-07-23 09:55:31",
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 5255262,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-08-06 01:57:33",
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 5442137,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-09-03 08:21:09",
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 5699928,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-10-16 07:32:24",
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 5798954,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-11-01 12:36:31",
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 6029074,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2023-12-05 20:02:25",
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 6352408,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-01-25 13:49:30",
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 6535509,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-02-28 08:50:44",
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 6702094,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-03-22 00:56:06",
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 6822057,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-04-11 03:33:53",
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 6992988,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-05-12 21:22:22",
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 7312036,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-06-21 16:01:37",
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 7517773,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-07-25 13:38:22",
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 7636339,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-08-15 03:57:19",
        "last_updated": "2024-08-28 09:30:31",
        "deleted": 1
      },
      {
        "id": 7830644,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-08-28 09:30:31",
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 8123668,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-09-15 14:35:32",
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 8152615,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-09-19 14:58:02",
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 8393520,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-10-15 14:46:42",
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 8727170,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-11-17 19:19:56",
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 8860094,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-11-27 11:27:08",
        "last_updated": "2024-11-27 12:15:54",
        "deleted": 1
      },
      {
        "id": 8863657,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-11-27 12:15:54",
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 9071552,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2024-12-07 03:07:12",
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 9375092,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-01-16 01:00:37",
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 9547890,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-02-03 14:04:34",
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 9805928,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-02-25 14:19:32",
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 9912148,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-03-12 01:09:23",
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 10117818,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-04-13 03:45:33",
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 10314123,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-05-06 15:25:51",
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 10536886,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-06-04 10:36:15",
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 10722593,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-07-04 10:30:43",
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 10944359,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-07-17 06:31:25",
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 11200292,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-08-03 19:36:27",
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 11352616,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-08-08 22:57:13",
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 11683837,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-08-25 06:33:58",
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 11877926,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-09-04 16:57:20",
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 12064100,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-10-04 03:51:04",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 12298465,
        "last_round_investors_count": 0,
        "total_rounds_count": 5,
        "last_round_type": "Series D",
        "last_round_date": "2020-06-06 00:00:00",
        "last_round_money_raised": "US$ 390.0M",
        "cb_url": "https://www.crunchbase.com/funding_round/grail-series-d--d1043fdf",
        "created": "2025-10-14 22:38:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      }
    ],
    "company_locations_collection": [
      {
        "id": 4797153,
        "company_id": 3524741,
        "location_address": "1525 O'Brien Drive; Menlo Park, CA 94025, US",
        "is_primary": 1,
        "created": "2019-10-20 10:52:51",
        "last_updated": "2021-08-20 11:16:41",
        "deleted": 1
      },
      {
        "id": 29093476,
        "company_id": 3524741,
        "location_address": "1525 O'Brien Drive; Menlo Park, CA 94025, US",
        "is_primary": 1,
        "created": "2021-08-26 21:15:59",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 84097169,
        "company_id": 3524741,
        "location_address": "1525 O'Brien Drive; Menlo Park, CA 94025, US",
        "is_primary": 1,
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      }
    ],
    "company_similar_collection": [
      {
        "id": 17976583,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/guardant-health",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2020-10-27 22:01:08",
        "deleted": 1
      },
      {
        "id": 17976584,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/freenome",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 17976585,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/illumina",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 17976586,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/my-helix",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2019-12-21 17:53:28",
        "deleted": 1
      },
      {
        "id": 17976587,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/grail-insights",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2020-10-27 22:01:08",
        "deleted": 1
      },
      {
        "id": 17976588,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/verily-life-sciences",
        "created": "2019-10-20 10:52:51",
        "last_updated": "2019-11-25 00:35:58",
        "deleted": 1
      },
      {
        "id": 50033881,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/23andme",
        "created": "2019-11-25 00:35:58",
        "last_updated": "2020-05-21 14:22:11",
        "deleted": 1
      },
      {
        "id": 59215488,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/10xgenomics",
        "created": "2019-12-21 17:53:28",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 75188983,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/verily-life-sciences",
        "created": "2020-01-26 10:51:16",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 75188994,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/invitae",
        "created": "2020-01-26 10:51:16",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 75188998,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/my-helix",
        "created": "2020-01-26 10:51:16",
        "last_updated": "2020-02-05 09:00:42",
        "deleted": 1
      },
      {
        "id": 75189001,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/natera",
        "created": "2020-01-26 10:51:16",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 84609707,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/verge-genomics",
        "created": "2020-02-05 09:00:42",
        "last_updated": "2020-03-19 02:26:09",
        "deleted": 1
      },
      {
        "id": 112804848,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/foundation-medicine",
        "created": "2020-03-19 02:26:09",
        "last_updated": "2020-05-24 19:59:45",
        "deleted": 1
      },
      {
        "id": 154495390,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/tempuslabs",
        "created": "2020-05-21 14:22:11",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 156208819,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/color",
        "created": "2020-05-24 19:59:45",
        "last_updated": "2021-02-14 06:58:32",
        "deleted": 1
      },
      {
        "id": 254138590,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/guardanthealth",
        "created": "2020-10-27 22:01:08",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 254138591,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/twist-bioscience",
        "created": "2020-10-27 22:01:08",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 372314195,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/genentech",
        "created": "2021-02-14 06:58:32",
        "last_updated": "2021-06-21 17:28:51",
        "deleted": 1
      },
      {
        "id": 452415366,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/illumina",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 452415367,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/guardanthealth",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 452415368,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/freenome",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 452415369,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/invitae",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 452415370,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/natera",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 452415371,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/10xgenomics",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 452415372,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/twist-bioscience",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 452415373,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/verily-life-sciences",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-03-05 22:35:30",
        "deleted": 1
      },
      {
        "id": 452415374,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/tempuslabs",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 452415375,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/genentech",
        "created": "2021-09-02 17:30:11",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 581107153,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/verily",
        "created": "2022-03-05 22:35:30",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 678164908,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/illumina",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 678164910,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/guardanthealth",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 678164913,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/invitae",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 678164915,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/natera",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 678164916,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/10xgenomics",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 678164917,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/twist-bioscience",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 678164918,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/freenome",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 678164919,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/tempuslabs",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 678164920,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/verily",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 678164921,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/genentech",
        "created": "2022-07-22 13:54:01",
        "last_updated": "2022-09-17 21:43:58",
        "deleted": 1
      },
      {
        "id": 711304634,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/exact-sciences",
        "created": "2022-09-17 21:43:58",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 768834292,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/myriad-genetics",
        "created": "2023-02-06 16:23:18",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 944343277,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/tempusai",
        "created": "2024-01-25 13:49:30",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1160948056,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/flatiron-health",
        "created": "2025-02-25 14:19:32",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1301105254,
        "company_id": 3524741,
        "url": "https://www.linkedin.com/company/genentech",
        "created": "2025-10-14 22:38:01",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      }
    ],
    "company_specialties_collection": [
      {
        "id": 98932589,
        "company_id": 3524741,
        "specialty": "Cancer Detection",
        "created": "2022-08-08 22:25:30",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 98932590,
        "company_id": 3524741,
        "specialty": "Cancer Biology",
        "created": "2022-08-08 22:25:30",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 98932591,
        "company_id": 3524741,
        "specialty": "Clinical Trials",
        "created": "2022-08-08 22:25:30",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 98932592,
        "company_id": 3524741,
        "specialty": "Computer Science",
        "created": "2022-08-08 22:25:30",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 98932593,
        "company_id": 3524741,
        "specialty": "Machine Learning",
        "created": "2022-08-08 22:25:30",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 98932594,
        "company_id": 3524741,
        "specialty": "Data Science",
        "created": "2022-08-08 22:25:30",
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 21377878,
        "company_id": 3524741,
        "specialty": "Cancer Detection",
        "created": "2018-07-10 23:50:43",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 21377879,
        "company_id": 3524741,
        "specialty": "Cancer Biology",
        "created": "2018-07-10 23:50:43",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 21377880,
        "company_id": 3524741,
        "specialty": "Clinical Trials",
        "created": "2018-07-10 23:50:43",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 21377881,
        "company_id": 3524741,
        "specialty": "Computer Science",
        "created": "2018-07-10 23:50:43",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 21377883,
        "company_id": 3524741,
        "specialty": "Machine Learning",
        "created": "2018-07-10 23:50:43",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      },
      {
        "id": 21377885,
        "company_id": 3524741,
        "specialty": "Data Science",
        "created": "2018-07-10 23:50:43",
        "last_updated": "2022-07-06 03:20:31",
        "deleted": 1
      }
    ],
    "company_stock_info_collection": [],
    "company_updates_collection": [
      {
        "id": 24740985,
        "company_id": 3524741,
        "urn": "urn:li:activity:6996476869529214977",
        "followers": 62465,
        "date": "1mo",
        "description": "We\u2019re honored to have Galleri Test included in TIME\u2019s Best Inventions of 2022 list! #TIMEBestInventions https://lnkd.in/e3UxMt4e",
        "reactions_count": 1639,
        "comments_count": 55,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 24740986,
        "company_id": 3524741,
        "urn": "urn:li:activity:7012148332894560256",
        "followers": 62465,
        "date": "8h",
        "description": "As we approach our annual winter break for GRAIL employees, Bob Ragusa, CEO of GRAIL, reflects on the significant milestones we have achieved in 2022 and what we are looking ahead to next year. As always, we greatly appreciate all those employees who will maintain critical operational functions throughout the holidays. https://bit.ly/3YOvzj5",
        "reactions_count": 104,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 24740987,
        "company_id": 3524741,
        "urn": "urn:li:activity:7010645952302620673",
        "followers": 62465,
        "date": "4d",
        "description": "Check out our new podcast, The Cancer SIGNAL, where members of the cancer community discuss multi-cancer early detection, its science and evolution, and how we are working to transform cancer detection. Subscribe now: https://bit.ly/3Lx4g6t #TheCancerSignal #DetectCancerEarly",
        "reactions_count": 102,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 24740988,
        "company_id": 3524741,
        "urn": "urn:li:activity:7009186601637453824",
        "followers": 62465,
        "date": "1w",
        "description": "We are expanding our collaboration with Point32Health, which will cover the cost of our #MultiCancerEarlyDetection test for eligible members in Maine. \n \nFor Maine residents, who have significantly higher rates of cancer than the national average, we hope this partnership helps facilitate early cancer detection when treatment can be more effective. For more information: https://bit.ly/3Fv174w",
        "reactions_count": 195,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 24740989,
        "company_id": 3524741,
        "urn": "urn:li:activity:7008462565336911873",
        "followers": 62465,
        "date": "1w",
        "description": "Is it time to refresh your resume? Join us this Thursday (12/15) 12pm PT for a free online resume workshop and learn the latest strategies for standing out when applying to new positions. https://bit.ly/3Bw6Wxy",
        "reactions_count": 48,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 24740990,
        "company_id": 3524741,
        "urn": "urn:li:activity:7008089093259579393",
        "followers": 62465,
        "date": "1w",
        "description": "Many thanks to the San Francisco Firefighters Cancer Prevention Foundation for funding, sponsoring and organizing this event to provide eligible active and retired members of the San Francisco Fire Department access to #MultiCancerEarlyDection testing.",
        "reactions_count": 108,
        "comments_count": 1,
        "reshared_post_author": "Galleri Test",
        "reshared_post_author_url": "https://www.linkedin.com/showcase/galleritest",
        "reshared_post_author_headline": null,
        "reshared_post_description": "Cancer is the leading cause of death among firefighters, causing 66% of #firefighter line-of-duty deaths in the U.S. from 2002-2019, according to the International Association of Fire Fighters.\n\nThis week, the San Francisco Firefighters Cancer Prevention Foundation is providing the #GalleriTest to eligible active and retired #firefighters and #EMTs at no cost.\n\nThey often risk their lives to keep us safe, and we are honored to be able to give back by offering our #MultiCancerEarlyDetection test. \n\n\n#CancerScreening #SFFCPF #SFFD",
        "reshared_post_followers": 4850,
        "reshared_post_date": "2w",
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 24740991,
        "company_id": 3524741,
        "urn": "urn:li:activity:7007045656930320385",
        "followers": 62465,
        "date": "2w",
        "description": "White House #CancerMoonshot just highlighted important government actions, and private sector progress, towards the President's goals to reduce the death rate from cancer by at least 50% over the next 25 years and \"end cancer as we know it today.\"\n\nAmong other important steps, the Moonshot highlighted GRAIL's real-world evidence partnership with the VA and the Veterans Health Foundation to provide access to multi-cancer early detection testing to 10k veterans over the next three years.",
        "reactions_count": 298,
        "comments_count": 5,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 24740992,
        "company_id": 3524741,
        "urn": "urn:li:activity:7007008103166529536",
        "followers": 62465,
        "date": "2w",
        "description": "What happens after a blood sample is collected for the Galleri test? A specific series of steps are followed that ultimately lead to either a \u201ccancer signal detected\u201d or \u201cno cancer signal detected\u201d result. For a more in depth understanding of how the Galleri test\u2019s process works, check out our latest podcast episode: https://bit.ly/3UEmype #TheCancerSignal",
        "reactions_count": 209,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 24740993,
        "company_id": 3524741,
        "urn": "urn:li:activity:7006315994717503488",
        "followers": 62465,
        "date": "2w",
        "description": "We\u2019re diving into the process a Galleri test sample goes through from beginning to end on the latest episode of #TheCancerSignal podcast. Rita Shaknovich, Vice President of Medical Affairs and Head of Clinical Laboratories at GRAIL, joins our host, Kim Thiboldeaux, to help our listeners better understand the science behind this new technology and its potential impact on the future of cancer.  https://lnkd.in/eqGVkhfK",
        "reactions_count": 81,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 24740994,
        "company_id": 3524741,
        "urn": "urn:li:activity:7005559800189050881",
        "followers": 62465,
        "date": "2w",
        "description": "Research conducted and recently published by JAMA Oncology has revealed the extent that the COVID-19 pandemic has had on preventative cancer screening behavior. Study results suggest that these decreased rates may lead to delayed diagnoses, which in turn may impact the likelihood of successful treatment once diagnosed. For the full article visit: https://lnkd.in/gwq9u7VA",
        "reactions_count": 115,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-16 16:24:39",
        "deleted": 1
      },
      {
        "id": 48069372,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018971567099379712",
        "followers": 63407,
        "date": "4d",
        "description": "? GRAIL has been named a #2023BuiltInBest workplace! Thank you Built In for this recognition. Check out the full list of honorees here: https://bit.ly/3vTejf1",
        "reactions_count": 144,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 48069373,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018618878419181569",
        "followers": 63407,
        "date": "5d",
        "description": "Valerie\u2019s gallbladder cancer was detected early, before any symptoms appeared, which made her treatment path less of a disruption to her active life. On #TheCancerSignal podcast, Valerie shares her experience pursuing multi-cancer early detection and how it changed her life. \n\nThe Cancer SIGNAL is available on all major podcast platforms.  \n\nApple: https://apple.co/3W0dso3\n\nSpotify: https://spoti.fi/3VK8wUn\n\nAmazon Music: https://amzn.to/3PbZAom\n\nAlso available on our website: https://bit.ly/3XbuJey",
        "reactions_count": 175,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 48069374,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018260626770640896",
        "followers": 63407,
        "date": "6d",
        "description": "Today, we announced the availability of a new research use-only methylation-based solution for biopharma companies. This technology will support cancer research and can be customized for specific use cases including prognosis, minimal residual disease detection, and recurrence monitoring across different cancer types. https://bit.ly/3GtlzmJ",
        "reactions_count": 371,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 48069375,
        "company_id": 3524741,
        "urn": "urn:li:activity:7012148332894560256",
        "followers": 63407,
        "date": "3w",
        "description": "As we approach our annual winter break for GRAIL employees, Bob Ragusa, CEO of GRAIL, reflects on the significant milestones we have achieved in 2022 and what we are looking ahead to next year. As always, we greatly appreciate all those employees who will maintain critical operational functions throughout the holidays. https://bit.ly/3YOvzj5",
        "reactions_count": 256,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 48069376,
        "company_id": 3524741,
        "urn": "urn:li:activity:7010645952302620673",
        "followers": 63407,
        "date": "3w",
        "description": "Check out our new podcast, The Cancer SIGNAL, where members of the cancer community discuss multi-cancer early detection, its science and evolution, and how we are working to transform cancer detection. Subscribe now: https://bit.ly/3Lx4g6t #TheCancerSignal #DetectCancerEarly",
        "reactions_count": 125,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 48069377,
        "company_id": 3524741,
        "urn": "urn:li:activity:7009186601637453824",
        "followers": 63407,
        "date": "1mo",
        "description": "We are expanding our collaboration with Point32Health, which will cover the cost of our #MultiCancerEarlyDetection test for eligible members in Maine. \n \nFor Maine residents, who have significantly higher rates of cancer than the national average, we hope this partnership helps facilitate early cancer detection when treatment can be more effective. For more information: https://bit.ly/3Fv174w",
        "reactions_count": 218,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 48069378,
        "company_id": 3524741,
        "urn": "urn:li:activity:7008462565336911873",
        "followers": 63407,
        "date": "1mo",
        "description": "Is it time to refresh your resume? Join us this Thursday (12/15) 12pm PT for a free online resume workshop and learn the latest strategies for standing out when applying to new positions. https://bit.ly/3Bw6Wxy",
        "reactions_count": 54,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 48069379,
        "company_id": 3524741,
        "urn": "urn:li:activity:7008089093259579393",
        "followers": 63407,
        "date": "1mo",
        "description": "Many thanks to the San Francisco Firefighters Cancer Prevention Foundation for funding, sponsoring and organizing this event to provide eligible active and retired members of the San Francisco Fire Department access to #MultiCancerEarlyDection testing.",
        "reactions_count": 140,
        "comments_count": 1,
        "reshared_post_author": "Galleri Test",
        "reshared_post_author_url": "https://www.linkedin.com/showcase/galleritest",
        "reshared_post_author_headline": null,
        "reshared_post_description": "Cancer is the leading cause of death among firefighters, causing 66% of #firefighter line-of-duty deaths in the U.S. from 2002-2019, according to the International Association of Fire Fighters.\n\nThis week, the San Francisco Firefighters Cancer Prevention Foundation is providing the #GalleriTest to eligible active and retired #firefighters and #EMTs at no cost.\n\nThey often risk their lives to keep us safe, and we are honored to be able to give back by offering our #MultiCancerEarlyDetection test. \n\n\n#CancerScreening #SFFCPF #SFFD",
        "reshared_post_followers": 5006,
        "reshared_post_date": "1mo",
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 48069380,
        "company_id": 3524741,
        "urn": "urn:li:activity:7007045656930320385",
        "followers": 63407,
        "date": "1mo",
        "description": "White House #CancerMoonshot just highlighted important government actions, and private sector progress, towards the President's goals to reduce the death rate from cancer by at least 50% over the next 25 years and \"end cancer as we know it today.\"\n\nAmong other important steps, the Moonshot highlighted GRAIL's real-world evidence partnership with the VA and the Veterans Health Foundation to provide access to multi-cancer early detection testing to 10k veterans over the next three years.",
        "reactions_count": 327,
        "comments_count": 5,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 48069381,
        "company_id": 3524741,
        "urn": "urn:li:activity:7007008103166529536",
        "followers": 63407,
        "date": "1mo",
        "description": "What happens after a blood sample is collected for the Galleri test? A specific series of steps are followed that ultimately lead to either a \u201ccancer signal detected\u201d or \u201cno cancer signal detected\u201d result. For a more in depth understanding of how the Galleri test\u2019s process works, check out our latest podcast episode: https://bit.ly/3UEmype #TheCancerSignal",
        "reactions_count": 219,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-01-24 12:15:21",
        "deleted": 1
      },
      {
        "id": 53860377,
        "company_id": 3524741,
        "urn": "urn:li:activity:7021841931747893248",
        "followers": 63805,
        "date": "4d",
        "description": "Four early adopter health systems are pursuing implementation of multi-cancer early detection, laying out a model for success. Our whitepaper with\u00a0Reuters Events Pharma\u00a0with input from VA Pittsburgh Healthcare,\u00a0Ochsner Cancer Institute,\u00a0Sarah Cannon\u00a0and\u00a0Providence, shares what they\u2019ve learned:\u00a0http://bit.ly/3whaX5H",
        "reactions_count": 197,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 53860378,
        "company_id": 3524741,
        "urn": "urn:li:activity:7021503479479234560",
        "followers": 63805,
        "date": "5d",
        "description": "In the American Cancer Society\u2019s latest report, #ProstateCancer incidence rates increased by 3% per year from 2014 to 2019, after two decades of decline. Earlier cancer detection can lead to improved patient outcomes, driving mortality rates down. GRAIL recommends adherence to age-specific cancer screening guidelines.",
        "reactions_count": 44,
        "comments_count": null,
        "reshared_post_author": "American Cancer Society",
        "reshared_post_author_url": "https://www.linkedin.com/company/american-cancer-society",
        "reshared_post_author_headline": null,
        "reshared_post_description": "In addition to a 33% decline in cancer mortality, the 2023 Cancer Facts & Figures Report shows cervical cancer rates dropped 65% from 2012-19 for women 20-24. But the report also highlights an alarming rise in prostate cancer, after 2 decades of decline. #EveryCancerEveryLife\n\nFull report: https://lnkd.in/gb8piSVm",
        "reshared_post_followers": 226044,
        "reshared_post_date": "1w",
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 53860379,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018971567099379712",
        "followers": 63805,
        "date": "1w",
        "description": "? GRAIL has been named a #2023BuiltInBest workplace! Thank you Built In for this recognition. Check out the full list of honorees here: https://bit.ly/3vTejf1",
        "reactions_count": 171,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 53860380,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018618878419181569",
        "followers": 63805,
        "date": "1w",
        "description": "Valerie\u2019s gallbladder cancer was detected early, before any symptoms appeared, which made her treatment path less of a disruption to her active life. On #TheCancerSignal podcast, Valerie shares her experience pursuing multi-cancer early detection and how it changed her life. \n\nThe Cancer SIGNAL is available on all major podcast platforms.  \n\nApple: https://apple.co/3W0dso3\n\nSpotify: https://spoti.fi/3VK8wUn\n\nAmazon Music: https://amzn.to/3PbZAom\n\nAlso available on our website: https://bit.ly/3XbuJey",
        "reactions_count": 194,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 53860381,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018260626770640896",
        "followers": 63805,
        "date": "2w",
        "description": "Today, we announced the availability of a new research use-only methylation-based solution for biopharma companies. This technology will support cancer research and can be customized for specific use cases including prognosis, minimal residual disease detection, and recurrence monitoring across different cancer types. https://bit.ly/3GtlzmJ",
        "reactions_count": 416,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 53860382,
        "company_id": 3524741,
        "urn": "urn:li:activity:7012148332894560256",
        "followers": 63805,
        "date": "1mo",
        "description": "As we approach our annual winter break for GRAIL employees, Bob Ragusa, CEO of GRAIL, reflects on the significant milestones we have achieved in 2022 and what we are looking ahead to next year. As always, we greatly appreciate all those employees who will maintain critical operational functions throughout the holidays. https://bit.ly/3YOvzj5",
        "reactions_count": 258,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 53860383,
        "company_id": 3524741,
        "urn": "urn:li:activity:7010645952302620673",
        "followers": 63805,
        "date": "1mo",
        "description": "Check out our new podcast, The Cancer SIGNAL, where members of the cancer community discuss multi-cancer early detection, its science and evolution, and how we are working to transform cancer detection. Subscribe now: https://bit.ly/3Lx4g6t #TheCancerSignal #DetectCancerEarly",
        "reactions_count": 126,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 53860384,
        "company_id": 3524741,
        "urn": "urn:li:activity:7009186601637453824",
        "followers": 63805,
        "date": "1mo",
        "description": "We are expanding our collaboration with Point32Health, which will cover the cost of our #MultiCancerEarlyDetection test for eligible members in Maine. \n \nFor Maine residents, who have significantly higher rates of cancer than the national average, we hope this partnership helps facilitate early cancer detection when treatment can be more effective. For more information: https://bit.ly/3Fv174w",
        "reactions_count": 219,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 53860385,
        "company_id": 3524741,
        "urn": "urn:li:activity:7008462565336911873",
        "followers": 63805,
        "date": "1mo",
        "description": "Is it time to refresh your resume? Join us this Thursday (12/15) 12pm PT for a free online resume workshop and learn the latest strategies for standing out when applying to new positions. https://bit.ly/3Bw6Wxy",
        "reactions_count": 55,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 53860386,
        "company_id": 3524741,
        "urn": "urn:li:activity:7008089093259579393",
        "followers": 63805,
        "date": "1mo",
        "description": "Many thanks to the San Francisco Firefighters Cancer Prevention Foundation for funding, sponsoring and organizing this event to provide eligible active and retired members of the San Francisco Fire Department access to #MultiCancerEarlyDection testing.",
        "reactions_count": 140,
        "comments_count": 1,
        "reshared_post_author": "Galleri Test",
        "reshared_post_author_url": "https://www.linkedin.com/showcase/galleritest",
        "reshared_post_author_headline": null,
        "reshared_post_description": "Cancer is the leading cause of death among firefighters, causing 66% of #firefighter line-of-duty deaths in the U.S. from 2002-2019, according to the International Association of Fire Fighters.\n\nThis week, the San Francisco Firefighters Cancer Prevention Foundation is providing the #GalleriTest to eligible active and retired #firefighters and #EMTs at no cost.\n\nThey often risk their lives to keep us safe, and we are honored to be able to give back by offering our #MultiCancerEarlyDetection test. \n\n\n#CancerScreening #SFFCPF #SFFD",
        "reshared_post_followers": 5117,
        "reshared_post_date": "1mo",
        "last_updated": "2023-02-06 16:23:18",
        "deleted": 1
      },
      {
        "id": 56550123,
        "company_id": 3524741,
        "urn": "urn:li:activity:7026554508830760960",
        "followers": 64450,
        "date": "4d",
        "description": "Prioritizing diversity and inclusion is a key element of the culture at GRAIL. To celebrate #BlackHistoryMonth we asked employees what this month means to them. Thank you Phylicia L Woods, Esq. for kicking it off with your reflections on working in the cancer space.",
        "reactions_count": 112,
        "comments_count": 5,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 56550124,
        "company_id": 3524741,
        "urn": "urn:li:activity:7024515694004195328",
        "followers": 64450,
        "date": "1w",
        "description": "This week, Jeffrey Venstrom, M.D. joined #PMWC23 to discuss cancer screening alongside a panel of fellow industry leaders. Many thanks to Priti Hedge of Foundation Medicine for moderating this important conversation.\n\nAt GRAIL, we aim to challenge and evolve the status quo in cancer detection through the development of new technologies using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science.",
        "reactions_count": 153,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 56550125,
        "company_id": 3524741,
        "urn": "urn:li:activity:7021841931747893248",
        "followers": 64450,
        "date": "2w",
        "description": "Four early adopter health systems are pursuing implementation of multi-cancer early detection, laying out a model for success. Our whitepaper with\u00a0Reuters Events Pharma\u00a0with input from VA Pittsburgh Healthcare,\u00a0Ochsner Cancer Institute,\u00a0Sarah Cannon\u00a0and\u00a0Providence, shares what they\u2019ve learned:\u00a0http://bit.ly/3whaX5H",
        "reactions_count": 278,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 56550126,
        "company_id": 3524741,
        "urn": "urn:li:activity:7021503479479234560",
        "followers": 64450,
        "date": "2w",
        "description": "In the American Cancer Society\u2019s latest report, #ProstateCancer incidence rates increased by 3% per year from 2014 to 2019, after two decades of decline. Earlier cancer detection can lead to improved patient outcomes, driving mortality rates down. GRAIL recommends adherence to age-specific cancer screening guidelines.",
        "reactions_count": 61,
        "comments_count": null,
        "reshared_post_author": "American Cancer Society",
        "reshared_post_author_url": "https://www.linkedin.com/company/american-cancer-society",
        "reshared_post_author_headline": null,
        "reshared_post_description": "In addition to a 33% decline in cancer mortality, the 2023 Cancer Facts & Figures Report shows cervical cancer rates dropped 65% from 2012-19 for women 20-24. But the report also highlights an alarming rise in prostate cancer, after 2 decades of decline. #EveryCancerEveryLife\n\nFull report: https://lnkd.in/gb8piSVm",
        "reshared_post_followers": 227909,
        "reshared_post_date": "3w",
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 56550127,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018971567099379712",
        "followers": 64450,
        "date": "3w",
        "description": "? GRAIL has been named a #2023BuiltInBest workplace! Thank you Built In for this recognition. Check out the full list of honorees here: https://bit.ly/3vTejf1",
        "reactions_count": 188,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 56550128,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018618878419181569",
        "followers": 64450,
        "date": "3w",
        "description": "Valerie\u2019s gallbladder cancer was detected early, before any symptoms appeared, which made her treatment path less of a disruption to her active life. On #TheCancerSignal podcast, Valerie shares her experience pursuing multi-cancer early detection and how it changed her life. \n\nThe Cancer SIGNAL is available on all major podcast platforms.  \n\nApple: https://apple.co/3W0dso3\n\nSpotify: https://spoti.fi/3VK8wUn\n\nAmazon Music: https://amzn.to/3PbZAom\n\nAlso available on our website: https://bit.ly/3XbuJey",
        "reactions_count": 245,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 56550129,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018260626770640896",
        "followers": 64450,
        "date": "3w",
        "description": "Today, we announced the availability of a new research use-only methylation-based solution for biopharma companies. This technology will support cancer research and can be customized for specific use cases including prognosis, minimal residual disease detection, and recurrence monitoring across different cancer types. https://bit.ly/3GtlzmJ",
        "reactions_count": 429,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 56550130,
        "company_id": 3524741,
        "urn": "urn:li:activity:7012148332894560256",
        "followers": 64450,
        "date": "1mo",
        "description": "As we approach our annual winter break for GRAIL employees, Bob Ragusa, CEO of GRAIL, reflects on the significant milestones we have achieved in 2022 and what we are looking ahead to next year. As always, we greatly appreciate all those employees who will maintain critical operational functions throughout the holidays. https://bit.ly/3YOvzj5",
        "reactions_count": 259,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 56550131,
        "company_id": 3524741,
        "urn": "urn:li:activity:7010645952302620673",
        "followers": 64450,
        "date": "1mo",
        "description": "Check out our new podcast, The Cancer SIGNAL, where members of the cancer community discuss multi-cancer early detection, its science and evolution, and how we are working to transform cancer detection. Subscribe now: https://bit.ly/3Lx4g6t #TheCancerSignal #DetectCancerEarly",
        "reactions_count": 127,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 56550132,
        "company_id": 3524741,
        "urn": "urn:li:activity:7009186601637453824",
        "followers": 64450,
        "date": "1mo",
        "description": "We are expanding our collaboration with Point32Health, which will cover the cost of our #MultiCancerEarlyDetection test for eligible members in Maine. \n \nFor Maine residents, who have significantly higher rates of cancer than the national average, we hope this partnership helps facilitate early cancer detection when treatment can be more effective. For more information: https://bit.ly/3Fv174w",
        "reactions_count": 220,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-02-12 09:18:52",
        "deleted": 1
      },
      {
        "id": 68737035,
        "company_id": 3524741,
        "urn": "urn:li:activity:7028772961197154304",
        "followers": 64715,
        "date": "4d",
        "description": "During #BlackHistoryMonth, Senior Medical Science Liaison Jason Carey reflects on the past and present inequities facing the Black community and how to address them. Throughout February, our BIPOC employee resource group has put together a variety of events and activities that will provide employees with opportunities to learn, engage in meaningful conversations, and celebrate the impact and legacy of Black history.",
        "reactions_count": 95,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 68737036,
        "company_id": 3524741,
        "urn": "urn:li:activity:7026554508830760960",
        "followers": 64715,
        "date": "1w",
        "description": "Prioritizing diversity and inclusion is a key element of the culture at GRAIL. To celebrate #BlackHistoryMonth we asked employees what this month means to them. Thank you Phylicia L Woods, Esq. for kicking it off with your reflections on working in the cancer space.",
        "reactions_count": 118,
        "comments_count": 5,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 68737037,
        "company_id": 3524741,
        "urn": "urn:li:activity:7024515694004195328",
        "followers": 64715,
        "date": "2w",
        "description": "This week, Jeffrey Venstrom, M.D. joined #PMWC23 to discuss cancer screening alongside a panel of fellow industry leaders. Many thanks to Priti Hedge of Foundation Medicine for moderating this important conversation.\n\nAt GRAIL, we aim to challenge and evolve the status quo in cancer detection through the development of new technologies using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science.",
        "reactions_count": 170,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 68737038,
        "company_id": 3524741,
        "urn": "urn:li:activity:7021841931747893248",
        "followers": 64715,
        "date": "3w",
        "description": "Four early adopter health systems are pursuing implementation of multi-cancer early detection, laying out a model for success. Our whitepaper with\u00a0Reuters Events Pharma\u00a0with input from VA Pittsburgh Healthcare,\u00a0Ochsner Cancer Institute,\u00a0Sarah Cannon\u00a0and\u00a0Providence, shares what they\u2019ve learned:\u00a0http://bit.ly/3whaX5H",
        "reactions_count": 292,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 68737039,
        "company_id": 3524741,
        "urn": "urn:li:activity:7021503479479234560",
        "followers": 64715,
        "date": "3w",
        "description": "In the American Cancer Society\u2019s latest report, #ProstateCancer incidence rates increased by 3% per year from 2014 to 2019, after two decades of decline. Earlier cancer detection can lead to improved patient outcomes, driving mortality rates down. GRAIL recommends adherence to age-specific cancer screening guidelines.",
        "reactions_count": 62,
        "comments_count": null,
        "reshared_post_author": "American Cancer Society",
        "reshared_post_author_url": "https://www.linkedin.com/company/american-cancer-society",
        "reshared_post_author_headline": null,
        "reshared_post_description": "In addition to a 33% decline in cancer mortality, the 2023 Cancer Facts & Figures Report shows cervical cancer rates dropped 65% from 2012-19 for women 20-24. But the report also highlights an alarming rise in prostate cancer, after 2 decades of decline. #EveryCancerEveryLife\n\nFull report: https://lnkd.in/gb8piSVm",
        "reshared_post_followers": 228703,
        "reshared_post_date": "1mo",
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 68737040,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018971567099379712",
        "followers": 64715,
        "date": "1mo",
        "description": "? GRAIL has been named a #2023BuiltInBest workplace! Thank you Built In for this recognition. Check out the full list of honorees here: https://bit.ly/3vTejf1",
        "reactions_count": 194,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 68737041,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018618878419181569",
        "followers": 64715,
        "date": "1mo",
        "description": "Valerie\u2019s gallbladder cancer was detected early, before any symptoms appeared, which made her treatment path less of a disruption to her active life. On #TheCancerSignal podcast, Valerie shares her experience pursuing multi-cancer early detection and how it changed her life. \n\nThe Cancer SIGNAL is available on all major podcast platforms.  \n\nApple: https://apple.co/3W0dso3\n\nSpotify: https://spoti.fi/3VK8wUn\n\nAmazon Music: https://amzn.to/3PbZAom\n\nAlso available on our website: https://bit.ly/3XbuJey",
        "reactions_count": 263,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 68737042,
        "company_id": 3524741,
        "urn": "urn:li:activity:7018260626770640896",
        "followers": 64715,
        "date": "1mo",
        "description": "Today, we announced the availability of a new research use-only methylation-based solution for biopharma companies. This technology will support cancer research and can be customized for specific use cases including prognosis, minimal residual disease detection, and recurrence monitoring across different cancer types. https://bit.ly/3GtlzmJ",
        "reactions_count": 432,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 68737043,
        "company_id": 3524741,
        "urn": "urn:li:activity:7012148332894560256",
        "followers": 64715,
        "date": "1mo",
        "description": "As we approach our annual winter break for GRAIL employees, Bob Ragusa, CEO of GRAIL, reflects on the significant milestones we have achieved in 2022 and what we are looking ahead to next year. As always, we greatly appreciate all those employees who will maintain critical operational functions throughout the holidays. https://bit.ly/3YOvzj5",
        "reactions_count": 259,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 68737044,
        "company_id": 3524741,
        "urn": "urn:li:activity:7010645952302620673",
        "followers": 64715,
        "date": "1mo",
        "description": "Check out our new podcast, The Cancer SIGNAL, where members of the cancer community discuss multi-cancer early detection, its science and evolution, and how we are working to transform cancer detection. Subscribe now: https://bit.ly/3Lx4g6t #TheCancerSignal #DetectCancerEarly",
        "reactions_count": 127,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-03-02 14:01:45",
        "deleted": 1
      },
      {
        "id": 91670715,
        "company_id": 3524741,
        "urn": "urn:li:activity:7036738726625968128",
        "followers": 65517,
        "date": "21h",
        "description": "At yesterday\u2019s media day for the Galleri Classic, our CEO Bob Ragusa shared a powerful reminder of the cause that's bringing us together: detecting cancer early, when it can be cured.\n\nTo learn more about the #GalleriClassic, visit thegallericlassic.com. #MCED",
        "reactions_count": 213,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 91670716,
        "company_id": 3524741,
        "urn": "urn:li:activity:7036350894640091137",
        "followers": 65517,
        "date": "1d",
        "description": "We\u2019re wrapping up #BlackHistoryMonth today with our last employee spotlight. Thanks to all those who shared their reflections on the significance of this month and their perspectives on Black history.",
        "reactions_count": 43,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 91670717,
        "company_id": 3524741,
        "urn": "urn:li:activity:7034963066211442688",
        "followers": 65517,
        "date": "5d",
        "description": "Due to the nature of their work, firefighters are at an increased risk of developing cancer in their lifetime, making early screening a critical tool for this group. \n\nThe Francisco Firefighters Cancer Prevention Foundation, a 501(c)3 charity, provided our multi-cancer early detection test to active and retired firefighters and EMTs of the San Francisco Fire Department at no cost. Over two weeks, more than 1,450 people were screened for a shared cancer signal across more than 50 types of cancer through a single blood draw. \n\nFor more info on the #SFFCPF, visit: www.sffcpf.org\n\nSee Important Safety Information here: https://bit.ly/3QHmPWo\n\n#ExtinguishCancer #FightFFCancer",
        "reactions_count": 222,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 91670718,
        "company_id": 3524741,
        "urn": "urn:li:activity:7034587701559353344",
        "followers": 65517,
        "date": "6d",
        "description": "Today, John Hancock announced expanded access to our multi-cancer early detection test for eligible life insurance customers participating in their Vitality PLUS program. \n\nThe Vitality PLUS program provides resources, including education, support, incentives and rewards, aimed to help customers live healthier lives. The new addition of MCED technology will help customers expand their tools for cancer screening.\n\nLearn how we\u2019re aiming to provide new levels of insight into a cancer diagnosis: https://bit.ly/3IkPb6S",
        "reactions_count": 151,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 91670719,
        "company_id": 3524741,
        "urn": "urn:li:activity:7034267553619169280",
        "followers": 65517,
        "date": "1w",
        "description": "At the inaugural Galleri Classic (March 20-26), we\u2019ll be \"hitting the greens\" with former World No. 1 golfer, 13-time PGA TOUR winner, and TV analyst David Duval and World Golf Hall of Fame member and Ladies Professional Golf Association (LPGA) player Juli Inkster to raise awareness about #MultiCancerEarlyDetection (MCED). Learn how the golfers are inspiring people at an elevated risk of cancer, such as those age 50 or older, to take proactive care of their health: https://lnkd.in/eAxbFN_f",
        "reactions_count": 197,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 91670720,
        "company_id": 3524741,
        "urn": "urn:li:activity:7032470004130283520",
        "followers": 65517,
        "date": "1w",
        "description": "Thanks to organizers and panelists for the discussion this week at #LBxSummit. During the panel moderated by Trevor Page, cross-functional leaders from pharma, academia and industry discussed the value of MRD and liquid biopsy tests, how they are rapidly gaining traction as clinically impactful solutions across the cancer care continuum from prognosis to surveillance and monitoring, and how they can help in driving equity and access. \n\nLearn how partnering with GRAIL can help accelerate your efforts to bring impactful solutions. https://bit.ly/3YUa67o",
        "reactions_count": 60,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 91670721,
        "company_id": 3524741,
        "urn": "urn:li:activity:7032012132057522176",
        "followers": null,
        "date": null,
        "description": null,
        "reactions_count": null,
        "comments_count": null,
        "reshared_post_author": "California Life Sciences (CLS)",
        "reshared_post_author_url": "https://www.linkedin.com/company/califesciences",
        "reshared_post_author_headline": null,
        "reshared_post_description": "We\u2019re thrilled to welcome the newest member of CLS\u2019s board of directors. Please join us in welcoming Megan P. Hall, Vice President of Medical Affairs at GRAIL. Hall leads the Medical Affairs group supporting the development and launch of Galleri, a blood-based multi-cancer early detection test. \n\n\u2b50 https://bit.ly/40Wy1Fd",
        "reshared_post_followers": 9392,
        "reshared_post_date": "2w",
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 91670722,
        "company_id": 3524741,
        "urn": "urn:li:activity:7031723138514108416",
        "followers": 65517,
        "date": "2w",
        "description": "In 2003, scientists successfully sequenced the human genome. Twenty years later, the field of genomics is continuing to advance, unlocking the potential to shift the cancer paradigm with multi-cancer early detection.\n\nOn the latest episode of The Cancer SIGNAL podcast, Amoolya Singh discusses the role of genomics and AI in multi-cancer early detection (MCED) and shares what excites her about the future of cancer screening. \n\nAvailable now on all major podcast platforms:  \nApple: https://apple.co/3W0dso3 \nSpotify: https://spoti.fi/3Kbe9Z8\nAmazon Music: https://amzn.to/3PbZAom \nTranscript available on our website: https://bit.ly/3IsZSWq",
        "reactions_count": 186,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 91670723,
        "company_id": 3524741,
        "urn": "urn:li:activity:7030946785602719744",
        "followers": 65517,
        "date": "2w",
        "description": "At GRAIL, diversity, inclusion, and equity are critical drivers to our success. We embrace talent from all backgrounds, seek out diverse perspectives, facilitate and invite open and authentic conversations by promoting ownership and accountability. #BlackHistoryMonth Rich S.T Gilliam",
        "reactions_count": 87,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 91670724,
        "company_id": 3524741,
        "urn": "urn:li:activity:7028772961197154304",
        "followers": 65517,
        "date": "3w",
        "description": "During #BlackHistoryMonth, Senior Medical Science Liaison Jason Carey reflects on the past and present inequities facing the Black community and how to address them. Throughout February, our BIPOC employee resource group has put together a variety of events and activities that will provide employees with opportunities to learn, engage in meaningful conversations, and celebrate the impact and legacy of Black history.",
        "reactions_count": 110,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-09 07:08:22",
        "deleted": 1
      },
      {
        "id": 125418269,
        "company_id": 3524741,
        "urn": "urn:li:activity:7049832396958957569",
        "followers": 67238,
        "date": "17h",
        "description": "A recent study published in Cancer Epidemiology showed that at earlier stages of cancer, the potential for definitive intervention is higher and more successful. \n\nIn this article, Jeff Venstrom, M.D., Chief Medical Officer at GRAIL, breaks down the impact of these findings and the power of multi-cancer early detection to disrupt the way we think about screening for and treating cancer. https://bit.ly/3zBdpG0",
        "reactions_count": 144,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 125418270,
        "company_id": 3524741,
        "urn": "urn:li:activity:7049409126744907777",
        "followers": 67238,
        "date": "1d",
        "description": "Last week at the WIRED Health conference in London, Sir Harpal Kumar, President, Biopharma Business & Europe at GRAIL, shared an overview of the cancer landscape, the history of GRAIL and the potential impact of multi-cancer early detection. https://bit.ly/40UGacc",
        "reactions_count": 177,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 125418271,
        "company_id": 3524741,
        "urn": "urn:li:activity:7049025371282763776",
        "followers": 67238,
        "date": "2d",
        "description": "We\u2019re expanding our partnership with Providence to offer its eligible patients across seven states access to GRAIL\u2019s #MultiCancerEarlyDetection (MCED) test, as part of a comprehensive range of health services.\n\nLearn more: https://bit.ly/3me4Rlc",
        "reactions_count": 126,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 125418272,
        "company_id": 3524741,
        "urn": "urn:li:activity:7047275748901953537",
        "followers": 67238,
        "date": "1w",
        "description": "This week GRAIL was recognized by Comparably with two 2023 awards - Best Company Outlook and Best HR Teams. Thank you to our employees who continue to rate GRAIL so highly. We are honored to be named on these lists.",
        "reactions_count": 198,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 125418273,
        "company_id": 3524741,
        "urn": "urn:li:activity:7045124457853538305",
        "followers": 67238,
        "date": "1w",
        "description": "The inaugural #GalleriClassic is in full swing at Mission Hills Country Club! Thanks to our ambassadors - PGA TOUR Champions player David Duval and World Golf Hall of Fame member and Ladies Professional Golf Association (LPGA) player Juli Inkster \u2013 for helping us raise awareness of #MultiCancerEarlyDetection. Proceeds from The Galleri Classic will fund local and cancer-related non-profit organizations focused on underserved populations. https://lnkd.in/g784XgvN",
        "reactions_count": 375,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 125418274,
        "company_id": 3524741,
        "urn": "urn:li:activity:7042516505481142272",
        "followers": 67238,
        "date": "2w",
        "description": "This week employees gathered on site in Menlo Park, CA and remotely for a #WomensHistoryMonth panel discussion, organized by our Women at GRAIL employee resource group, featuring rising leaders at GRAIL. Speakers discussed the individuality of finding work life balance, the value in mentorship and the courage to take up space. Thank you to our panelists and all who joined!\n\nClaire O'Connell Neda Ronaghi Amelia Adams Hannah Voelker Sara Balch Tina Amirkiai",
        "reactions_count": 255,
        "comments_count": 6,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 125418275,
        "company_id": 3524741,
        "urn": "urn:li:activity:7041813855693365248",
        "followers": 67238,
        "date": "3w",
        "description": "\"I can\u2019t wait for what this next phase of life holds.\"\n\nDavid Duval, 13-time PGA TOUR winner and Galleri Classic ambassador, shares why he's excited to raise awareness of #MultiCancerEarlyDetection.",
        "reactions_count": 256,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 125418276,
        "company_id": 3524741,
        "urn": "urn:li:activity:7041089375467630592",
        "followers": 67238,
        "date": "3w",
        "description": "Colorectal cancer is the second leading cause of cancer-related deaths in the country. In the latest episode of #TheCancerSignal podcast, advocates Michael Sapienza and Charles R. Rogers, PhD, MPH, MS, MCHES\u00ae of the Colorectal Cancer Alliance discuss the importance of early detection and the work being done to make cancer care more equitable and accessible. #ColorectalCancerAwarenessMonth\n\nListen now on all major podcast platforms:  \nApple: https://apple.co/3W0dso3 \nSpotify: https://spoti.fi/3Kbe9Z8\nGoogle: https://bit.ly/3Fmp9j4 \nAmazon Music: https://amzn.to/3PbZAom \nTranscript available on our website: https://bit.ly/3JcDzDs",
        "reactions_count": 101,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 125418277,
        "company_id": 3524741,
        "urn": "urn:li:activity:7039265280807587840",
        "followers": 67238,
        "date": "4w",
        "description": "Happy birthday GRAIL! Yesterday we celebrated GRAIL's 7th birthday, gathering across our sites and virtually with remote employees. Our CEO, Bob Ragusa, reflected on our history and the extraordinary progress we've made in this short period. A panel of long-time employees shared how the mission continues to drive them every day. Thank you to all our teams whose commitment and passion bring us closer to changing the trajectory of cancer mortality.",
        "reactions_count": 604,
        "comments_count": 11,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 125418278,
        "company_id": 3524741,
        "urn": "urn:li:activity:7037114186211950592",
        "followers": 67238,
        "date": "1mo",
        "description": "Happy Women\u2019s History Month! Thanks to this all-women weekend team from our Menlo Park clinical lab, who recently posed for a picture on International Day of Women and Girls in Science! Women make up 55% of the workforce at GRAIL, each contributing to our critical mission of detecting cancer early, when it can be cured.  \n\nOur \u201cWomen at GRAIL\u201d employee resource group has been busy planning activities to celebrate women throughout March, focusing on career development, leading in STEM and what they\u2019re most proud of. \n\nVy Reichow Marilyn Guaresti Bianca Munoz Alma Barrios Cruz Danielle Asaro",
        "reactions_count": 247,
        "comments_count": 5,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-04-26 11:37:25",
        "deleted": 1
      },
      {
        "id": 152656859,
        "company_id": 3524741,
        "urn": "urn:li:activity:7056298914047504385",
        "followers": 68253,
        "date": "1d",
        "description": "Health disparities in cancer are preventing minority communities from getting the screening and care they need. Dr. Gary Puckrein, President and CEO of National Minority Quality Forum, joins #TheCancerSignal podcast to discuss the organization\u2019s work to quantify health disparities and how to address them. \n\n#NationalMinorityHealthMonth\n\nFind us on all major podcast platforms:  \nApple: https://apple.co/3W0dso3 \nSpotify: https://spoti.fi/3Kbe9Z8\nGoogle: https://bit.ly/3Fmp9j4 \nTranscript and other platform links: https://bit.ly/41PtC6A",
        "reactions_count": 39,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 152656860,
        "company_id": 3524741,
        "urn": "urn:li:activity:7055185960866607104",
        "followers": 68253,
        "date": "4d",
        "description": "Our next monthly newsletter will be in subscribers' inboxes next week - sign up now to stay up to date on all things GRAIL: https://bit.ly/40kF9cT",
        "reactions_count": 16,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 152656861,
        "company_id": 3524741,
        "urn": "urn:li:activity:7054862632054312960",
        "followers": 68253,
        "date": "5d",
        "description": "Health equity can\u2019t be achieved without equal access to cancer screening and other health services. On our podcast The Cancer SIGNAL we recently discussed how multi-cancer early detection can play a role in health equity. \n\nListen and get direct links to your podcast app here: https://bit.ly/3JcDzDs \n\n#NationalMinorityHealthMonth",
        "reactions_count": 54,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 152656862,
        "company_id": 3524741,
        "urn": "urn:li:activity:7054552448283136000",
        "followers": 68253,
        "date": "6d",
        "description": "Our latest study results, presented in a late-breaking poster session at #AACR23, revealed that GRAIL\u2019s methylation technology can detect multiple types of cancer without a tissue sample, offering a versatile option for a range of research uses.\n\nLearn more about how these data impact the clinical utility of our post-diagnosis methylation-based solution: https://bit.ly/41IQbJY",
        "reactions_count": 96,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 152656863,
        "company_id": 3524741,
        "urn": "urn:li:activity:7054083693585289218",
        "followers": 68253,
        "date": "1w",
        "description": "FirstHealth of the Carolinas will be the first health system in North Carolina to offer our MCED test as part of comprehensive screening and care for people with elevated cancer risk. FirstHealth\u2019s new cancer center will support people who receive a \"cancer signal detected\" test result with diagnostic evaluation and treatment if needed.\n\nLearn more about how we\u2019re bringing innovative, high-quality technologies to communities with the aim to transform cancer screening and early detection: https://bit.ly/40yeKZr",
        "reactions_count": 118,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 152656864,
        "company_id": 3524741,
        "urn": "urn:li:activity:7053829986591346689",
        "followers": 68253,
        "date": "1w",
        "description": "In partnership with AstraZeneca, we presented findings during a poster session at #AACR23 that support clinical utility of a methylation-based pan hematologic malignancy classifier based on GRAIL\u2019s platform. \n\nRead more about the results that could show a method to standardize the detection of residual cancer in people who have been treated for various types of blood cancer: https://bit.ly/3UIbjhc",
        "reactions_count": 302,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 152656865,
        "company_id": 3524741,
        "urn": "urn:li:activity:7053385574837063680",
        "followers": 68253,
        "date": "1w",
        "description": "Dr. Earl Hubbell, Distinguished Scientist, Bioinformatics at GRAIL, has been recognized in the Best of AACR Journals for his work evaluating the impact of adding multi-cancer early detection testing to usual cancer care. He and other co-authors found that #MCED testing could substantially reduce overall cancer mortality if added to standard of care. \n\nCheck out the results: https://bit.ly/40czxRK #AACR23",
        "reactions_count": 370,
        "comments_count": 16,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 152656866,
        "company_id": 3524741,
        "urn": "urn:li:activity:7051647184848457728",
        "followers": 68253,
        "date": "2w",
        "description": "We\u2019re working to transform cancer signal detection across all stages of cancer \u2013 and our rigorous clinical development program supports that.\n\nAt #AACR23, we\u2019re presenting a late-breaking poster session and five additional poster sessions showcasing how our targeted methylation technology supports cancer detection in pre-symptomatic to post-diagnosis settings.\n\nFind out more about our presentations: https://bit.ly/3UufCg7",
        "reactions_count": 80,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 152656867,
        "company_id": 3524741,
        "urn": "urn:li:activity:7051218862528155648",
        "followers": 68253,
        "date": "2w",
        "description": "70% of cancer deaths are from cancers without recommended screening, including many uncommon cancer types. Multi-cancer early detection (#MCED) makes it possible to test for many types of cancer at once \u2013 but the status quo is to assess risk for individual cancers rather than for cancer as a whole.\n\nIn the latest episode of #TheCancerSignal podcast, guests Dr. Alpa Patel from the American Cancer Society and GRAIL\u2019s Dr. Christina Clarke Dur, PhD, MPH explain how we measure cancer risk and how our understanding of the disease is changing. \n\nListen now on all major podcast platforms:  \nApple: https://apple.co/3W0dso3 \nSpotify: https://spoti.fi/3Kbe9Z8\nGoogle: https://bit.ly/3Fmp9j4 \nTranscript and other platform links: https://bit.ly/3Ks4Tho",
        "reactions_count": 209,
        "comments_count": 5,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 152656868,
        "company_id": 3524741,
        "urn": "urn:li:activity:7050121334445502464",
        "followers": 68253,
        "date": "2w",
        "description": "Early detection and cancer have been proven to significantly improve survival rates  and reduce the cost and complexity of treatment for cancers with recommended screenings. Learn more about the potential of multi-cancer early detection: https://bit.ly/3ZIaWUJ #WorldHealthDay #MCED",
        "reactions_count": 450,
        "comments_count": 5,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-05-11 23:23:03",
        "deleted": 1
      },
      {
        "id": 174048321,
        "company_id": 3524741,
        "urn": "urn:li:activity:7061372538626404352",
        "followers": 68983,
        "date": "2d",
        "description": "What makes a good multi-cancer early detection test? On our podcast #TheCancerSignal, Amoolya Singh discusses the benefit of identifying the cancer signal of origin.  \n\nListen to the episode: https://bit.ly/414AITV #MCED",
        "reactions_count": 79,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 174048322,
        "company_id": 3524741,
        "urn": "urn:li:activity:7060281760026091520",
        "followers": 68983,
        "date": "5d",
        "description": "Cancer mortality is decreasing, but there\u2019s still much work to be done. Adding multi-cancer early detection (MCED) testing to standard cancer screenings can help detect cancer earlier, often before it\u2019s symptomatic or has spread.\n\nGRAIL President Joshua Ofman MD, MSHS explains more in this article: https://bit.ly/3ND3hVu",
        "reactions_count": 213,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 174048323,
        "company_id": 3524741,
        "urn": "urn:li:activity:7059271612218404864",
        "followers": 68983,
        "date": "1w",
        "description": "GRAIL employees from coast to coast joined Pancreatic Cancer Action Network for #PanCANPurpleStride this past weekend. Together we helped raise money and awareness for pancreatic cancer research and support. Thank you to all who made these walks such a powerful experience.",
        "reactions_count": 156,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 174048324,
        "company_id": 3524741,
        "urn": "urn:li:activity:7057019268697092096",
        "followers": 68983,
        "date": "2w",
        "description": "Cancer treatment is more likely to be successful when cancer is diagnosed earlier. #MultiCancerEarlyDetection tests look for cancer signals in the blood to help make this possible. #DetectCancerEarly",
        "reactions_count": 389,
        "comments_count": 9,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 174048325,
        "company_id": 3524741,
        "urn": "urn:li:activity:7056298914047504385",
        "followers": 68983,
        "date": "2w",
        "description": "Health disparities in cancer are preventing minority communities from getting the screening and care they need. Dr. Gary Puckrein, President and CEO of National Minority Quality Forum, joins #TheCancerSignal podcast to discuss the organization\u2019s work to quantify health disparities and how to address them. \n\n#NationalMinorityHealthMonth\n\nFind us on all major podcast platforms:  \nApple: https://apple.co/3W0dso3 \nSpotify: https://spoti.fi/3Kbe9Z8\nGoogle: https://bit.ly/3Fmp9j4 \nTranscript and other platform links: https://bit.ly/41PtC6A",
        "reactions_count": 63,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 174048326,
        "company_id": 3524741,
        "urn": "urn:li:activity:7055185960866607104",
        "followers": 68983,
        "date": "2w",
        "description": "Our next monthly newsletter will be in subscribers' inboxes next week - sign up now to stay up to date on all things GRAIL: https://bit.ly/40kF9cT",
        "reactions_count": 23,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 174048327,
        "company_id": 3524741,
        "urn": "urn:li:activity:7054862632054312960",
        "followers": 68983,
        "date": "2w",
        "description": "Health equity can\u2019t be achieved without equal access to cancer screening and other health services. On our podcast The Cancer SIGNAL we recently discussed how multi-cancer early detection can play a role in health equity. \n\nListen and get direct links to your podcast app here: https://bit.ly/3JcDzDs \n\n#NationalMinorityHealthMonth",
        "reactions_count": 61,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 174048328,
        "company_id": 3524741,
        "urn": "urn:li:activity:7054552448283136000",
        "followers": 68983,
        "date": "3w",
        "description": "Our latest study results, presented in a late-breaking poster session at #AACR23, revealed that GRAIL\u2019s methylation technology can detect multiple types of cancer without a tissue sample, offering a versatile option for a range of research uses.\n\nLearn more about how these data impact the clinical utility of our post-diagnosis methylation-based solution: https://bit.ly/41IQbJY",
        "reactions_count": 116,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 174048329,
        "company_id": 3524741,
        "urn": "urn:li:activity:7054083693585289218",
        "followers": 68983,
        "date": "3w",
        "description": "FirstHealth of the Carolinas will be the first health system in North Carolina to offer our MCED test as part of comprehensive screening and care for people with elevated cancer risk. FirstHealth\u2019s new cancer center will support people who receive a \"cancer signal detected\" test result with diagnostic evaluation and treatment if needed.\n\nLearn more about how we\u2019re bringing innovative, high-quality technologies to communities with the aim to transform cancer screening and early detection: https://bit.ly/40yeKZr",
        "reactions_count": 123,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 174048330,
        "company_id": 3524741,
        "urn": "urn:li:activity:7053829986591346689",
        "followers": 68983,
        "date": "3w",
        "description": "In partnership with AstraZeneca, we presented findings during a poster session at #AACR23 that support clinical utility of a methylation-based pan hematologic malignancy classifier based on GRAIL\u2019s platform. \n\nRead more about the results that could show a method to standardize the detection of residual cancer in people who have been treated for various types of blood cancer: https://bit.ly/3UIbjhc",
        "reactions_count": 328,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-06-20 19:18:55",
        "deleted": 1
      },
      {
        "id": 217990246,
        "company_id": 3524741,
        "urn": "urn:li:activity:7076550524413562880",
        "followers": 70966,
        "date": "1d",
        "description": "The importance of recognizing Juneteenth cannot be understated. GRAIL observes Juneteenth as a company holiday in the US and we encourage employees to pause and reflect on the significance of this day.",
        "reactions_count": 33,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 217990247,
        "company_id": 3524741,
        "urn": "urn:li:activity:7075152496205144065",
        "followers": 70966,
        "date": "5d",
        "description": "Multi-cancer early detection is different from standard cancer screening because it looks for abnormal DNA that\u2019s shed in the blood, allowing for screening of more than 50 types of cancer, most of which do not have recommended screenings.\n\nAmoolya Singh, our Senior Vice President of Data Science and Chief Scientific Officer, explains more about #MCED on The Cancer SIGNAL podcast: https://bit.ly/414AITV",
        "reactions_count": 210,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 217990248,
        "company_id": 3524741,
        "urn": "urn:li:activity:7074419070212657152",
        "followers": 70966,
        "date": "1w",
        "description": "What does it mean to show up authentically? For Sameer, it means feeling free to no longer hide who he is. This #PrideMonth one of our focuses is to create opportunities for members of the LGBTQIA+ community to share their stories, experiences, and perspectives. In amplifying these voices, we hope to foster a greater understanding and appreciation for the experiences of this community.",
        "reactions_count": 77,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 217990249,
        "company_id": 3524741,
        "urn": "urn:li:activity:7072620600032124928",
        "followers": 70966,
        "date": "1w",
        "description": "How has our understanding of cancer biology, growth, and screening evolved with the latest data?\n\nChristina Clarke Dur, PhD, MPH and Earl Hubbell answer this question and more as they discuss one of the abstracts GRAIL shared at #ASCO23. Catch up on all the GRAIL news from the congress: https://bit.ly/42yM1nX",
        "reactions_count": 160,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 217990250,
        "company_id": 3524741,
        "urn": "urn:li:activity:7071126213984940033",
        "followers": 70966,
        "date": "2w",
        "description": "Yesterday at #ASCO23, we shared an analysis from the PATHFINDER study showing how the ability to predict the cancer signal origin (the tissue or organ associated with a cancer signal) can help lead to diagnostic resolution. \n\nFind out more about why cancer signal origin is crucial to #MCED: https://bit.ly/42qM59k\n\n#DetectCancerEarly",
        "reactions_count": 247,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 217990251,
        "company_id": 3524741,
        "urn": "urn:li:activity:7070826730541735937",
        "followers": 70966,
        "date": "2w",
        "description": "Another highlight out of #ASCO23: today we announced real-world data showing that our multi-cancer early detection (#MCED) test reliably detected a cancer signal and predicted cancer signal origin in asymptomatic individuals, performing consistently with previous large-scale clinical studies. \n\nSee the press release: https://bit.ly/43KnWMd",
        "reactions_count": 427,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 217990252,
        "company_id": 3524741,
        "urn": "urn:li:activity:7070389397170348032",
        "followers": 70966,
        "date": "2w",
        "description": "At #ASCO23, GRAIL and the University of Oxford will present results from SYMPLIFY, showcasing the potential of multi-cancer early detection (MCED) testing to improve outcomes for people presenting with non-specific symptoms.\n\nSir Harpal Kumar discusses how our first analysis of MCED in a symptomatic population reveals exciting potential. Find out more: https://lnkd.in/edfqqjHk",
        "reactions_count": 381,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 217990253,
        "company_id": 3524741,
        "urn": "urn:li:activity:7070093001087176705",
        "followers": 70966,
        "date": "2w",
        "description": "#Pride2023 is here and we are excited to kick off the festivities with events throughout the month that will aim to both celebrate and deepen our knowledge of the LGBTQIA+ community, including its history, issues, and experiences. \n\nAt GRAIL, we are fostering an environment that celebrates diversity, educates, and provides support. Together, we will create a workplace where every individual feels valued, respected, and empowered to be their authentic selves.",
        "reactions_count": 83,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 217990254,
        "company_id": 3524741,
        "urn": "urn:li:activity:7069706326632755200",
        "followers": 70966,
        "date": "2w",
        "description": "Multi-cancer early detection testing can determine the origin of a cancer signal in the body, helping facilitate follow-up testing. Learn how #genomics and AI make this possible on our podcast, #TheCancerSignal: https://bit.ly/414AITV \n\nAnd stay tuned for more data about #MCED coming out of #ASCO23!",
        "reactions_count": 137,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 217990255,
        "company_id": 3524741,
        "urn": "urn:li:activity:7067257366999621633",
        "followers": 70966,
        "date": "3w",
        "description": "Mary had no symptoms when she joined her partner in getting screened for #cancer with a multi-cancer early detection test. The results showed a positive cancer signal with a colorectal origin, and a subsequent colonoscopy found a 5 cm mass in her colon. Mary\u2019s cancer was caught in stage II, making it easier for her doctors to treat successfully.",
        "reactions_count": 323,
        "comments_count": 6,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-07-23 09:55:31",
        "deleted": 1
      },
      {
        "id": 255825617,
        "company_id": 3524741,
        "urn": "urn:li:activity:7087538102948298752",
        "followers": 72539,
        "date": "3d",
        "description": "Data published today in the Journal of Clinical Oncology showed that GRAIL\u2019s multi-cancer early detection test detected a cancer signal with high sensitivity and specificity and accurately predicted cancer signal origin in people with signs and symptoms that could indicate cancer.\n\nThis is another proof point for the use of #MCED in patients experiencing symptoms, following the recent readout of SYMPLIFY data at ASCO. Read the results: https://bit.ly/3K3ynmB",
        "reactions_count": 139,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 255825618,
        "company_id": 3524741,
        "urn": "urn:li:activity:7087107481008500736",
        "followers": 72539,
        "date": "4d",
        "description": "\u201cThere would have been very little doctors could do for me if it had advanced just a little bit more.\u201d After being diagnosed with early stage pancreatic cancer, Roger\u2019s doctor said he was the luckiest person he\u2019d ever met. See his multi-cancer early detection story.",
        "reactions_count": 82,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 255825619,
        "company_id": 3524741,
        "urn": "urn:li:activity:7084603926313873409",
        "followers": 72539,
        "date": "1w",
        "description": "Jordan Karlitz MD, FACG, AGAF and Whitney Jones recently joined Collaborative Group of the Americas Inherited Cancer Organization (CGA IGC) for a podcast episode to discuss all things multi-cancer early detection (#MCED). Check it out for a thorough overview of the topic. https://bit.ly/3O9FZ9y #CGAIGC23 \n\nSee Important Safety Information at https://bit.ly/3EC3jIx",
        "reactions_count": 84,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 255825620,
        "company_id": 3524741,
        "urn": "urn:li:activity:7080555593802870784",
        "followers": 72539,
        "date": "3w",
        "description": "Next week is our second annual summer break for employees. We hope everyone takes this time to disconnect and recharge as we look ahead to the second half of the year. We extend our thanks and appreciation to those employees who will maintain our labs and other critical operations during this time.",
        "reactions_count": 146,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 255825621,
        "company_id": 3524741,
        "urn": "urn:li:activity:7079862601991499777",
        "followers": 72539,
        "date": "3w",
        "description": "We stand unified with our colleagues as we foster an authentic, supportive and safe environment and work towards a more inclusive society. Thank you to our employees who have shared their perspectives and experiences this #PrideMonth.",
        "reactions_count": 48,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 255825622,
        "company_id": 3524741,
        "urn": "urn:li:activity:7079127710911852544",
        "followers": 72539,
        "date": "3w",
        "description": "In 2022, an estimated 1.9 million new cancer cases were diagnosed, according to the American Cancer Society. By working to detect cancer signals early through tools including multi-cancer early detection (#MCED) tests, we can potentially enable earlier treatment to improve outcomes. \n\nLearn more about #MCED. https://bit.ly/3XhZYWo \n\n#DetectCancerEarly",
        "reactions_count": 150,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 255825623,
        "company_id": 3524741,
        "urn": "urn:li:activity:7077680154453368832",
        "followers": 72539,
        "date": "1mo",
        "description": "Multi-cancer early detection testing represents an opportunity to reduce the profound toll of late-stage cancer diagnoses. However, existing clinical trial structures make it hard for #MCED testing research to move forward.\nIn this article, GRAIL\u2019s Dr. Eric Klein proposes a modern approach for cancer screening trials, in order to accelerate clinical evaluation of these promising technologies and their translation into clinical practice. https://bit.ly/469tYb5",
        "reactions_count": 103,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 255825624,
        "company_id": 3524741,
        "urn": "urn:li:activity:7077331240797761536",
        "followers": 72539,
        "date": "1mo",
        "description": "Lynch syndrome is an inherited disorder that increases one\u2019s risk for many types of cancer, including some for which standard screenings are not available. In the latest episode of #TheCancerSignal podcast, Robin Dubin, co-founder of AliveAndKickn, and Dr. Jordan Karlitz MD, FACG, AGAF discuss how genetics impact cancer risk and how multi-cancer early detection testing can play a role in surveillance protocols.\n\n?\ufe0fFind us on all major podcast platforms:  \nApple: https://apple.co/3W0dso3 \nSpotify: https://spoti.fi/3Kbe9Z8\nGoogle: https://bit.ly/3Fmp9j4 \nTranscript and other platform links: https://bit.ly/4469rlW",
        "reactions_count": 90,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 255825625,
        "company_id": 3524741,
        "urn": "urn:li:activity:7077057600416047104",
        "followers": 72539,
        "date": "1mo",
        "description": "The Lancet Oncology has published our SYMPLIFY study results, first shared at #ASCO23. This study is the first large-scale evaluation of a multi-cancer early detection test in people experiencing possible cancer symptoms who were referred for diagnostic follow-up. \n\nThe analysis demonstrated the feasibility of using an #MCED test to assist clinicians with decisions regarding referral from primary care. Learn more about the results: https://bit.ly/3CBYiOb",
        "reactions_count": 252,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 255825626,
        "company_id": 3524741,
        "urn": "urn:li:activity:7076550524413562880",
        "followers": 72539,
        "date": "1mo",
        "description": "The importance of recognizing Juneteenth cannot be understated. GRAIL observes Juneteenth as a company holiday in the US and we encourage employees to pause and reflect on the significance of this day.",
        "reactions_count": 48,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-08-06 01:57:33",
        "deleted": 1
      },
      {
        "id": 274991221,
        "company_id": 3524741,
        "urn": "urn:li:activity:7092862160011173889",
        "followers": 73185,
        "date": "1d",
        "description": "US Wellness will now offer Galleri\u00ae to eligible employees through its network of employers as part of its suite of onsite and remote health and wellbeing services. Learn more: https://lnkd.in/emT-TcZ5. \n\nSee important safety information https://lnkd.in/d_fp9JR5.",
        "reactions_count": 40,
        "comments_count": null,
        "reshared_post_author": "US Wellness",
        "reshared_post_author_url": "https://www.linkedin.com/company/us-wellness",
        "reshared_post_author_headline": null,
        "reshared_post_description": "US Wellness will now offer Galleri\u00ae, a multi-cancer early detection (MCED) screening test to eligible employees through its network of employers as part of its suite of onsite and remote health and wellbeing services. US Wellness works with organizations nationwide to deliver solutions that prevent or reduce health claims and improve overall health and wellbeing.\n\nRead the full press release on our website under NEWS: https://lnkd.in/emT-TcZ5\n\n#healthcare #healthandwellness #corporatewellness #womanownedbusiness  #cancerawareness #cancerresearch #nurse #prevention",
        "reshared_post_followers": 1826,
        "reshared_post_date": "2d",
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 274991222,
        "company_id": 3524741,
        "urn": "urn:li:activity:7092551455206690816",
        "followers": 73185,
        "date": "2d",
        "description": "Valerie didn\u2019t have concerns about her health, but read about GRAIL\u2019s multi-cancer early detection #MCED technology and decided to take the test. Her results detected a cancer signal, and follow-up diagnostic testing confirmed the presence of early stage gallbladder cancer.\n\n? Watch Valerie\u2019s story: https://bit.ly/3OcFUkd",
        "reactions_count": 77,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 274991223,
        "company_id": 3524741,
        "urn": "urn:li:activity:7089276912270729216",
        "followers": 73185,
        "date": "1w",
        "description": "Roger had no symptoms when he took a multi-cancer early detection test, so he was surprised when his results showed a cancer signal with two cancer signal origins. Through follow-up testing, doctors diagnosed Roger with stage II pancreatic cancer - a moment he will never forget.\n\nRoger shares his experience with #MCED on our podcast, #TheCancerSignal. ?\ufe0f Listen on your favorite platform:\nApple: https://apple.co/3W0dso3 \nSpotify: https://spoti.fi/3Kbe9Z8\nGoogle: https://bit.ly/3Fmp9j4 \nTranscript + links to other platforms: https://bit.ly/3OqIBQn",
        "reactions_count": 115,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 274991224,
        "company_id": 3524741,
        "urn": "urn:li:activity:7087538102948298752",
        "followers": 73185,
        "date": "2w",
        "description": "Data published today in the Journal of Clinical Oncology showed that GRAIL\u2019s multi-cancer early detection test detected a cancer signal with high sensitivity and specificity and accurately predicted cancer signal origin in people with signs and symptoms that could indicate cancer.\n\nThis is another proof point for the use of #MCED in patients experiencing symptoms, following the recent readout of SYMPLIFY data at ASCO. Read the results: https://bit.ly/3K3ynmB",
        "reactions_count": 213,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 274991225,
        "company_id": 3524741,
        "urn": "urn:li:activity:7087107481008500736",
        "followers": 73185,
        "date": "2w",
        "description": "\u201cThere would have been very little doctors could do for me if it had advanced just a little bit more.\u201d After being diagnosed with early stage pancreatic cancer, Roger\u2019s doctor said he was the luckiest person he\u2019d ever met. See his multi-cancer early detection story.",
        "reactions_count": 96,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 274991226,
        "company_id": 3524741,
        "urn": "urn:li:activity:7084603926313873409",
        "followers": 73185,
        "date": "3w",
        "description": "Jordan Karlitz MD, FACG, AGAF and Whitney Jones recently joined Collaborative Group of the Americas Inherited Cancer Organization (CGA IGC) for a podcast episode to discuss all things multi-cancer early detection (#MCED). Check it out for a thorough overview of the topic. https://bit.ly/3O9FZ9y #CGAIGC23 \n\nSee Important Safety Information at https://bit.ly/3EC3jIx",
        "reactions_count": 89,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 274991227,
        "company_id": 3524741,
        "urn": "urn:li:activity:7080555593802870784",
        "followers": 73185,
        "date": "1mo",
        "description": "Next week is our second annual summer break for employees. We hope everyone takes this time to disconnect and recharge as we look ahead to the second half of the year. We extend our thanks and appreciation to those employees who will maintain our labs and other critical operations during this time.",
        "reactions_count": 147,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 274991228,
        "company_id": 3524741,
        "urn": "urn:li:activity:7079862601991499777",
        "followers": 73185,
        "date": "1mo",
        "description": "We stand unified with our colleagues as we foster an authentic, supportive and safe environment and work towards a more inclusive society. Thank you to our employees who have shared their perspectives and experiences this #PrideMonth.",
        "reactions_count": 50,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 274991229,
        "company_id": 3524741,
        "urn": "urn:li:activity:7079127710911852544",
        "followers": 73185,
        "date": "1mo",
        "description": "In 2022, an estimated 1.9 million new cancer cases were diagnosed, according to the American Cancer Society. By working to detect cancer signals early through tools including multi-cancer early detection (#MCED) tests, we can potentially enable earlier treatment to improve outcomes. \n\nLearn more about #MCED. https://bit.ly/3XhZYWo \n\n#DetectCancerEarly",
        "reactions_count": 151,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 274991230,
        "company_id": 3524741,
        "urn": "urn:li:activity:7077680154453368832",
        "followers": 73185,
        "date": "1mo",
        "description": "Multi-cancer early detection testing represents an opportunity to reduce the profound toll of late-stage cancer diagnoses. However, existing clinical trial structures make it hard for #MCED testing research to move forward.\nIn this article, GRAIL\u2019s Dr. Eric Klein proposes a modern approach for cancer screening trials, in order to accelerate clinical evaluation of these promising technologies and their translation into clinical practice. https://bit.ly/469tYb5",
        "reactions_count": 103,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-09-03 08:21:09",
        "deleted": 1
      },
      {
        "id": 306072930,
        "company_id": 3524741,
        "urn": "urn:li:activity:7102694491005804547",
        "followers": null,
        "date": "3d",
        "description": "Happy Pride, Silicon Valley! This past weekend, members and allies of GRAIL\u2019s Pride employee resource group participated in the Silicon Valley Pride Parade - this year's theme was \"Living Out Loud.\" We had a wonderful time celebrating diversity, love and the LGBTQIA+ community. #SVPride",
        "reactions_count": 193,
        "comments_count": 7,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 306072931,
        "company_id": 3524741,
        "urn": "urn:li:activity:7100103151357190144",
        "followers": null,
        "date": "1w",
        "description": "Today we announced a new research collaboration with Whitman-Walker and Cancer Support Community that will evaluate multi-cancer early detection screening to increase cancer detection in underserved populations. \n\nLearn more: https://bit.ly/3sp9pZ3",
        "reactions_count": 263,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 306072932,
        "company_id": 3524741,
        "urn": "urn:li:activity:7099392462053355520",
        "followers": null,
        "date": "1w",
        "description": "The war on cancer has been happening for more than 50 years. Despite remarkable advances, it often feels like cancer is winning. Our approach to cancer screening has the potential to shift the paradigm. Read more from Jeffrey Venstrom, MD, GRAIL's Chief Medical Officer, about adding multi-cancer early detection: https://bit.ly/3FiXmkg",
        "reactions_count": 123,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 306072933,
        "company_id": 3524741,
        "urn": "urn:li:activity:7097611428076871680",
        "followers": null,
        "date": "2w",
        "description": "Mary\u2019s partner encouraged her to take GRAIL\u2019s #MCED test despite having a clean bill of health. The test detected a cancer signal and after diagnostic testing, she was diagnosed with colon #cancer. \n\n? Hear from Mary and her doctor about the promise of early detection: https://bit.ly/3Qc13xF",
        "reactions_count": 80,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 306072934,
        "company_id": 3524741,
        "urn": "urn:li:activity:7095781166955274240",
        "followers": null,
        "date": "3w",
        "description": "In many cases, cancer is found too late, when it has already spread, and effective treatment options are more limited. Advancing the science and adoption of multi-cancer early detection is an urgent priority. \n\nGRAIL President Joshua Ofman MD, MSHS shares how adding #MCED can play a role in supporting unmet clinical and public health needs, especially for addressing late-stage cancer treatment costs: https://bit.ly/3sa2McP",
        "reactions_count": 251,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 306072935,
        "company_id": 3524741,
        "urn": "urn:li:activity:7094735929906470912",
        "followers": null,
        "date": "3w",
        "description": "Voting is open for #SXSW 2024! Vote for Joshua Ofman MD, MSHS, GRAIL\u2019s President, to be a keynote speaker on the critical need to detect cancer as early as possible. Multi-cancer early detection has the potential to shift the cancer paradigm and your vote can help spread awareness of this issue. https://bit.ly/45lEL0y \n\nSXSW",
        "reactions_count": 182,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 306072936,
        "company_id": 3524741,
        "urn": "urn:li:activity:7092862160011173889",
        "followers": null,
        "date": "1mo",
        "description": "US Wellness will now offer Galleri\u00ae to eligible employees through its network of employers as part of its suite of onsite and remote health and wellbeing services. Learn more: https://lnkd.in/emT-TcZ5. \n\nSee important safety information https://lnkd.in/d_fp9JR5.",
        "reactions_count": 62,
        "comments_count": null,
        "reshared_post_author": "US Wellness",
        "reshared_post_author_url": "https://www.linkedin.com/company/us-wellness",
        "reshared_post_author_headline": null,
        "reshared_post_description": "US Wellness will now offer Galleri\u00ae, a multi-cancer early detection (MCED) screening test to eligible employees through its network of employers as part of its suite of onsite and remote health and wellbeing services. US Wellness works with organizations nationwide to deliver solutions that prevent or reduce health claims and improve overall health and wellbeing.\n\nRead the full press release on our website under NEWS: https://lnkd.in/emT-TcZ5\n\n#healthcare #healthandwellness #corporatewellness #womanownedbusiness  #cancerawareness #cancerresearch #nurse #prevention",
        "reshared_post_followers": null,
        "reshared_post_date": "1mo",
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 306072937,
        "company_id": 3524741,
        "urn": "urn:li:activity:7092551455206690816",
        "followers": null,
        "date": "1mo",
        "description": "Valerie didn\u2019t have concerns about her health, but read about GRAIL\u2019s multi-cancer early detection #MCED technology and decided to take the test. Her results detected a cancer signal, and follow-up diagnostic testing confirmed the presence of early stage gallbladder cancer.\n\n? Watch Valerie\u2019s story: https://bit.ly/3OcFUkd",
        "reactions_count": 122,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 306072938,
        "company_id": 3524741,
        "urn": "urn:li:activity:7089276912270729216",
        "followers": null,
        "date": "1mo",
        "description": "Roger had no symptoms when he took a multi-cancer early detection test, so he was surprised when his results showed a cancer signal with two cancer signal origins. Through follow-up testing, doctors diagnosed Roger with stage II pancreatic cancer - a moment he will never forget.\n\nRoger shares his experience with #MCED on our podcast, #TheCancerSignal. ?\ufe0f Listen on your favorite platform:\nApple: https://apple.co/3W0dso3 \nSpotify: https://spoti.fi/3Kbe9Z8\nGoogle: https://bit.ly/3Fmp9j4 \nTranscript + links to other platforms: https://bit.ly/3OqIBQn",
        "reactions_count": 130,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 306072939,
        "company_id": 3524741,
        "urn": "urn:li:activity:7087538102948298752",
        "followers": null,
        "date": "1mo",
        "description": "Data published today in the Journal of Clinical Oncology showed that GRAIL\u2019s multi-cancer early detection test detected a cancer signal with high sensitivity and specificity and accurately predicted cancer signal origin in people with signs and symptoms that could indicate cancer.\n\nThis is another proof point for the use of #MCED in patients experiencing symptoms, following the recent readout of SYMPLIFY data at ASCO. Read the results: https://bit.ly/3K3ynmB",
        "reactions_count": 224,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-10-16 07:32:24",
        "deleted": 1
      },
      {
        "id": 345475626,
        "company_id": 3524741,
        "urn": "urn:li:activity:7112779168773234688",
        "followers": null,
        "date": "2w",
        "description": "GRAIL has been recognized on Fortune's 2023 #ChangeTheWorld list, as one of 50 companies driving positive social impact. \n\nThis accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Learn more: https://bit.ly/3ZB1KDu",
        "reactions_count": 495,
        "comments_count": 13,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 345475627,
        "company_id": 3524741,
        "urn": "urn:li:activity:7118656787477585921",
        "followers": null,
        "date": "2d",
        "description": "The Cancer SIGNAL podcast is one year old! We\u2019ve explored early cancer detection from a variety of angles: reducing health disparities, understanding genomics, patient perspectives and more. \n\n?\ufe0fSubscribe or check out transcripts here: https://bit.ly/3Lx4g6t #MCED",
        "reactions_count": 41,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 345475628,
        "company_id": 3524741,
        "urn": "urn:li:activity:7118598764449124353",
        "followers": null,
        "date": "2d",
        "description": "Mass\u00a0Mutual\u00a0announced their new Health and Wellness Program for eligible policyowners, which will include multi-cancer early detection. Learn more below.",
        "reactions_count": 26,
        "comments_count": 1,
        "reshared_post_author": "MassMutual",
        "reshared_post_author_url": "https://www.linkedin.com/company/massmutual-financial-group",
        "reshared_post_author_headline": null,
        "reshared_post_description": "MassMutual is pleased to announce the launch of our Health and Wellness Program, which provides tools to eligible policyowners to empower them with knowledge about their health so they can make informed, proactive health decisions that can help them lead longer, healthier lives. Learn more.",
        "reshared_post_followers": null,
        "reshared_post_date": "4d",
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 345475629,
        "company_id": 3524741,
        "urn": "urn:li:activity:7118260042620915712",
        "followers": null,
        "date": "3d",
        "description": "At #HLTH2023, GRAIL's VP of Corporate Affairs, Megan P. Hall, joined a panel discussion on how novel screening technologies like multi-cancer early detection can be added to the current standard of care. \n\nLearn more about #MCED: https://bit.ly/45wf8ux",
        "reactions_count": 183,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 345475630,
        "company_id": 3524741,
        "urn": "urn:li:activity:7117210621799985153",
        "followers": null,
        "date": "6d",
        "description": "Cancer rates among American Indian and Alaska Native individuals have been found to be 2% higher than among White individuals for incidence, but 18% higher for mortality. This #IndigenousPeoplesDay hear from Melissa Buffalo, CEO of the American Indian Cancer Foundation, on what is being done to address the needs of this population.  \n\nListen here: https://bit.ly/46eTqer",
        "reactions_count": 79,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 345475631,
        "company_id": 3524741,
        "urn": "urn:li:activity:7116146697851809794",
        "followers": null,
        "date": "1w",
        "description": "We're excited to share our new partnership with Accarent Health, a leader in value-based care for oncology. Learn\u00a0more below.",
        "reactions_count": 94,
        "comments_count": null,
        "reshared_post_author": "Accarent Health",
        "reshared_post_author_url": "https://www.linkedin.com/company/accarent-health",
        "reshared_post_author_headline": null,
        "reshared_post_description": "Accarent Health to Offer GRAIL\u2019s Galleri\u00ae, a Multi-Cancer Early Detection Test to its Network and Members.  Read the release here: https://lnkd.in/eHin7i7S",
        "reshared_post_followers": null,
        "reshared_post_date": "1w",
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 345475632,
        "company_id": 3524741,
        "urn": "urn:li:activity:7115846910501912576",
        "followers": null,
        "date": "1w",
        "description": "The Lancet has just published comprehensive findings from our PATHFINDER study. The latest results spotlight how adding a multi-cancer early detection screening test to standard of care screening more than doubled the number of new cancers detected, with nearly half in early stages. \n\nSee more insights: https://bit.ly/3LQpX2H",
        "reactions_count": 471,
        "comments_count": 9,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 345475633,
        "company_id": 3524741,
        "urn": "urn:li:activity:7115836854095994880",
        "followers": null,
        "date": "1w",
        "description": "The Lancet has just published comprehensive findings from our PATHFINDER study. The latest results spotlight how adding a multi-cancer early detection screening test to standard of care screening more than doubled the number of new cancers detected, with nearly half in early stages. \n\nSee more insights: https://bit.ly/3LQpX2H",
        "reactions_count": 471,
        "comments_count": 9,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 345475634,
        "company_id": 3524741,
        "urn": "urn:li:activity:7115361715499724800",
        "followers": null,
        "date": "1w",
        "description": "Our VP of Corporate Affairs and Distinguished Scientist Megan P. Hall is joining the #HLTH2023 conversation with other industry peers to discuss the potential benefits of novel early cancer screening technologies. \n\nFor more event information and to register to attend or watch online, visit: https://bit.ly/3LNDAQd",
        "reactions_count": 67,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 345475635,
        "company_id": 3524741,
        "urn": "urn:li:activity:7114958550719688704",
        "followers": null,
        "date": "1w",
        "description": "This past weekend at #AACRDisp23, our team presented data on multi-cancer early detection in diverse and medically underserved populations. We demonstrated that DNA methylation patterns associated with race and ethnicity do not significantly contribute to classifier performance. \n\nWe also showed that implementing a multi-cancer early detection test as an employee benefit offers an approach to detect cancers for which there is no screening method and the potential to address socioeconomic disparities in screening.",
        "reactions_count": 137,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-11-01 12:36:31",
        "deleted": 1
      },
      {
        "id": 363772869,
        "company_id": 3524741,
        "urn": "urn:li:activity:7112779168773234688",
        "followers": null,
        "date": "1mo",
        "description": "GRAIL has been recognized on Fortune's 2023 #ChangeTheWorld list, as one of 50 companies driving positive social impact. \n\nThis accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Learn more: https://bit.ly/3ZB1KDu",
        "reactions_count": 511,
        "comments_count": 14,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 363772870,
        "company_id": 3524741,
        "urn": "urn:li:activity:7125118044573499392",
        "followers": null,
        "date": "22h",
        "description": "The PATHFINDER study revealed some compelling implications for the future of multi-cancer early detection testing and its benefits when added to recommended #cancer screenings.\n\n?\ufe0fDr. Chuck McDonnell, radiologist at Sutter Medical Group and PATHFINDER principal investigator, joins the latest episode of #TheCancerSignal podcast to dig into the research findings. Listen here: https://bit.ly/3SlxuuE",
        "reactions_count": 47,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 363772871,
        "company_id": 3524741,
        "urn": "urn:li:activity:7123450159409033217",
        "followers": null,
        "date": "5d",
        "description": "Jeffrey Venstrom, M.D. participated in the panel \"Challenges and Opportunities of Multi-Cancer Early Detection Tests\" at the Precision Oncology & Diagnostics meeting in Chicago to discuss the advancement of MCEDs to reduce cancer burden.",
        "reactions_count": 69,
        "comments_count": null,
        "reshared_post_author": "Jeffrey Venstrom, M.D.",
        "reshared_post_author_url": "https://www.linkedin.com/in/jeffrey-venstrom",
        "reshared_post_author_headline": "Chief Medical Officer at GRAIL | Physician-Scientist | Changing How the World Understands Cancer",
        "reshared_post_description": "It was a pleasure joining leading experts on a panel about multi-cancer early detection during the Precision Oncology & Diagnostics Summit in Chicago today. We had a great discussion about the role MCEDs can play in cancer screenings and innovative ways of designing clinical trials to support clinical implementation, and health equity.  \n\nThank you Alpa Patel, Wendy Rubinstein, MD, PhD, Michelle Le Beau",
        "reshared_post_followers": null,
        "reshared_post_date": "5d",
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 363772872,
        "company_id": 3524741,
        "urn": "urn:li:activity:7122609555858980864",
        "followers": null,
        "date": "1w",
        "description": "Year 2 of The Cancer SIGNAL Podcast is coming, and we're excited to bring you even more insights into the world of multi-cancer early detection! \n\n?\ufe0fJoin us on this new chapter of discovery and hope: https://bit.ly/3Lx4g6t",
        "reactions_count": 54,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 363772873,
        "company_id": 3524741,
        "urn": "urn:li:activity:7122214541429534720",
        "followers": null,
        "date": "1w",
        "description": "Our team received a Presidential Poster Award for two of our abstracts at this year\u2019s #ACG2023. Both datasets revealed the promise of multi-cancer early detection (#MCED) in discovering a cancer signal and its origin in individuals from the PATHFINDER study who had gastrointestinal cancers and to differentiate colon and rectal cancer detection in those newly diagnosed with colorectal cancer.\n\nLearn more about our pioneering cancer screening technologies: www.grail.com \nJordan Karlitz MD, FACG, AGAF \nMatthew Margolis",
        "reactions_count": 221,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 363772874,
        "company_id": 3524741,
        "urn": "urn:li:activity:7121485426225270784",
        "followers": null,
        "date": "1w",
        "description": "Our team at #ACG2023 is sharing two abstracts that demonstrate the potential of our #MCED technology to detect cancers in individuals without suspicion of #cancer and to differentiate cancer detection in those newly diagnosed. Learn about our latest work: www.grail.com",
        "reactions_count": 58,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 363772875,
        "company_id": 3524741,
        "urn": "urn:li:activity:7121144832298811393",
        "followers": null,
        "date": "1w",
        "description": "We recently held our second annual DEI Week featuring ten sessions, both in person and virtual, for all employees to participate in. Discussions focused on equity in healthcare, allyship, DEI in business and more. Plus we held an employee resource group fair for everyone to learn more about the groups they can get involved with. \n\nThanks to all involved in making this week an engaging and thought-provoking opportunity to learn and connect. \nRayshawnda Madison Ysabel Duron Brandon Mahal Traci Sanders BRENTLEY WRIGHT, CDE\u00ae Ayoka G.",
        "reactions_count": 115,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 363772876,
        "company_id": 3524741,
        "urn": "urn:li:activity:7120481172337426432",
        "followers": null,
        "date": "1w",
        "description": "As we mark a year of The Cancer SIGNAL podcast, we want to hear your thoughts. Fill out this quick survey to help shape the future of our show: https://bit.ly/3PV8bfZ",
        "reactions_count": 23,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 363772877,
        "company_id": 3524741,
        "urn": "urn:li:activity:7120110729470373889",
        "followers": null,
        "date": "2w",
        "description": "Comprehensive cancer care begins with screening. Today, we announced a strategic collaboration with HCA Healthcare and Sarah Cannon to offer multi-cancer early detection paired with multidisciplinary care coordination to eligible individuals. \n\nTogether we aim to advance the cancer care experience, from screening onward. Learn more: https://bit.ly/3FjImBx #MCED",
        "reactions_count": 158,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 363772878,
        "company_id": 3524741,
        "urn": "urn:li:activity:7118656787477585921",
        "followers": null,
        "date": "2w",
        "description": "The Cancer SIGNAL podcast is one year old! We\u2019ve explored early cancer detection from a variety of angles: reducing health disparities, understanding genomics, patient perspectives and more. \n\n?\ufe0fSubscribe or check out transcripts here: https://bit.ly/3Lx4g6t #MCED",
        "reactions_count": 57,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2023-12-05 20:02:25",
        "deleted": 1
      },
      {
        "id": 401983484,
        "company_id": 3524741,
        "urn": "urn:li:activity:7112779168773234688",
        "followers": null,
        "date": "2mo",
        "description": "GRAIL has been recognized on Fortune's 2023 #ChangeTheWorld list, as one of 50 companies driving positive social impact. \n\nThis accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Learn more: https://bit.ly/3ZB1KDu",
        "reactions_count": 529,
        "comments_count": 14,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 401983485,
        "company_id": 3524741,
        "urn": "urn:li:activity:7136018580965400576",
        "followers": null,
        "date": "5d",
        "description": "On the latest episode of #TheCancerSignal podcast, Alpa Patel and Christina Clarke Dur, PhD, MPH discuss research on how the COVID-19 pandemic limited access to cancer screening and the impact this had on early cancer detection, particularly in marginalized communities. \n\n?\ufe0fListen and subscribe here: https://bit.ly/40YYW3F",
        "reactions_count": 81,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 401983486,
        "company_id": 3524741,
        "urn": "urn:li:activity:7132369188135833600",
        "followers": null,
        "date": "2w",
        "description": "We\u2019re initiating a first-of-its-kind real-world study designed to further evaluate the clinical impact of multi-cancer early detection (#MCED) screening among Medicare beneficiaries, including racial and ethnic minorities or those living in medically underserved areas.\n\nWith age being the most significant risk factor for #cancer, Medicare beneficiaries face the highest unmet need for early cancer detection. \n\nThe study is designed to meet the aspirations of the Cancer Moonshot\u2019s goal of advancing early detection, add to our robust ongoing real-world evidence generation, and continue to demonstrate Galleri\u2019s clinical benefit for early detection.\nLearn more: https://bit.ly/3QPzLvK\n\nPlease see enclosed video providing a study overview.",
        "reactions_count": 440,
        "comments_count": 8,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 401983487,
        "company_id": 3524741,
        "urn": "urn:li:activity:7131297205205811200",
        "followers": null,
        "date": "2w",
        "description": "We are proud to announce that GRAIL has received ISO 13485 Certification, which indicates that GRAIL has implemented robust policies and procedures for the development and manufacture of regulated medical products. https://bit.ly/3R1ADyB",
        "reactions_count": 398,
        "comments_count": 10,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 401983488,
        "company_id": 3524741,
        "urn": "urn:li:activity:7130219624855441409",
        "followers": null,
        "date": "3w",
        "description": "We presented data at this year\u2019s #ISPOREurope demonstrating the real-world potential of multi-cancer early detection (#MCED) technology.\n\nThe results found:\n?The importance of early cancer detection to potentially attenuate symptoms and affect the overall health-related quality of life. \n?The potential for MCED testing to be cost-effective across a wide range of clinical hypotheses on mortality and incidence.\n\nFind out more: https://bit.ly/3ufa1Bd",
        "reactions_count": 185,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 401983489,
        "company_id": 3524741,
        "urn": "urn:li:activity:7128060616639987712",
        "followers": null,
        "date": "3w",
        "description": "We are proud to be recognized as one of the top biopharma companies on BioSpace's 2024 Best Places to Work list. Thousands of life science community members voted on the award nominees, with a focus on culture, career growth, development opportunities, leadership, and innovation.\n\nOur team is driven by purpose, united by the pursuit of a better way to address the enormous toll that #cancer has on patients, their families and society as a whole. \n\nLearn more: https://bit.ly/3TOYVtU",
        "reactions_count": 343,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 401983490,
        "company_id": 3524741,
        "urn": "urn:li:activity:7127342208755646464",
        "followers": null,
        "date": "4w",
        "description": "While Cindy's husband, Carlos, was facing his own cancer experience, he encouraged her to take a multi-cancer early detection test. The blood draw revealed a \u201ccancer signal detected\u201d result.\n\nCindy shares what happened next, and why she and Carlos believe it\u2019s important to be proactive about your health: https://bit.ly/44RHQVD",
        "reactions_count": 94,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 401983491,
        "company_id": 3524741,
        "urn": "urn:li:activity:7125118044573499392",
        "followers": null,
        "date": "1mo",
        "description": "The PATHFINDER study revealed some compelling implications for the future of multi-cancer early detection testing and its benefits when added to recommended #cancer screenings.\n\n?\ufe0fDr. Chuck McDonnell, radiologist at Sutter Medical Group and PATHFINDER principal investigator, joins the latest episode of #TheCancerSignal podcast to dig into the research findings. Listen here: https://bit.ly/3SlxuuE",
        "reactions_count": 80,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 401983492,
        "company_id": 3524741,
        "urn": "urn:li:activity:7123450159409033217",
        "followers": null,
        "date": "1mo",
        "description": "Jeffrey Venstrom, M.D. participated in the panel \"Challenges and Opportunities of Multi-Cancer Early Detection Tests\" at the Precision Oncology & Diagnostics meeting in Chicago to discuss the advancement of MCEDs to reduce cancer burden.",
        "reactions_count": 79,
        "comments_count": null,
        "reshared_post_author": "Jeffrey Venstrom, M.D.",
        "reshared_post_author_url": "https://www.linkedin.com/in/jeffrey-venstrom",
        "reshared_post_author_headline": "Chief Medical Officer at GRAIL | Physician-Scientist | Changing How the World Understands Cancer",
        "reshared_post_description": "It was a pleasure joining leading experts on a panel about multi-cancer early detection during the Precision Oncology & Diagnostics Summit in Chicago today. We had a great discussion about the role MCEDs can play in cancer screenings and innovative ways of designing clinical trials to support clinical implementation, and health equity.  \n\nThank you Alpa Patel, Wendy Rubinstein, MD, PhD, Michelle Le Beau",
        "reshared_post_followers": null,
        "reshared_post_date": "1mo",
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 401983493,
        "company_id": 3524741,
        "urn": "urn:li:activity:7122609555858980864",
        "followers": null,
        "date": "1mo",
        "description": "Year 2 of The Cancer SIGNAL Podcast is coming, and we're excited to bring you even more insights into the world of multi-cancer early detection! \n\n?\ufe0fJoin us on this new chapter of discovery and hope: https://bit.ly/3Lx4g6t",
        "reactions_count": 63,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-01-25 13:49:30",
        "deleted": 1
      },
      {
        "id": 458118968,
        "company_id": 3524741,
        "urn": "urn:li:activity:7112779168773234688",
        "followers": null,
        "date": "4mo",
        "description": "GRAIL has been recognized on Fortune's 2023 #ChangeTheWorld list, as one of 50 companies driving positive social impact. \n\nThis accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Learn more: https://bit.ly/3ZB1KDu",
        "reactions_count": 555,
        "comments_count": 16,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 458118969,
        "company_id": 3524741,
        "urn": "urn:li:activity:7155586506705813504",
        "followers": null,
        "date": "1d",
        "description": "Part 2 of our interview with Krissa Smith from Susan G. Komen on #TheCancerSignal podcast unravels how #BRCA and other mutations affect cancer risk and impact families. \n\n?\ufe0fListen now to learn more about genetics and cancer risk \u2013 and how emerging screening technology like multi-cancer early detection can help: https://bit.ly/495cIEB",
        "reactions_count": 49,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 458118970,
        "company_id": 3524741,
        "urn": "urn:li:activity:7153748046235807745",
        "followers": null,
        "date": "6d",
        "description": "The American Cancer Society released its Cancer Facts & Figures 2024 report \u2013 for the first time, it is estimated that more than 2 million new cancer cases will be diagnosed in the US this year. \n\nAdding multi-cancer early detection (#MCED) testing to standard cancer screenings is a proactive way to screen for the deadliest cancers, including those that don\u2019t have recommended screening tests.",
        "reactions_count": 62,
        "comments_count": null,
        "reshared_post_author": "American Cancer Society",
        "reshared_post_author_url": "https://www.linkedin.com/company/american-cancer-society",
        "reshared_post_author_headline": null,
        "reshared_post_description": "The American Cancer Society Cancer Facts & Figures 2024 report is here\u00a0with data detailing the current cancer burden in the US,\u00a0progress that\u2019s been made, and what preventive steps you can take to help reduce your cancer risk. Deep dive into this report to equip yourself, health professionals, educators, and policy makers with discussion points to effectively advocate for people facing cancer.\u00a0\nWith breast, prostate, colorectal (ages 0-54), and cervical (ages 30-44) cancers on the rise, it's important to get screened. Hear more from our CEO Dr. Karen Knudsen.\nFull report: https://lnkd.in/gRkVKQh5",
        "reshared_post_followers": null,
        "reshared_post_date": "1w",
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 458118971,
        "company_id": 3524741,
        "urn": "urn:li:activity:7153432054699859968",
        "followers": null,
        "date": "1w",
        "description": "As we learn more about the link between DNA mutations and cancer risk, genetic testing is becoming increasingly useful for high-risk individuals to protect their health. Krissa Smith from Susan G. Komen joins the latest episode of #TheCancerSignal podcast to share her own family\u2019s journey with genetic testing and the unique #cancer screening needs for those with a cancer-related genetic mutation.\n\n?\ufe0fListen and subscribe to hear the second part of the interview as soon as it\u2019s out: https://bit.ly/3U4Oia3",
        "reactions_count": 57,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 458118972,
        "company_id": 3524741,
        "urn": "urn:li:activity:7152797653196505088",
        "followers": null,
        "date": "1w",
        "description": "Today we commemorate the enduring legacy of Dr. Martin Luther King Jr., a visionary leader who championed justice and equality for all. At GRAIL, our commitment to promoting diversity, equity, and inclusion (DEI) within our workplace remains unwavering. This day serves as a poignant reminder of the strides we've made and the ongoing journey towards a more just and equitable world.",
        "reactions_count": 28,
        "comments_count": null,
        "reshared_post_author": "Rayshawnda Madison",
        "reshared_post_author_url": "https://www.linkedin.com/in/rayshawndamadison",
        "reshared_post_author_headline": "Senior Director Diversity, Equity and Inclusion at GRAIL",
        "reshared_post_description": "On this MLK Day, we reflect on the enduring legacy of Dr. Martin Luther King Jr., a visionary leader who dedicated his life to justice and equality. The principles he championed are universal, transcending time and organizations. In the spirit of Dr. King's profound impact, let us pledge to be active contributors to creating truly inclusive environments. Embracing diversity, equity, and inclusion isn't just a commitment\u2014it's a collective responsibility that extends beyond any workplace. May this MLK Day inspire us all to uphold the principles of diversity, equity, and inclusion not just today but every day. Simple acts, like listening to others' perspectives and engaging in initiatives, contribute to the ongoing progress. Together, let's build a culture of belonging where every voice is heard and valued. #MLKDay #DiversityandInclusion #EqualityForAll art by Keebs Laurent",
        "reshared_post_followers": null,
        "reshared_post_date": "1w",
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 458118973,
        "company_id": 3524741,
        "urn": "urn:li:activity:7151230038204436481",
        "followers": null,
        "date": "1w",
        "description": "We're partnering with BeniComp Health Solutions, a customized health plan provider, to bring multi-cancer early detection (#MCED) testing to Benicomp Select members.\n\nAs part of their program, BeniComp offers an innovative approach to controlling health costs by identifying risks at an early stage. \n\nTogether we're transforming #cancer care through proactive health management. Learn more: https://bit.ly/48JEExA",
        "reactions_count": 119,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 458118974,
        "company_id": 3524741,
        "urn": "urn:li:activity:7150947164850966528",
        "followers": null,
        "date": "2w",
        "description": "In a recent GRAIL study published in MDPI researchers analyzed a novel screening method called tumor methylated fraction (TMeF), a tissue-free, non-invasive way to estimate the amount of cancer-indicative methylation patterns within circulating tumor DNA. This method can be used to determine the amount of #cancer in the body and help doctors predict outcomes and recommend treatments for patients.\n\nLearn more about how the technology works and how TMeF could be used to supplement current cancer screening methods in the future: https://bit.ly/4aOHcwh",
        "reactions_count": 148,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 458118975,
        "company_id": 3524741,
        "urn": "urn:li:activity:7150551306259099648",
        "followers": null,
        "date": "2w",
        "description": "We're honored to once again be named a Best Place to Work by Built In! Thank you to Built In for this recognition. Check out the full list of honorees here: https://bit.ly/3HahiW2\n#2024BuiltInBest",
        "reactions_count": 97,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 458118976,
        "company_id": 3524741,
        "urn": "urn:li:activity:7150176677195644929",
        "followers": null,
        "date": "2w",
        "description": "For over a year our podcast, The Cancer SIGNAL, has featured perspectives on multi-cancer early detection - from scientists and patients, to experts and advocates. As early #cancer screening technology continues to advance, we\u2019ll be here exploring its potential.\n\nSubscribe here: https://bit.ly/3Lx4g6t",
        "reactions_count": 65,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 458118977,
        "company_id": 3524741,
        "urn": "urn:li:activity:7149132210732756992",
        "followers": null,
        "date": "2w",
        "description": "As we kick off the New Year, our CEO Bob Ragusa reflects on the significant progress we made in 2023 and what\u2019s to come in 2024 and beyond: https://bit.ly/48e14at",
        "reactions_count": 211,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-02-28 08:50:44",
        "deleted": 1
      },
      {
        "id": 489696216,
        "company_id": 3524741,
        "urn": "urn:li:activity:7112779168773234688",
        "followers": null,
        "date": "5mo",
        "description": "GRAIL has been recognized on Fortune's 2023 #ChangeTheWorld list, as one of 50 companies driving positive social impact. \n\nThis accomplishment is only possible due to the steadfast dedication of our employees, who are working together every day to redefine the status quo of cancer detection. Learn more: https://bit.ly/3ZB1KDu",
        "reactions_count": 569,
        "comments_count": 16,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 489696217,
        "company_id": 3524741,
        "urn": "urn:li:activity:7167915795501563905",
        "followers": null,
        "date": "1d",
        "description": "New on the podcast \u2013 Cindy\u2019s story: https://bit.ly/3TaaQ8q After her husband\u2019s #cancer treatment was successfully completed, Cindy decided to proactively take a multi-cancer early detection test. She was shocked when it returned a cancer signal detected result. \n\nListen to her story and subscribe for future episodes. #TheCancerSignal \n\nApple Podcasts: https://apple.co/3W0dso3\nSpotify: https://spoti.fi/3T8pay9 \nAmazon Music: https://amzn.to/3PbZAom",
        "reactions_count": 31,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 489696218,
        "company_id": 3524741,
        "urn": "urn:li:activity:7161794901104357376",
        "followers": null,
        "date": "2w",
        "description": "This week GRAILers gathered to celebrate the upcoming #LunarNewYear. Best wishes and good fortune to all in the Year of the Dragon! \n#DiversityAndInclusion",
        "reactions_count": 131,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 489696219,
        "company_id": 3524741,
        "urn": "urn:li:activity:7161405170625437696",
        "followers": null,
        "date": "2w",
        "description": "From addressing health disparities to advancing the science of cancer genomics, multi-cancer early detection has implications for many aspects of #cancer screening and care. We\u2019re exploring the impacts of this technology on our podcast, The Cancer SIGNAL.\n\nSubscribe here for new monthly episodes: https://bit.ly/42x1y9v",
        "reactions_count": 72,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 489696220,
        "company_id": 3524741,
        "urn": "urn:li:activity:7160337691337773057",
        "followers": null,
        "date": "3w",
        "description": "We\u2019re excited to announce the name change of BIG (Black & Brown Influencers at GRAIL) in time for #BlackHistoryMonth! Anwell Wilbekin and Rich S.T Gilliam, co-leaders of BIG, unveil the new identity and outline upcoming events. We've curated insightful panel discussions on influence and health equity, along with a creative virtual paint night. Stay tuned for a month filled with celebration and empowerment at GRAIL! #DiversityAndInclusion #GRAILproud",
        "reactions_count": 120,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 489696221,
        "company_id": 3524741,
        "urn": "urn:li:activity:7159233095714414592",
        "followers": null,
        "date": "3w",
        "description": "Proactive tools, like multi-cancer early detection tests, are helping people take more control of their health \u2013 but there\u2019s more work to be done to help #CloseTheCareGap.\n\nAhead of #WorldCancerDay, we\u2019re revisiting our podcast interview with Dr. Gary Puckrein, President and CEO of the National Minority Quality Forum, as he discusses how we can address barriers to equity in cancer screening. Hear more in this episode of #TheCancerSignal: https://bit.ly/49eqd5z \n\nFind us on all major podcast platforms:  \nApple: https://apple.co/3W0dso3  \nSpotify: https://spoti.fi/3Kbe9Z8 \nGoogle: https://bit.ly/3Fmp9j4",
        "reactions_count": 68,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 489696222,
        "company_id": 3524741,
        "urn": "urn:li:activity:7158873338633723905",
        "followers": null,
        "date": "3w",
        "description": "Today we announced that Curative will bring multi-cancer early detection (#MCED) testing to all members over the age of 50 and to all other members with risk factors for developing cancer. \n\nFind out more: https://bit.ly/3UpYo5E \n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests. See Important Safety Information at https://lnkd.in/d_fp9JR5",
        "reactions_count": 113,
        "comments_count": null,
        "reshared_post_author": "Curative",
        "reshared_post_author_url": "https://www.linkedin.com/company/curativeinc",
        "reshared_post_author_headline": null,
        "reshared_post_description": "What if early cancer detection was easier and simpler? With Galleri, it can be. Galleri Test screens for a signal shared by 50+ types of cancer with a single blood test and is now available to eligible Curative members.\n\nRead the full release here: https://lnkd.in/gaMTwN89\n\nVisit our website to confirm your eligibility and request your Galleri test today?https://lnkd.in/gNnZ4CiZ\n\n*Further testing is required to diagnose cancer\n#Healthcare #CancerDetection #PreventiveCare GRAIL",
        "reshared_post_followers": null,
        "reshared_post_date": "3w",
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 489696223,
        "company_id": 3524741,
        "urn": "urn:li:activity:7158477497800503296",
        "followers": null,
        "date": "3w",
        "description": "At The Galleri Classic this year, we're raising awareness about the importance of #cancer screening and the potential of multi-cancer early detection\u00a0testing, in partnership with PGA TOUR Champions winner Steve Stricker and World Golf Hall of Fame member Juli Inkster. Click through to find out more about this year's event. #MCED #GalleriClassic",
        "reactions_count": 35,
        "comments_count": null,
        "reshared_post_author": "Galleri Test",
        "reshared_post_author_url": "https://www.linkedin.com/showcase/galleritest",
        "reshared_post_author_headline": null,
        "reshared_post_description": "GRAIL is partnering with PGA TOUR Champions winner Steve Stricker and World Golf Hall of Fame member Juli Inkster to continue raising awareness around multi-cancer early detection testing\u00a0(#MCED) ahead of The Galleri Classic PGA TOUR Champions Tournament, coming up March 25\u201331. Learn more: https://lnkd.in/gntD_tBP \n\n #GalleriClassic",
        "reshared_post_followers": null,
        "reshared_post_date": "4w",
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 489696224,
        "company_id": 3524741,
        "urn": "urn:li:activity:7155586506705813504",
        "followers": null,
        "date": "1mo",
        "description": "Part 2 of our interview with Krissa Smith from Susan G. Komen on #TheCancerSignal podcast unravels how #BRCA and other mutations affect cancer risk and impact families. \n\n?\ufe0fListen now to learn more about genetics and cancer risk \u2013 and how emerging screening technology like multi-cancer early detection can help: https://bit.ly/495cIEB",
        "reactions_count": 62,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 489696225,
        "company_id": 3524741,
        "urn": "urn:li:activity:7153748046235807745",
        "followers": null,
        "date": "1mo",
        "description": "The American Cancer Society released its Cancer Facts & Figures 2024 report \u2013 for the first time, it is estimated that more than 2 million new cancer cases will be diagnosed in the US this year. \n\nAdding multi-cancer early detection (#MCED) testing to standard cancer screenings is a proactive way to screen for the deadliest cancers, including those that don\u2019t have recommended screening tests.",
        "reactions_count": 76,
        "comments_count": 1,
        "reshared_post_author": "American Cancer Society",
        "reshared_post_author_url": "https://www.linkedin.com/company/american-cancer-society",
        "reshared_post_author_headline": null,
        "reshared_post_description": "The American Cancer Society Cancer Facts & Figures 2024 report is here\u00a0with data detailing the current cancer burden in the US,\u00a0progress that\u2019s been made, and what preventive steps you can take to help reduce your cancer risk. Deep dive into this report to equip yourself, health professionals, educators, and policy makers with discussion points to effectively advocate for people facing cancer.\u00a0\nWith breast, prostate, colorectal (ages 0-54), and cervical (ages 30-44) cancers on the rise, it's important to get screened. Hear more from our CEO Dr. Karen Knudsen.\nFull report: https://lnkd.in/gRkVKQh5",
        "reshared_post_followers": null,
        "reshared_post_date": "1mo",
        "last_updated": "2024-03-22 00:56:06",
        "deleted": 1
      },
      {
        "id": 515894572,
        "company_id": 3524741,
        "urn": "urn:li:activity:7172988428068864000",
        "followers": null,
        "date": "1w",
        "description": "Happy 8th birthday GRAIL! Last week we celebrated GRAIL\u2019s birthday with employees from coast to coast and with those working remotely. We reflected on the milestones that make up our rich history and heard from many GRAILers who have been a part of GRAIL\u2019s evolution over the past several years. \n\nThank you to our teams for your unwavering commitment to our mission and for making everything we do possible!",
        "reactions_count": 345,
        "comments_count": 6,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 515894573,
        "company_id": 3524741,
        "urn": "urn:li:activity:7176625877701529601",
        "followers": null,
        "date": "7h",
        "description": "Improved cancer screening protocols are helping decrease the number of deaths due to colorectal cancer, but the number remains far too high. Listen to this episode of #TheCancerSignal podcast to learn more about the positive impact of early detection for #ColorectalCancer patients: https://bit.ly/4bWLFxD",
        "reactions_count": 55,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 515894574,
        "company_id": 3524741,
        "urn": "urn:li:activity:7175893354788855809",
        "followers": null,
        "date": "2d",
        "description": "When reflecting on her leadership style, GRAIL SVP Linda Peters comes back to the importance of mentorship. She credits the mentors who helped make her a leader, and passes on what she\u2019s learned to the next generation of rising stars. This #WomensHistoryMonth, we\u2019re grateful to her and all the other women at GRAIL dedicated to our mission of detecting cancer early, when it can be cured. #GRAILproud",
        "reactions_count": 121,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 515894575,
        "company_id": 3524741,
        "urn": "urn:li:activity:7175479832456122369",
        "followers": null,
        "date": "3d",
        "description": "GRAIL announced today that participants from Japan, via a collaboration with AstraZeneca, will have their samples tested using GRAIL\u2019s novel risk classification test on its Methylation Platform. This assay has been validated for recurrence risk classification in newly diagnosed Stage I lung adenocarcinoma.\n\nRead more about the collaboration: https://bit.ly/3PNTFHV",
        "reactions_count": 277,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 515894576,
        "company_id": 3524741,
        "urn": "urn:li:activity:7174430664140722178",
        "followers": null,
        "date": "6d",
        "description": "An important part of GRAIL's recent birthday celebration was to spend time together giving back to those impacted by cancer. Across sites and remotely, we supported local cancer charities by filling wellness gift bags and writing letters of encouragement for cancer patients, and assembling rocking chairs to give to children with cancer. As we look back at how far we have come, we are also dedicated to giving forward to the cancer community. #GRAILproud",
        "reactions_count": 149,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 515894577,
        "company_id": 3524741,
        "urn": "urn:li:activity:7173718974365396995",
        "followers": null,
        "date": "1w",
        "description": "#ColorectalCancer has a 5-year relative survival rate of about 90% when found early \u2013 but only about 4 out of 10 colorectal cancers are diagnosed at this early stage. \n\nAdding multi-cancer early detection testing could play a role in changing this trend. Learn more about the impact of #MCED testing: \nhttps://lnkd.in/dURYxZc5\n\n#ColorectalCancerAwarenessMonth",
        "reactions_count": 112,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 515894578,
        "company_id": 3524741,
        "urn": "urn:li:activity:7173372440906055682",
        "followers": null,
        "date": "1w",
        "description": "We\u2019re thrilled to share GRAIL's CEO, Bob Ragusa, was recognized with the 2023 Life Sciences Voice Top Industry Leaders Award. His exceptional and influential leadership plays a key role in our work to redefine the status quo in cancer detection. \n\nCongratulations to Bob and his fellow award winners for this achievement: https://lnkd.in/gWEC7cr3\n\n#LifeSciencesLeaders #HealthcareLeadership #MultiCancerEarlyDetection",
        "reactions_count": 102,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 515894579,
        "company_id": 3524741,
        "urn": "urn:li:activity:7171910137052385281",
        "followers": null,
        "date": "1w",
        "description": "This #WomensHistoryMonth, we're featuring women at GRAIL who embody character, courage and commitment - our key focus areas this month. For Tieming Ji, mentorship has been key to living these values throughout her career. Now she brings that same dedication to leading a biostatistics team at GRAIL. #GRAILproud #InternationalWomensDay",
        "reactions_count": 49,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 515894580,
        "company_id": 3524741,
        "urn": "urn:li:activity:7171271804047585280",
        "followers": null,
        "date": "2w",
        "description": "Meet our legendary ambassadors representing the Galleri multi-cancer early detection test ahead of the second annual #GalleriClassic tournament March 25\u201331.\n\nSteve Stricker is a 17-time PGATOUR Champions winner and the 2023 PGA TOUR Champions Player of the Year.\n\nJuli Inkster is an Ladies Professional Golf Association (LPGA) and World Golf Hall of Fame member and 31-time winner on the LPGA Tour, including seven major championships.\n\nSteve and Juli are partnering with GRAIL to raise awareness about the\nimportance of adding the Galleri multi-cancer early detection test, a new proactive tool for screening for cancer early, to your recommended screenings.\n\nTo learn more about Galleri and see Important Safety Information, visit Galleri.com.\n\nRx only. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests.\n\n#PGAtour #GalleriClassic #pgatourchampions #desertgolf #GalleriTest",
        "reactions_count": 67,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 515894581,
        "company_id": 3524741,
        "urn": "urn:li:activity:7171182892142784516",
        "followers": null,
        "date": "2w",
        "description": "\u201cThere was no indication in my regular panel, bloodwork or physical that showed any signs of this.\u201d\n\nAt a routine appointment, Jonathan\u2019s doctor suggested he take a multi-cancer early detection (MCED) test, even though he had no symptoms. Jonathan shares the unexpected results, and what happened next.",
        "reactions_count": 145,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-04-11 03:33:53",
        "deleted": 1
      },
      {
        "id": 536016733,
        "company_id": 3524741,
        "urn": "urn:li:activity:7172988428068864000",
        "followers": null,
        "date": "1mo",
        "description": "Happy 8th birthday GRAIL! Last week we celebrated GRAIL\u2019s birthday with employees from coast to coast and with those working remotely. We reflected on the milestones that make up our rich history and heard from many GRAILers who have been a part of GRAIL\u2019s evolution over the past several years. \n\nThank you to our teams for your unwavering commitment to our mission and for making everything we do possible!",
        "reactions_count": 383,
        "comments_count": 6,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 536016734,
        "company_id": 3524741,
        "urn": "urn:li:activity:7183867097683251201",
        "followers": null,
        "date": "10h",
        "description": "A #cancer diagnosis can be life-changing \u2013 personally, emotionally, and even economically. At #NCCN2024, we presented a study in collaboration with the National Coalition for Cancer Survivorship on how cancer affects employment and productivity. \n\nSee the full poster: https://bit.ly/3U9vCFN",
        "reactions_count": 95,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 536016735,
        "company_id": 3524741,
        "urn": "urn:li:activity:7183516549759021056",
        "followers": null,
        "date": "1d",
        "description": "We presented three abstracts at #AACR24, covering a range of data findings: \n\n\u27a1\ufe0f The first real-world evaluation of repeat multi-cancer early detection (MCED), 10-18 months from initial MCED testing \n\n\u27a1\ufe0f 4-year overall survival follow-up results showing the prognostic significance of detecting cancer with a methylation-based cfDNA platform\n\n\u27a1\ufe0f Results exhibiting the power of our MCED test to preferentially detect high grade, clinically significant prostate cancer over indolent cases. \n\nThese data further support the potential of our Methylation Platform to transform cancer screening and reiterate the potential benefits of population-scale asymptomatic (or early) cancer detection. \n\nAdditionally, our own Christina Clarke Dur, PhD, MPH participated in a panel on how the industry is currently conceptualizing cancer risk in the setting of current cancer screening guidelines and how the introduction of new single and multi-cancer early detection technologies may warrant a shift in thinking.\n\nTo learn more about GRAIL at AACR 2024, visit: https://bit.ly/4aN8kuR",
        "reactions_count": 154,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 536016736,
        "company_id": 3524741,
        "urn": "urn:li:activity:7182119068768829440",
        "followers": null,
        "date": "5d",
        "description": "April is Cancer Prevention and Early Detection Month! Routine screenings can mean better outcomes for your health\u2014that means more treatment options, more healthy days ahead and more time with the people you love. Learn more: https://bit.ly/3VFUuG6",
        "reactions_count": 107,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 536016737,
        "company_id": 3524741,
        "urn": "urn:li:activity:7181698376353116161",
        "followers": null,
        "date": "6d",
        "description": "Multi-cancer early detection testing is a new approach to finding cancer early. Learn more: https://bit.ly/49mKgxJ",
        "reactions_count": 104,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 536016738,
        "company_id": 3524741,
        "urn": "urn:li:activity:7180963274060963841",
        "followers": null,
        "date": "1w",
        "description": "We\u2019re excited to announce the Galleri multi-cancer early detection test is part of Symetra Life Insurance Company\u2019s new Cancer Care Compass\u2120 rider package, offering more people access to a comprehensive collection of services designed to help them live their longest, healthiest life.\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri should be used in addition to healthcare provider recommended screening tests. See Important Safety Information at https://lnkd.in/d_fp9JR5",
        "reactions_count": 129,
        "comments_count": 5,
        "reshared_post_author": "Symetra",
        "reshared_post_author_url": "https://www.linkedin.com/company/symetra",
        "reshared_post_author_headline": null,
        "reshared_post_description": "We\u2019re excited to introduce our latest innovation\u2014Symetra\u2019s Cancer Care Compass, a first-of-its-kind life insurance rider package offering a unique combination of cancer care benefits and services to help our customers live longer and healthier lives. Read our press release to learn more about this industry-first offering: https://ow.ly/W7IY50R612M",
        "reshared_post_followers": null,
        "reshared_post_date": "1w",
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 536016739,
        "company_id": 3524741,
        "urn": "urn:li:activity:7180605602232991745",
        "followers": null,
        "date": "1w",
        "description": "Identifying and analyzing DNA shed by #cancer cells can help screen for some of the deadliest cancers that don\u2019t have recommended screening today. Learn more about a new approach to finding cancer early: https://bit.ly/49pMsET",
        "reactions_count": 97,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 536016740,
        "company_id": 3524741,
        "urn": "urn:li:activity:7179465605987586051",
        "followers": null,
        "date": "1w",
        "description": "Steve Stricker, one of the Galleri ambassadors at this year\u2019s The Galleri Classic knows it\u2019s important to be proactive about your health. That\u2019s why he took the Galleri test at our mobile pod here at the tournament.\n\nThe Galleri test can be done as a simple annual blood test that screens for a \"fingerprint\" of some of the deadliest cancers before they become symptomatic.\n\nWhether you\u2019re here at the tournament or following along from home, consider speaking to your doctor about multi-cancer early detection testing and the Galleri test.\n\nTo learn more and see Important Safety Information, visit https://lnkd.in/e8uAV9CW.\n\nRx only. Galleri should be used in addition to recommended screening tests. The Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.",
        "reactions_count": 120,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 536016741,
        "company_id": 3524741,
        "urn": "urn:li:activity:7179162224840601600",
        "followers": null,
        "date": "1w",
        "description": "\u201cMy mother passed away at age 52 from cancer, so as I had just turned 50 I decided it was my turn to take the test.\u201d\n\nJennifer's proactive approach to multi-cancer early detection testing with her husband, Jonathan, led to an unexpected discovery when he received a \u201ccancer signal detected\u201d result.",
        "reactions_count": 94,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 536016742,
        "company_id": 3524741,
        "urn": "urn:li:activity:7178742569932103681",
        "followers": null,
        "date": "2w",
        "description": "At #AACR24, look out for new data on the clinical utility of our Methylation Platform across the cancer continuum and the impact of multi-cancer early detection testing. \n\nThe new data will highlight the potential of our targeted Methylation Platform across early detection and precision oncology settings. \n\nSee the details here, including three oral presentations from GRAIL: https://lnkd.in/dPSD9Zf2",
        "reactions_count": 127,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-05-12 21:22:22",
        "deleted": 1
      },
      {
        "id": 566625759,
        "company_id": 3524741,
        "urn": "urn:li:activity:7194048163115077634",
        "followers": null,
        "date": "4d",
        "description": "Tune in to the LinkedIn Live discussion \u201cInnovating with Early Cancer Detection in Leading Health Systems: Exploring the role and implementation of multi-cancer early detection (MCED) testing,\u201d where the panelists from Mercy and Providence will discuss how MCED testing works in their health care systems. Click here to RSVP: https://bit.ly/3ybzayH \n\u00a0\n#MCED #CancerScreening",
        "reactions_count": 48,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 566625760,
        "company_id": 3524741,
        "urn": "urn:li:activity:7194750805256617985",
        "followers": null,
        "date": "2d",
        "description": "This week, the Cancer Moonshot shared updates from those in the private sector working to advance cancer screening and prevention. Among the updates was GRAIL's real-world evidence program investigating the use of multi-cancer early detection in addition to recommended cancer screenings. See the full Cancer Moonshot update below and learn more about our research collaboration with the U.S. Department of Veterans Affairs and the Veterans Health Administration: https://bit.ly/44yGyQG",
        "reactions_count": 106,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 566625761,
        "company_id": 3524741,
        "urn": "urn:li:activity:7194384404654215169",
        "followers": null,
        "date": "3d",
        "description": "Our data at #ISPOR2024 investigated the larger emotional and economic impacts of #cancer screening. Here\u2019s what we found:\n\n\u2705 Negative multi-cancer early detection test results may have positive emotional impacts and improve other health behaviors, like adhering to future recommended cancer screening.\n? Cancer screenings improve life expectancy and provide good economic value in many scenarios, particularly among higher risk groups.\n? Existing assessments may underestimate the full value and impacts on society of cancer screenings by only considering certain costs or examining too short a time period.\n? Post-metastasis cancer diagnoses drive up healthcare costs and have lower success treatment rates, indicating that spending on cancer care among certain groups may be substantially reduced if cancers could be diagnosed earlier.\n\nSee the full posters: https://bit.ly/3ufa1Bd",
        "reactions_count": 123,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 566625762,
        "company_id": 3524741,
        "urn": "urn:li:activity:7193960340676628480",
        "followers": null,
        "date": "4d",
        "description": "Diagnosing ovarian cancer early can improve the five-year survival rate for patients. Learn more from World Ovarian Cancer Coalition: https://bit.ly/2R5xMs1 \n\n#WorldOvarianCancerDay",
        "reactions_count": 84,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 566625763,
        "company_id": 3524741,
        "urn": "urn:li:activity:7193622366294355970",
        "followers": null,
        "date": "5d",
        "description": "?\ufe0f Don\u2019t miss the latest episode of The Cancer SIGNAL: https://lnkd.in/e5yumdj8 \n\nJonathon Rendina, PhD, MPH and Dwight Venson from Whitman-Walker discuss the disparities faced by LGBTQ+ people when seeking cancer screening. \n\nThe INCLUDE study, a collaboration between Whitman-Walker, Cancer Support Community and GRAIL, aims to discover the impact of offering multi-cancer early detection testing to people at a federally qualified health center. Hear more about Whitman-Walker\u2019s work and the INCLUDE study in the full episode.\n\nApple Podcasts: https://apple.co/3W0dso3\nSpotify: https://spoti.fi/3T8pay9  \nAmazon Music: https://amzn.to/3PbZAom",
        "reactions_count": 50,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 566625764,
        "company_id": 3524741,
        "urn": "urn:li:activity:7193281128294666243",
        "followers": null,
        "date": "6d",
        "description": "In 2024, more than 2 million new cancer cases are expected to be  diagnosed in the US, according to the American Cancer Society. \n\nMulti-cancer early detection testing can help screen for many of the deadliest cancers that don\u2019t have recommended screenings today. Finding particularly deadly cancers early may offer a chance to improve outcomes. \n\nLearn more about MCED: https://lnkd.in/gZvZZ6gS",
        "reactions_count": 58,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 566625765,
        "company_id": 3524741,
        "urn": "urn:li:activity:7191085164880441344",
        "followers": null,
        "date": "1w",
        "description": "Making #cancer screening more equitable could have a significant impact on outcomes for people in minority groups. In honor of #NationalMinorityHealthMonth, we\u2019re looking back at episodes of #TheCancerSignal podcast where we explored the challenges of health disparities: \n\n?\ufe0f Episode 6 highlights the importance of colorectal cancer screening in the Black community: https://lnkd.in/eQPKCq3c\n\n?\ufe0f Dr. Gary Puckrein of the National Minority Quality Forum joins episode 8 to discuss how disparities in care lead to inequitable cancer outcomes: https://lnkd.in/eBmjAwh3\n\n?\ufe0f Melissa Buffalo of the American Indian Cancer Foundation takes a closer look at the cancer burden faced by Native Americans and efforts to reduce disparities in episode 12: https://lnkd.in/euCRAj4u\n\n?\ufe0f Episode 17 addresses the lower prevalence of genetic testing among people of color in the U.S., creating barriers to proactive screening: https://lnkd.in/ev-sVtEZ\n\n?\ufe0f Episode 19 showcases how inequities can begin at the clinical trial level, and how newer clinical trials are working to counteract these biases: https://lnkd.in/eqvkrtjb",
        "reactions_count": 51,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 566625766,
        "company_id": 3524741,
        "urn": "urn:li:activity:7189635855207014400",
        "followers": null,
        "date": "2w",
        "description": "MDEdge interviewed Ora Gordon, M.D, M.S., FACMG about her #AACR24 session on the potential impact of repeat multi-cancer early detection (MCED) testing. \n\nRead the article: https://lnkd.in/eVtWgP_Z\n\n\u201cIt is still early, and the numbers are very small, but the detection of early-stage cancers with second annual testing is very encouraging as these are the cases where MCED testing could have the greatest impact in improving outcomes through earlier treatment,\u201d shares Dr. Gordon.",
        "reactions_count": 62,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 566625767,
        "company_id": 3524741,
        "urn": "urn:li:activity:7189309119248355330",
        "followers": null,
        "date": "2w",
        "description": "\u201cI didn\u2019t worry a bit. I was positive I was picture-perfect healthy.\u201d\n\nAt a routine check-up, David\u2019s doctor recommended he take a multi-cancer early detection (MCED) test, even though he showed no symptoms. His test showed a \u201cCancer Signal Detected\u201d result, leading to additional tests and a cancer diagnosis. David shares how his life has \u2013 and hasn\u2019t \u2013 changed since.",
        "reactions_count": 105,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 566625768,
        "company_id": 3524741,
        "urn": "urn:li:activity:7188549954003423232",
        "followers": null,
        "date": "2w",
        "description": "Though cancer is being treated far more effectively, healthcare professionals can\u2019t treat what hasn\u2019t been found. While recommended screenings look for five specific cancers today, nearly 70% of deaths are caused by cancers without a recommended screening. Advancing the science and adoption of multi-cancer early detection (MCED) testing is an urgent priority. \n\nLearn more about MCED: https://bit.ly/4amRFOL",
        "reactions_count": 128,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-06-21 16:01:37",
        "deleted": 1
      },
      {
        "id": 619783051,
        "company_id": 3524741,
        "urn": "urn:li:activity:7194048163115077634",
        "followers": null,
        "date": "1mo",
        "description": "Tune in to the LinkedIn Live discussion \u201cInnovating with Early Cancer Detection in Leading Health Systems: Exploring the role and implementation of multi-cancer early detection (MCED) testing,\u201d where the panelists from Mercy and Providence will discuss how MCED testing works in their health care systems. Click here to RSVP: https://bit.ly/3ybzayH \n\u00a0\n#MCED #CancerScreening",
        "reactions_count": 126,
        "comments_count": 20,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 619783052,
        "company_id": 3524741,
        "urn": "urn:li:activity:7207418779587280896",
        "followers": null,
        "date": "22h",
        "description": "#MensHealthMonth can serve as a reminder that men are at higher risk for several types of cancer, including colorectal cancer.\n\nScreening technology and recommendations are evolving. Learn more: https://bit.ly/4chfmZF",
        "reactions_count": 39,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 619783053,
        "company_id": 3524741,
        "urn": "urn:li:activity:7205971236504383489",
        "followers": null,
        "date": "4d",
        "description": "Rich believes in being proactive about his health, from eating a balanced diet to exercising regularly. So when he had the chance to take a multi-cancer early detection test, it was an easy decision.\n\nHowever, Rich screened positive, meaning DNA fragments that act like a unique \"fingerprint\" of cancer had been detected. After diagnostic evaluation, he was diagnosed with cancer.",
        "reactions_count": 78,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 619783054,
        "company_id": 3524741,
        "urn": "urn:li:activity:7203789621703442432",
        "followers": null,
        "date": "1w",
        "description": "The LGBTQ+ community faces critical barriers to cancer screenings, from cost to fear of discrimination from healthcare providers. On The Cancer SIGNAL podcast, Dr. Scout, Executive Director of the National LGBT Cancer Network, shares insights into initiatives to reduce disparities in LGBTQ+ cancer screening: https://bit.ly/3RbIdX4\n\n#PrideMonth",
        "reactions_count": 44,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 619783055,
        "company_id": 3524741,
        "urn": "urn:li:activity:7203084216480215040",
        "followers": null,
        "date": "1w",
        "description": "GRAILers and colleagues joined the Lurie Cancer Center for their 31st annual Cancer Survivors\u2019 Celebration Walk & 5K Grant Park\u2019s Arvey Field. Thanks to all who participated! #NCSD2024 #LurieCelebrates",
        "reactions_count": 188,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 619783056,
        "company_id": 3524741,
        "urn": "urn:li:activity:7203019187009507328",
        "followers": null,
        "date": "1w",
        "description": "As we commemorate National Cancer Survivors Day today, we\u2019re spotlighting survivor stories in which multi-cancer early detection testing played a role.\nThese stories drive us in our mission to detect cancer early, when it can be cured. #NCSD2024 #ASCO24",
        "reactions_count": 102,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 619783057,
        "company_id": 3524741,
        "urn": "urn:li:activity:7202742204430172161",
        "followers": null,
        "date": "1w",
        "description": "At #ASCO24, we shared data showing that among Medicare patients, adding multi-cancer early detection testing may increase diagnostic efficiency and reduce the time to cancer diagnosis. Read the poster: https://bit.ly/3X5v4Tb",
        "reactions_count": 213,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 619783058,
        "company_id": 3524741,
        "urn": "urn:li:activity:7202672904352714752",
        "followers": null,
        "date": "2w",
        "description": "At #ASCO24, we are sharing data from our PATHFINDER clinical trial demonstrating that adding multi-cancer early detection testing led to diagnosis of cancer recurrence and new primary cancers in cancer survivors at least three years after their initial diagnosis. \n\nOur Senior Medical Director Dr. Jordan Karlitz MD, FACG, AGAF shares more in this video. See the full poster: https://bit.ly/3V7XhWO",
        "reactions_count": 133,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 619783059,
        "company_id": 3524741,
        "urn": "urn:li:activity:7202402573205594112",
        "followers": null,
        "date": "2w",
        "description": "Cindy had no symptoms or health concerns, but as a carrier of a BRCA1 genetic mutation, she agreed when her OBGYN recommended she take a multi-cancer early detection test. When the result showed a Cancer Signal Detected, she was referred to an Adventist Health oncologist, who confirmed an early stage cancer diagnosis after additional testing. See her story.",
        "reactions_count": 70,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 619783060,
        "company_id": 3524741,
        "urn": "urn:li:activity:7201676766648619010",
        "followers": null,
        "date": "2w",
        "description": "GRAIL was honored to host the leadership of the National Medical Association for a lab tour and visit to discuss the promise of MCED technologies in reducing the cancer burden for everyone.",
        "reactions_count": 61,
        "comments_count": null,
        "reshared_post_author": "National Medical Association",
        "reshared_post_author_url": "https://www.linkedin.com/company/national-medical-association",
        "reshared_post_author_headline": null,
        "reshared_post_description": "The National Medical Association (NMA) recently met with GRAIL senior leadership and toured their state-of-the-art lab in Menlo Park, California. GRAIL, a leading biotechnology company, is at the forefront of developing multi-cancer early detection tests. During the visit the NMA leadership reiterated the need for prevention, screening and early detection for all but specifically with minority communities. This NMA and GRAIL reaffirmed the shared mission of advancing healthcare equity and improving cancer detection and access to innovation for all.\n\n#NationalMedicalAssociation #GRAIL #Biotechnology #CancerScreening #HealthcareInnovation #MedicalAdvancements #EarlyDetection #HealthcareEquity #MenloPark #NMAMeeting #CancerAwareness #mced",
        "reshared_post_followers": null,
        "reshared_post_date": "3w",
        "last_updated": "2024-07-25 13:38:22",
        "deleted": 1
      },
      {
        "id": 657334200,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211101105311666177",
        "followers": null,
        "date": "1mo",
        "description": "Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9",
        "reactions_count": 724,
        "comments_count": 22,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 657334201,
        "company_id": 3524741,
        "urn": "urn:li:activity:7220090856454635520",
        "followers": null,
        "date": "5d",
        "description": "When Valerie first read about multi-cancer early detection testing she became intrigued by its potential. Even though she felt healthy, she decided to get tested. Her surprising Cancer Signal Detected result led to follow-up exams that helped doctors diagnose her with cancer.\n\nValerie shares how early detection affected her experiences \u2013 here: https://bit.ly/4cNAPd6 #CancerScreening",
        "reactions_count": 64,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 657334202,
        "company_id": 3524741,
        "urn": "urn:li:activity:7219689878375075842",
        "followers": null,
        "date": "1w",
        "description": "Today we\u2019re announcing the first participant enrolled in our Real-world Evidence to Advance Multi-Cancer Early Detection Health Equity (REACH) Galleri-Medicare study at Community Health Network. We\u2019re evaluating the clinical impact of our multi-cancer early detection (MCED) test in the Medicare population, including racial and ethnic minorities and seniors from historically under-served communities. \n\nThe three-year, multi-center study will evaluate and compare up to 50,000 Medicare beneficiaries who have received usual care plus an annual MCED test, in addition to recommended cancer screenings, with others who will not receive an annual MCED test. Medicare will cover the costs of MCED testing and routine items and services for study participants.\n\nWith more than half of all cancer diagnoses among seniors, our commitment at GRAIL is to provide broad, equitable MCED test access to groups that are at the highest risk and underrepresented in clinical research \u2013 including the Medicare population.\n\nRead more about the news: https://bit.ly/3Wsdeci",
        "reactions_count": 309,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 657334203,
        "company_id": 3524741,
        "urn": "urn:li:activity:7219025513871278081",
        "followers": null,
        "date": "1w",
        "description": "We are excited to share the Journal of Thoracic Oncology has published a study supporting a methylation-based cell-free DNA assay in a cohort of patients with resectable stage I-II NSCLC. Read more about the findings:  https://bit.ly/3WqgKUo",
        "reactions_count": 92,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 657334204,
        "company_id": 3524741,
        "urn": "urn:li:activity:7218662369814548480",
        "followers": null,
        "date": "1w",
        "description": "Clinical trials update: We\u2019ve completed planned enrollment for the PATHFINDER 2 study and the third and final round of study visits for the NHS-Galleri trial.\n\nBoth studies successfully enrolled a diverse population, with participants representing various socio-economic, ethnic, gender and age groups. Learn more: https://bit.ly/4bDJZHW",
        "reactions_count": 212,
        "comments_count": 8,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 657334205,
        "company_id": 3524741,
        "urn": "urn:li:activity:7216124473547128834",
        "followers": null,
        "date": "2w",
        "description": "After reading about multi-cancer early detection testing, Roger spoke to his healthcare provider to learn more. Because he had no symptoms, he didn\u2019t expect the news that his test had yielded a Cancer Signal Detected result.\n\nLearn how proactive screening changed Roger's #cancer journey: https://bit.ly/3xNV0Zg",
        "reactions_count": 97,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 657334206,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211821883913048067",
        "followers": null,
        "date": "4w",
        "description": "CEO Bob Ragusa joined proud GRAIL employees in Times Square yesterday to celebrate this significant milestone for our company. #NasdaqListed $GRAL",
        "reactions_count": 829,
        "comments_count": 11,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 657334207,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211353783379849216",
        "followers": null,
        "date": "1mo",
        "description": "Today GRAIL is joining #NasdaqListed as $GRAL. The hard work and dedication of all GRAILers has made this achievement possible. We are fortunate to have each of you on this journey with us. \n\nLearn more: investors.grail.com",
        "reactions_count": 299,
        "comments_count": 7,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 657334208,
        "company_id": 3524741,
        "urn": "urn:li:activity:7209600058239918080",
        "followers": null,
        "date": "1mo",
        "description": "Rich, a devoted father from New Jersey, always prioritized staying healthy for his family. When his doctor suggested he take a multi-cancer early detection (MCED) test, a screening tool that allows doctors to screen for many of the deadliest cancers, including those with no recommended screening tests, he was on board. \n\nDespite having no symptoms and no family history of cancer, Rich received a Cancer Signal Detected result with predicted Cancer Signal Origin to help guide next steps.",
        "reactions_count": 129,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 657334209,
        "company_id": 3524741,
        "urn": "urn:li:activity:7209222011473010688",
        "followers": null,
        "date": "1mo",
        "description": "#Juneteenth is a day of deep significance, and at GRAIL we proudly observe it as a company holiday. We encourage our employees to take a moment to reflect on the history and importance of this day. #GRAILproud",
        "reactions_count": 64,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-08-15 03:57:19",
        "deleted": 1
      },
      {
        "id": 676335351,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211101105311666177",
        "followers": null,
        "date": "1mo",
        "description": "Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9",
        "reactions_count": 734,
        "comments_count": 22,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 676335352,
        "company_id": 3524741,
        "urn": "urn:li:activity:7229217666870231041",
        "followers": null,
        "date": "1d",
        "description": "Today GRAIL reported Q2 2024 financial results. Read more: https://bit.ly/3M38DqT",
        "reactions_count": 21,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 676335353,
        "company_id": 3524741,
        "urn": "urn:li:activity:7227669277154103297",
        "followers": null,
        "date": "5d",
        "description": "In randomized controlled trials (RCTs) of #cancer screening, late-stage cancer incidence may function as an early surrogate for mortality. \n\nA new review of 33 RCTs finds a strong linear association between late-stage cancer incidence and mortality, offering a potential alternative endpoint that could provide useful results in less time. Read more here: https://lnkd.in/g4w3n4NN",
        "reactions_count": 94,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 676335354,
        "company_id": 3524741,
        "urn": "urn:li:activity:7226596808951541763",
        "followers": null,
        "date": "1w",
        "description": "Welcome Susanna Quinn  \u2013 the new host of The Cancer SIGNAL podcast! https://bit.ly/3WBF18V\n\nSusanna, an ovarian cancer survivor and advocate, is passionate about GRAIL\u2019s mission of detecting cancer early, when it can be cured. To introduce us, the Cancer SIGNAL\u2019s inaugural host Kim Thiboldeaux interviews Susanna about her cancer story and how it\u2019s shaped her outlook on life and health.",
        "reactions_count": 37,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 676335355,
        "company_id": 3524741,
        "urn": "urn:li:activity:7224803343901097985",
        "followers": null,
        "date": "1w",
        "description": "Proactive screening plays a vital role in detecting #LungCancer and other cancers early, when they are often easier to treat.  This #WorldLungCancerDay, learn more about the screening guidelines and some of the available tools from American Cancer Society: https://bit.ly/3WkaLiU",
        "reactions_count": 44,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 676335356,
        "company_id": 3524741,
        "urn": "urn:li:activity:7224508377253527552",
        "followers": null,
        "date": "2w",
        "description": "We will issue financial results for the second quarter 2024 on Tuesday, August 13, 2024. Register for the live teleconference on https://bit.ly/3SynZr7. \n\nSee more details: https://bit.ly/3Yr28FJ",
        "reactions_count": 64,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 676335357,
        "company_id": 3524741,
        "urn": "urn:li:activity:7224125366976573440",
        "followers": null,
        "date": "2w",
        "description": "? We are thrilled to announce Susanna Quinn is joining The Cancer SIGNAL podcast as our new host! As a cancer survivor, entrepreneur, writer and philanthropist, Susanna will bring her experience and perspectives to these conversations around early cancer detection. Subscribe now to get notifications for new episodes! \n\nhttps://bit.ly/4c42Mwb \n\n#HealthCarePodcast #CancerEducation",
        "reactions_count": 83,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 676335358,
        "company_id": 3524741,
        "urn": "urn:li:activity:7223745120750198784",
        "followers": null,
        "date": "2w",
        "description": "Our talented summer interns are making a real impact across various departments, while also finding time to give back to their communities. We are incredibly proud of their achievements and grateful for their dedication in driving innovative projects forward. \n\n#GRAILproud #Internship",
        "reactions_count": 141,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 676335359,
        "company_id": 3524741,
        "urn": "urn:li:activity:7222642836570062848",
        "followers": null,
        "date": "2w",
        "description": "Novel cancer screening technologies, like multi-cancer early detection (MCED) tests, hold great promise for reducing the burden of late-stage cancers and related cancer mortality, but new approaches are required to evaluate their effectiveness.\n\nSir Harpal Kumar, President of GRAIL Europe, shares his perspective in Molecular  Oncology as to why innovative trial designs with earlier endpoints are needed to demonstrate the potential benefits of novel screening technologies, like MCEDs, more rapidly.\n\nRead the publication to learn more: https://bit.ly/4c0C7jG",
        "reactions_count": 80,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 676335360,
        "company_id": 3524741,
        "urn": "urn:li:activity:7220090856454635520",
        "followers": null,
        "date": "3w",
        "description": "When Valerie first read about multi-cancer early detection testing she became intrigued by its potential. Even though she felt healthy, she decided to get tested. Her surprising Cancer Signal Detected result led to follow-up exams that helped doctors diagnose her with cancer.\n\nValerie shares how early detection affected her experiences \u2013 here: https://bit.ly/4cNAPd6 #CancerScreening",
        "reactions_count": 88,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-15 14:35:32",
        "deleted": 1
      },
      {
        "id": 726797117,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211101105311666177",
        "followers": null,
        "date": "2mo",
        "description": "Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9",
        "reactions_count": 745,
        "comments_count": 23,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 726797118,
        "company_id": 3524741,
        "urn": "urn:li:activity:7240310325701419008",
        "followers": null,
        "date": "2d",
        "description": "At #ESMO24, GRAIL will be presenting a variety of data centered on enhancing our knowledge of multi-cancer early detection (MCED) testing, as well as on use of GRAIL technology in pharma research applications. Visit us at our posters and presentations! \n\nInterested in meeting and learning more about biopharma partnership opportunities? Reach out at PharmaBD@grailbio.com",
        "reactions_count": 48,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 726797119,
        "company_id": 3524741,
        "urn": "urn:li:activity:7240043084460253184",
        "followers": null,
        "date": "2d",
        "description": "For firefighters, the battle doesn\u2019t end when the fire is out. Health risks such as cancer are a constant concern, but new tools may be able to help. The Chicago Fire Department shares how tools like multi-cancer early detection (MCED) testing are helping them stay ahead of these unseen dangers.  \n \nLearn more: https://bit.ly/47vdew3\n \n#MCED #CancerScreening",
        "reactions_count": 55,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 726797120,
        "company_id": 3524741,
        "urn": "urn:li:activity:7236767432579694592",
        "followers": null,
        "date": "1w",
        "description": "Join us at #WorldCDx as Eric Fung, MD, PhD, SVP of Clinical Development, shares how GRAIL\u2019s tissue-free methylation platform is uniquely positioned to revolutionize cancer care. Dr. Fung will present new data demonstrating utility across the patient care continuum to advance biopharma therapeutic strategies.\n\nContact us at PharmaBD@grailbio.com to learn about partnership opportunities.\n\n#PrecisionOncology",
        "reactions_count": 78,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 726797121,
        "company_id": 3524741,
        "urn": "urn:li:activity:7235019682448035840",
        "followers": null,
        "date": "2w",
        "description": "JCO Precision Oncology has published our findings that clinical utility of our multi-cancer early detection (MCED) test preferentially detects a cancer signal in the presence of high-grade (aggressive) and high stage, clinically significant prostate cancer over slow-growing cases. \n\nThis analysis reinforces the potential of MCED to minimize the overdiagnosis of prostate cases that may not need treatment.\n\nLearn more about the data: https://bit.ly/3TafgvI\n\nBased on a clinical study of people ages 50 to 79, around 1% are expected to receive a cancer signal detected result which includes predicted Cancer Signal Origin(s). After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis. The overall sensitivity in study participants with prostate cancer was 11.2% (3.2% for stage I, 4.9% stage II, 14.0% stage III, 83.3% stage IV).",
        "reactions_count": 103,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 726797122,
        "company_id": 3524741,
        "urn": "urn:li:activity:7234623611699912704",
        "followers": null,
        "date": "2w",
        "description": "After facing cancer, Tami became a passionate advocate for early screening. She and her family joined GRAIL\u2019s PATHFINDER study on multi-cancer early detection (MCED) testing. \n\nTami shares her experiences with cancer and MCED testing: https://bit.ly/4dxhYDH",
        "reactions_count": 56,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 726797123,
        "company_id": 3524741,
        "urn": "urn:li:activity:7234217631895928834",
        "followers": null,
        "date": "2w",
        "description": "GRAIL was thrilled to \"GET LOUD\" at Silicon Valley Pride again this year! Thanks to our volunteers and everyone at #SVpride who brought the community together for a special weekend to celebrate diversity, equality and love!",
        "reactions_count": 87,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 726797124,
        "company_id": 3524741,
        "urn": "urn:li:activity:7232101240346714112",
        "followers": null,
        "date": "3w",
        "description": "Keith is a retiree with an engineering background who loves understanding how things work. He was eager to speak to his healthcare provider about multi-cancer early detection testing (MCED). \n\nKeith shares his experiences \u2013 and why he finds the possibilities of MCED so exciting \u2013 in this video: https://bit.ly/3L6ZUUf",
        "reactions_count": 53,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 726797125,
        "company_id": 3524741,
        "urn": "urn:li:activity:7229217666870231041",
        "followers": null,
        "date": "1mo",
        "description": "Today GRAIL reported Q2 2024 financial results. Read more: https://bit.ly/3M38DqT",
        "reactions_count": 35,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 726797126,
        "company_id": 3524741,
        "urn": "urn:li:activity:7227669277154103297",
        "followers": null,
        "date": "1mo",
        "description": "In randomized controlled trials (RCTs) of #cancer screening, late-stage cancer incidence may function as an early surrogate for mortality. \n\nA new review of 33 RCTs finds a strong linear association between late-stage cancer incidence and mortality, offering a potential alternative endpoint that could provide useful results in less time. Read more here: https://lnkd.in/g4w3n4NN",
        "reactions_count": 127,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-09-19 14:58:02",
        "deleted": 1
      },
      {
        "id": 730892031,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211101105311666177",
        "followers": null,
        "date": "2mo",
        "description": "Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9",
        "reactions_count": 746,
        "comments_count": 23,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 730892032,
        "company_id": 3524741,
        "urn": "urn:li:activity:7241789252416503808",
        "followers": null,
        "date": "1d",
        "description": "We brought several innovative presentations to #ESMO24, focused on advancing our understanding of how GRAIL technology can be applied in clinical trials, and the impact of multi-cancer early detection (MCED) testing. Here are the highlights from our research:\n \n? Early real-world evidence stresses the importance of persistent workups, particularly in patients with multiple positive tests (e.g., a positive test followed by a negative workup, then a positive retest), where the risk of cancer remains high and requires vigilant follow-up.\n\n? Cell-free DNA analysis reveals that cancer signals may be detectable up to 30 months before diagnosis, opening doors to earlier interventions.\n \n? Participant-reported data suggest that MCED testing helps drive proactive health behaviors, especially among those identified as high risk for cancer.\n \n? Economic and clinical models demonstrate the potential benefits of MCED testing for individuals with hereditary cancer syndromes, with implications for both patient outcomes and healthcare costs.\n \n?Exploratory analysis suggests that measuring circulating tumor DNA (ctDNA) may help identify people with Stage 3 unresectable non-small cell lung cancer (NSCLC) who could benefit from more treatment after radiation therapy.\n \n? Clearance of ctDNA from the blood during treatment could signal improved outcomes in certain bladder cancer patients, serving as a potential marker of treatment success.\n \nGo deeper. Explore our full presentations: https://bit.ly/3XbEQlk",
        "reactions_count": 78,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 730892033,
        "company_id": 3524741,
        "urn": "urn:li:activity:7241093982770847744",
        "followers": null,
        "date": "3d",
        "description": "\u201cOur Cuban culture is all about family, staying close together.\u201d \n\nAs we celebrate #HispanicHeritageMonth, we reflect on the cultural values that shape us. For Cindy, her strong connection to her family drove her to seek proactive cancer screening. \n\nHer story speaks to the importance of prioritizing your health and having a strong family support system. https://bit.ly/44RHQVD",
        "reactions_count": 33,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 730892034,
        "company_id": 3524741,
        "urn": "urn:li:activity:7240310325701419008",
        "followers": null,
        "date": "5d",
        "description": "At #ESMO24, GRAIL will be presenting a variety of data centered on enhancing our knowledge of multi-cancer early detection (MCED) testing, as well as on use of GRAIL technology in pharma research applications. Visit us at our posters and presentations! \n\nInterested in meeting and learning more about biopharma partnership opportunities? Reach out at PharmaBD@grailbio.com",
        "reactions_count": 55,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 730892035,
        "company_id": 3524741,
        "urn": "urn:li:activity:7240043084460253184",
        "followers": null,
        "date": "6d",
        "description": "For firefighters, the battle doesn\u2019t end when the fire is out. Health risks such as cancer are a constant concern, but new tools may be able to help. The Chicago Fire Department shares how tools like multi-cancer early detection (MCED) testing are helping them stay ahead of these unseen dangers.  \n \nLearn more: https://bit.ly/47vdew3\n \n#MCED #CancerScreening",
        "reactions_count": 59,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 730892036,
        "company_id": 3524741,
        "urn": "urn:li:activity:7236767432579694592",
        "followers": null,
        "date": "2w",
        "description": "Join us at #WorldCDx as Eric Fung, MD, PhD, SVP of Clinical Development, shares how GRAIL\u2019s tissue-free methylation platform is uniquely positioned to revolutionize cancer care. Dr. Fung will present new data demonstrating utility across the patient care continuum to advance biopharma therapeutic strategies.\n\nContact us at PharmaBD@grailbio.com to learn about partnership opportunities.\n\n#PrecisionOncology",
        "reactions_count": 79,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 730892037,
        "company_id": 3524741,
        "urn": "urn:li:activity:7235019682448035840",
        "followers": null,
        "date": "2w",
        "description": "JCO Precision Oncology has published our findings that clinical utility of our multi-cancer early detection (MCED) test preferentially detects a cancer signal in the presence of high-grade (aggressive) and high stage, clinically significant prostate cancer over slow-growing cases. \n\nThis analysis reinforces the potential of MCED to minimize the overdiagnosis of prostate cases that may not need treatment.\n\nLearn more about the data: https://bit.ly/3TafgvI\n\nBased on a clinical study of people ages 50 to 79, around 1% are expected to receive a cancer signal detected result which includes predicted Cancer Signal Origin(s). After diagnostic evaluation, around 40% of these people are expected to have a confirmed cancer diagnosis. The overall sensitivity in study participants with prostate cancer was 11.2% (3.2% for stage I, 4.9% stage II, 14.0% stage III, 83.3% stage IV).",
        "reactions_count": 107,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 730892038,
        "company_id": 3524741,
        "urn": "urn:li:activity:7234623611699912704",
        "followers": null,
        "date": "3w",
        "description": "After facing cancer, Tami became a passionate advocate for early screening. She and her family joined GRAIL\u2019s PATHFINDER study on multi-cancer early detection (MCED) testing. \n\nTami shares her experiences with cancer and MCED testing: https://bit.ly/4dxhYDH",
        "reactions_count": 57,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 730892039,
        "company_id": 3524741,
        "urn": "urn:li:activity:7234217631895928834",
        "followers": null,
        "date": "3w",
        "description": "GRAIL was thrilled to \"GET LOUD\" at Silicon Valley Pride again this year! Thanks to our volunteers and everyone at #SVpride who brought the community together for a special weekend to celebrate diversity, equality and love!",
        "reactions_count": 89,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 730892040,
        "company_id": 3524741,
        "urn": "urn:li:activity:7232101240346714112",
        "followers": null,
        "date": "4w",
        "description": "Keith is a retiree with an engineering background who loves understanding how things work. He was eager to speak to his healthcare provider about multi-cancer early detection testing (MCED). \n\nKeith shares his experiences \u2013 and why he finds the possibilities of MCED so exciting \u2013 in this video: https://bit.ly/3L6ZUUf",
        "reactions_count": 53,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-10-15 14:46:42",
        "deleted": 1
      },
      {
        "id": 761503642,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211101105311666177",
        "followers": null,
        "date": "3mo",
        "description": "Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9",
        "reactions_count": 750,
        "comments_count": 23,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 761503643,
        "company_id": 3524741,
        "urn": "urn:li:activity:7246590410230243328",
        "followers": null,
        "date": "2d",
        "description": "?\ufe0f It\u2019s #NationalPodcastDay! Have you subscribed to The Cancer SIGNAL? Check out GRAIL\u2019s podcast where experts, advocates and patients discuss the stories and science behind early cancer detection. From multi-cancer early detection (MCED) testing to cancer genomics, we are exploring the future of cancer screening from a wide variety of perspectives. \n\nListen on Apple, Spotify, Amazon Music or wherever you get your podcasts. https://apple.co/3W0dso3",
        "reactions_count": 23,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 761503644,
        "company_id": 3524741,
        "urn": "urn:li:activity:7244384268678807553",
        "followers": null,
        "date": "1w",
        "description": "Seven in 10 Americans are behind on at least one guideline recommended cancer screening. Jody Hoyos, CEO of the Prevent Cancer Foundation, joins host Susanna Quinn on the latest episode of #TheCancerSignal podcast to discuss cancer screening behaviors and why early cancer detection is so critical for patients. Listen on Apple, Spotify, Amazon Music or wherever you get your podcasts.\n\nhttps://apple.co/3XuNgEo",
        "reactions_count": 32,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 761503645,
        "company_id": 3524741,
        "urn": "urn:li:activity:7244041333751898113",
        "followers": null,
        "date": "1w",
        "description": "National Hereditary Breast and Ovarian Cancer Week highlights the importance of understanding genetic factors in breast cancer and ovarian cancer. \n\nIn this previous podcast episode, we spotlight recent advances in the fight against hereditary breast cancer. Krissa Smith from Susan G. Komen shares about #BRCA gene research, its impact on #BreastCancer risk, and her family\u2019s experience with hereditary breast cancer. \n\nListen on Apple, Spotify, Amazon Music or wherever you get your podcasts.  https://apple.co/3B10W2p  \n\n#HBOCWeek",
        "reactions_count": 44,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 761503646,
        "company_id": 3524741,
        "urn": "urn:li:activity:7242916682149609474",
        "followers": null,
        "date": "1w",
        "description": "A recently published study in Health Affairs explores barriers and facilitators to multi-cancer early detection (MCED) adoption in marginalized communities. Addressing psychological impacts, provider relationships, trust, and accessibility can enhance adoption and advance health equity. \n\nRead more here: https://lnkd.in/gs9nbhXB\n\n#HealthEquity #MCED #CancerScreening",
        "reactions_count": 37,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 761503647,
        "company_id": 3524741,
        "urn": "urn:li:activity:7242581537366401024",
        "followers": null,
        "date": "1w",
        "description": "Results from multi-cancer early detection (MCED) testing led doctors to conduct further testing that diagnosed Dave\u2019s cancer early, allowing him to start treatment before it affected his lifestyle. \n\nLearn more about MCED testing: https://bit.ly/4d8o38q\n\n#BloodCancerAwarenessMonth",
        "reactions_count": 94,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 761503648,
        "company_id": 3524741,
        "urn": "urn:li:activity:7241789252416503808",
        "followers": null,
        "date": "2w",
        "description": "We brought several innovative presentations to #ESMO24, focused on advancing our understanding of how GRAIL technology can be applied in clinical trials, and the impact of multi-cancer early detection (MCED) testing. Here are the highlights from our research:\n \n? Early real-world evidence stresses the importance of persistent workups, particularly in patients with multiple positive tests (e.g., a positive test followed by a negative workup, then a positive retest), where the risk of cancer remains high and requires vigilant follow-up.\n\n? Cell-free DNA analysis reveals that cancer signals may be detectable up to 30 months before diagnosis, opening doors to earlier interventions.\n \n? Participant-reported data suggest that MCED testing helps drive proactive health behaviors, especially among those identified as high risk for cancer.\n \n? Economic and clinical models demonstrate the potential benefits of MCED testing for individuals with hereditary cancer syndromes, with implications for both patient outcomes and healthcare costs.\n \n?Exploratory analysis suggests that measuring circulating tumor DNA (ctDNA) may help identify people with Stage 3 unresectable non-small cell lung cancer (NSCLC) who could benefit from more treatment after radiation therapy.\n \n? Clearance of ctDNA from the blood during treatment could signal improved outcomes in certain bladder cancer patients, serving as a potential marker of treatment success.\n \nGo deeper. Explore our full presentations: https://bit.ly/3XbEQlk",
        "reactions_count": 105,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 761503649,
        "company_id": 3524741,
        "urn": "urn:li:activity:7241093982770847744",
        "followers": null,
        "date": "2w",
        "description": "\u201cOur Cuban culture is all about family, staying close together.\u201d \n\nAs we celebrate #HispanicHeritageMonth, we reflect on the cultural values that shape us. For Cindy, her strong connection to her family drove her to seek proactive cancer screening. \n\nHer story speaks to the importance of prioritizing your health and having a strong family support system. https://bit.ly/44RHQVD",
        "reactions_count": 40,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 761503650,
        "company_id": 3524741,
        "urn": "urn:li:activity:7240310325701419008",
        "followers": null,
        "date": "2w",
        "description": "At #ESMO24, GRAIL will be presenting a variety of data centered on enhancing our knowledge of multi-cancer early detection (MCED) testing, as well as on use of GRAIL technology in pharma research applications. Visit us at our posters and presentations! \n\nInterested in meeting and learning more about biopharma partnership opportunities? Reach out at PharmaBD@grailbio.com",
        "reactions_count": 60,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 761503651,
        "company_id": 3524741,
        "urn": "urn:li:activity:7240043084460253184",
        "followers": null,
        "date": "2w",
        "description": "For firefighters, the battle doesn\u2019t end when the fire is out. Health risks such as cancer are a constant concern, but new tools may be able to help. The Chicago Fire Department shares how tools like multi-cancer early detection (MCED) testing are helping them stay ahead of these unseen dangers.  \n \nLearn more: https://bit.ly/47vdew3\n \n#MCED #CancerScreening",
        "reactions_count": 77,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-17 19:19:56",
        "deleted": 1
      },
      {
        "id": 813824497,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211101105311666177",
        "followers": null,
        "date": "4mo",
        "description": "Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9",
        "reactions_count": 760,
        "comments_count": 23,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 813824498,
        "company_id": 3524741,
        "urn": "urn:li:activity:7263275340796485632",
        "followers": null,
        "date": "1d",
        "description": "GRAILers in San Francisco proudly participated in The Leukemia & Lymphoma Society's #LightTheNight walk, standing in solidarity with those impacted by blood cancers. Over the past few weeks, our team worked together to raise funds and awareness, culminating in a powerful evening of community and hope. We are honored to support the fight against blood cancer and to join others in making a difference.",
        "reactions_count": 40,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 813824499,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262917727185453058",
        "followers": null,
        "date": "1d",
        "description": "We are LIVE on LinkedIn for \u201cThe Cutting Edge of Wellness Programs: Early Cancer Detection\u201d with Lindsay Hanson, Chief Marketing Officer at John Hancock, and moderator Megan Hall, PhD, from GRAIL. Join us now: https://bit.ly/4hsKCrL",
        "reactions_count": 20,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 813824500,
        "company_id": 3524741,
        "urn": "urn:li:activity:7256696554281918464",
        "followers": null,
        "date": "2w",
        "description": "Tune in to our LinkedIn Live event, \u201cThe Cutting Edge of Wellness Programs: Early Cancer Detection.\u201d John Hancock Chief Marketing Officer Lindsay Hanson will discuss why multi-cancer early detection testing has become a key part of their offering to customers. RSVP here: https://bit.ly/4fmtcv7\n\nLindsay Hanson\nMegan P. Hall\n\n#MCED #CancerScreening",
        "reactions_count": 99,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 813824501,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262837718810873858",
        "followers": null,
        "date": "2d",
        "description": "We\u2019re proud to partner with John Hancock and Home Base to bring the Galleri test to veterans and active-duty special ops forces at higher risk of cancer. Together, we\u2019re expanding cancer screening and supporting those who have served. \n\nRx only. See Important Safety Information: https://lnkd.in/d_fp9JR5",
        "reactions_count": 35,
        "comments_count": 2,
        "reshared_post_author": "John Hancock",
        "reshared_post_author_url": "https://www.linkedin.com/company/john-hancock",
        "reshared_post_author_headline": null,
        "reshared_post_description": "We are excited to announce John Hancock is providing free access to GRAIL\u2019s multi-cancer early detection test to special operations veterans receiving care through Home Base \u2013 a national nonprofit dedicated to healing the invisible wounds for veterans, service members, their families and families of the fallen.  \n\nThe U.S. Department of Veterans Affairs reports approximately 56,000 veterans\u202fare diagnosed with cancer each year, 16% of which are rare cancers often discovered at later stages and many of which are commonly unscreened. Preventative care and early detection are key components of our mission to help people live longer, healthier, better lives. We are proud to bring this technology to our special operations veterans at Home Base who have done so much for our communities through their service. \n\nLearn more: https://ow.ly/fcHW50U62BK\n\n[MLINY110724659-1]",
        "reshared_post_followers": null,
        "reshared_post_date": "3d",
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 813824502,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262597864978022400",
        "followers": null,
        "date": "2d",
        "description": "Tomorrow, we will be live on LinkedIn hosting \u201cThe Cutting Edge of Wellness Programs: Early Cancer Detection.\u201d Hear from an industry leader about how multi-cancer early detection (MCED) testing is being used as a life insurance benefit and what this means for customers. \n\nRSVP here: https://bit.ly/4hsKCrL\n\n#MCED #CancerScreening",
        "reactions_count": 29,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 813824503,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262211816691245057",
        "followers": null,
        "date": "3d",
        "description": "Today GRAIL reported Q3 2024 financial results. Read more: https://bit.ly/4hDpyyW",
        "reactions_count": 19,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 813824504,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262130295372414977",
        "followers": null,
        "date": "4d",
        "description": "In our upcoming LinkedIn Live event, Lindsay Hanson, Chief Marketing Officer at John Hancock, will share why the life insurance carrier chose to offer multi-cancer early detection (MCED) testing as a benefit to their customers.\n\nRSVP for the event today: https://bit.ly/4hsKCrL\n\n#MCED #CancerScreening",
        "reactions_count": 32,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 813824505,
        "company_id": 3524741,
        "urn": "urn:li:activity:7260673685844369409",
        "followers": null,
        "date": "1w",
        "description": "We will be going live on LinkedIn next week! During the special event, GRAIL\u2019s Megan Hall, PhD, and John Hancock\u2019s Chief Marketing Officer Lindsay Hanson will discuss being the first life insurance carrier to offer multi-cancer early detection (MCED) testing through their Vitality Program to help customers keep their health top-of-mind. RSVP for the event today: https://bit.ly/4hsKCrL\n\n#MCED #CancerScreening",
        "reactions_count": 60,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 813824506,
        "company_id": 3524741,
        "urn": "urn:li:activity:7259268203791425537",
        "followers": null,
        "date": "1w",
        "description": "In an effort to help customers take a more proactive approach to their health, John Hancock was the first life insurance carrier to offer multi-cancer early detection (MCED) testing as a benefit. Tune in to our special LinkedIn Live event to hear more. \n\nRSVP for the event: https://bit.ly/4hsKCrL\n\n#MCED #CancerScreening",
        "reactions_count": 60,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-11-27 11:27:08",
        "deleted": 1
      },
      {
        "id": 825337675,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211101105311666177",
        "followers": null,
        "date": "5mo",
        "description": "Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9",
        "reactions_count": 760,
        "comments_count": 23,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 825337676,
        "company_id": 3524741,
        "urn": "urn:li:activity:7267204719322771458",
        "followers": null,
        "date": "19h",
        "description": "Rich believed he had low cancer risk based on his family health history. But after a recommendation from their doctor, Rich and his wife Staci decided to add multi-cancer early detection testing to their cancer screening routine.\n\nLearn more about his cancer experience.",
        "reactions_count": 25,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 825337677,
        "company_id": 3524741,
        "urn": "urn:li:activity:7265026888006279168",
        "followers": null,
        "date": "6d",
        "description": "According to the CDC, cancer is one of the leading causes of death for firefighters in the US. With the increased risks of modern fire environments, proactive cancer screening is critical. Watch to learn why these firefighter leaders are prioritizing multi-cancer early detection (MCED) testing as part of their annual health protocol for both active duty and retired service members.\n\n#FirefighterCancer #OccupationalCancer",
        "reactions_count": 50,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 825337678,
        "company_id": 3524741,
        "urn": "urn:li:activity:7264384885052592130",
        "followers": null,
        "date": "1w",
        "description": "We\u2019ve reached a milestone in collaboration with AstraZeneca: the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. \n\nLearn more: https://bit.ly/3YSag0N #LungCancer",
        "reactions_count": 315,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 825337679,
        "company_id": 3524741,
        "urn": "urn:li:activity:7263275340796485632",
        "followers": null,
        "date": "1w",
        "description": "GRAILers in San Francisco proudly participated in The Leukemia & Lymphoma Society's #LightTheNight walk, standing in solidarity with those impacted by blood cancers. Over the past few weeks, our team worked together to raise funds and awareness, culminating in a powerful evening of community and hope. We are honored to support the fight against blood cancer and to join others in making a difference.",
        "reactions_count": 66,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 825337680,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262917727185453058",
        "followers": null,
        "date": "1w",
        "description": "We are LIVE on LinkedIn for \u201cThe Cutting Edge of Wellness Programs: Early Cancer Detection\u201d with Lindsay Hanson, Chief Marketing Officer at John Hancock, and moderator Megan Hall, PhD, from GRAIL. Join us now: https://bit.ly/4hsKCrL",
        "reactions_count": 21,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 825337681,
        "company_id": 3524741,
        "urn": "urn:li:activity:7256696554281918464",
        "followers": null,
        "date": "4w",
        "description": "Tune in to our LinkedIn Live event, \u201cThe Cutting Edge of Wellness Programs: Early Cancer Detection.\u201d John Hancock Chief Marketing Officer Lindsay Hanson will discuss why multi-cancer early detection testing has become a key part of their offering to customers. RSVP here: https://bit.ly/4fmtcv7\n\nLindsay Hanson\nMegan P. Hall\n\n#MCED #CancerScreening",
        "reactions_count": 104,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 825337682,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262837718810873858",
        "followers": null,
        "date": "1w",
        "description": "We\u2019re proud to partner with John Hancock and Home Base to bring the Galleri test to veterans and active-duty special ops forces at higher risk of cancer. Together, we\u2019re expanding cancer screening and supporting those who have served. \n\nRx only. See Important Safety Information: https://lnkd.in/d_fp9JR5",
        "reactions_count": 43,
        "comments_count": 2,
        "reshared_post_author": "John Hancock",
        "reshared_post_author_url": "https://www.linkedin.com/company/john-hancock",
        "reshared_post_author_headline": null,
        "reshared_post_description": "We are excited to announce John Hancock is providing free access to GRAIL\u2019s multi-cancer early detection test to special operations veterans receiving care through Home Base \u2013 a national nonprofit dedicated to healing the invisible wounds for veterans, service members, their families and families of the fallen.  \n\nThe U.S. Department of Veterans Affairs reports approximately 56,000 veterans\u202fare diagnosed with cancer each year, 16% of which are rare cancers often discovered at later stages and many of which are commonly unscreened. Preventative care and early detection are key components of our mission to help people live longer, healthier, better lives. We are proud to bring this technology to our special operations veterans at Home Base who have done so much for our communities through their service. \n\nLearn more: https://ow.ly/fcHW50U62BK\n\n[MLINY110724659-1]",
        "reshared_post_followers": null,
        "reshared_post_date": "1w",
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 825337683,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262597864978022400",
        "followers": null,
        "date": "1w",
        "description": "Tomorrow, we will be live on LinkedIn hosting \u201cThe Cutting Edge of Wellness Programs: Early Cancer Detection.\u201d Hear from an industry leader about how multi-cancer early detection (MCED) testing is being used as a life insurance benefit and what this means for customers. \n\nRSVP here: https://bit.ly/4hsKCrL\n\n#MCED #CancerScreening",
        "reactions_count": 35,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 825337684,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262211816691245057",
        "followers": null,
        "date": "2w",
        "description": "Today GRAIL reported Q3 2024 financial results. Read more: https://bit.ly/4hDpyyW",
        "reactions_count": 26,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2024-12-07 03:07:12",
        "deleted": 1
      },
      {
        "id": 844341689,
        "company_id": 3524741,
        "urn": "urn:li:activity:7211101105311666177",
        "followers": null,
        "date": "5mo",
        "description": "Today begins a new chapter for GRAIL as an independent, publicly traded company. We will be listed under $GRAL on Nasdaq as of the market open June 25. Learn more: https://bit.ly/3S4T1H9",
        "reactions_count": 762,
        "comments_count": 23,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 844341690,
        "company_id": 3524741,
        "urn": "urn:li:activity:7269740774135640064",
        "followers": null,
        "date": "2d",
        "description": "After taking a multi-cancer early detection (MCED) test, Mercy informed Mike that the results showed a Cancer Signal Detected. Mercy quickly assembled a care team for Mike, who helped determine the necessary next steps. \n\nIn this video, Mike talks with oncologist Dr. Daniel Mackey about his care team\u2019s impact during his cancer experience: https://lnkd.in/d9qXVENh",
        "reactions_count": 31,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 844341691,
        "company_id": 3524741,
        "urn": "urn:li:activity:7267606859895738368",
        "followers": null,
        "date": "1w",
        "description": "We\u2019re all wishing the Dallas Cowboys' Tad Carper a speedy recovery after learning about his recent cancer diagnosis. We are glad that Tad\u2019s cancer was caught early, using the Galleri\u00ae multi-cancer early detection test as a first step. \n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.\n\nRx only. See Important Safety Information: https://lnkd.in/d_fp9JR5",
        "reactions_count": 223,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 844341692,
        "company_id": 3524741,
        "urn": "urn:li:activity:7267204719322771458",
        "followers": null,
        "date": "1w",
        "description": "Rich believed he had low cancer risk based on his family health history. But after a recommendation from their doctor, Rich and his wife Staci decided to add multi-cancer early detection testing to their cancer screening routine.\n\nLearn more about his cancer experience.",
        "reactions_count": 46,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 844341693,
        "company_id": 3524741,
        "urn": "urn:li:activity:7265026888006279168",
        "followers": null,
        "date": "2w",
        "description": "According to the CDC, cancer is one of the leading causes of death for firefighters in the US. With the increased risks of modern fire environments, proactive cancer screening is critical. Watch to learn why these firefighter leaders are prioritizing multi-cancer early detection (MCED) testing as part of their annual health protocol for both active duty and retired service members.\n\n#FirefighterCancer #OccupationalCancer",
        "reactions_count": 56,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 844341694,
        "company_id": 3524741,
        "urn": "urn:li:activity:7264384885052592130",
        "followers": null,
        "date": "2w",
        "description": "We\u2019ve reached a milestone in collaboration with AstraZeneca: the first patient has been tested for eligibility with the investigational GRAIL Non-Small Cell Lung Cancer (NSCLC) ctDNA Assay in the global TROPION-Lung12 Phase 3 study evaluating adjuvant treatment regimens in patients with Stage I adenocarcinoma NSCLC. \n\nLearn more: https://bit.ly/3YSag0N #LungCancer",
        "reactions_count": 357,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 844341695,
        "company_id": 3524741,
        "urn": "urn:li:activity:7263275340796485632",
        "followers": null,
        "date": "2w",
        "description": "GRAILers in San Francisco proudly participated in The Leukemia & Lymphoma Society's #LightTheNight walk, standing in solidarity with those impacted by blood cancers. Over the past few weeks, our team worked together to raise funds and awareness, culminating in a powerful evening of community and hope. We are honored to support the fight against blood cancer and to join others in making a difference.",
        "reactions_count": 70,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 844341696,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262917727185453058",
        "followers": null,
        "date": "3w",
        "description": "We are LIVE on LinkedIn for \u201cThe Cutting Edge of Wellness Programs: Early Cancer Detection\u201d with Lindsay Hanson, Chief Marketing Officer at John Hancock, and moderator Megan Hall, PhD, from GRAIL. Join us now: https://bit.ly/4hsKCrL",
        "reactions_count": 24,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 844341697,
        "company_id": 3524741,
        "urn": "urn:li:activity:7256696554281918464",
        "followers": null,
        "date": "1mo",
        "description": "Tune in to our LinkedIn Live event, \u201cThe Cutting Edge of Wellness Programs: Early Cancer Detection.\u201d John Hancock Chief Marketing Officer Lindsay Hanson will discuss why multi-cancer early detection testing has become a key part of their offering to customers. RSVP here: https://bit.ly/4fmtcv7\n\nLindsay Hanson\nMegan P. Hall\n\n#MCED #CancerScreening",
        "reactions_count": 107,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 844341698,
        "company_id": 3524741,
        "urn": "urn:li:activity:7262837718810873858",
        "followers": null,
        "date": "3w",
        "description": "We\u2019re proud to partner with John Hancock and Home Base to bring the Galleri test to veterans and active-duty special ops forces at higher risk of cancer. Together, we\u2019re expanding cancer screening and supporting those who have served. \n\nRx only. See Important Safety Information: https://lnkd.in/d_fp9JR5",
        "reactions_count": 47,
        "comments_count": 2,
        "reshared_post_author": "John Hancock",
        "reshared_post_author_url": "https://www.linkedin.com/company/john-hancock",
        "reshared_post_author_headline": null,
        "reshared_post_description": "We are excited to announce John Hancock is providing free access to GRAIL\u2019s multi-cancer early detection test to special operations veterans receiving care through Home Base \u2013 a national nonprofit dedicated to healing the invisible wounds for veterans, service members, their families and families of the fallen.  \n\nThe U.S. Department of Veterans Affairs reports approximately 56,000 veterans\u202fare diagnosed with cancer each year, 16% of which are rare cancers often discovered at later stages and many of which are commonly unscreened. Preventative care and early detection are key components of our mission to help people live longer, healthier, better lives. We are proud to bring this technology to our special operations veterans at Home Base who have done so much for our communities through their service. \n\nLearn more: https://ow.ly/fcHW50U62BK\n\n[MLINY110724659-1]",
        "reshared_post_followers": null,
        "reshared_post_date": "3w",
        "last_updated": "2025-01-16 01:00:37",
        "deleted": 1
      },
      {
        "id": 887722895,
        "company_id": 3524741,
        "urn": "urn:li:activity:7284719876319887360",
        "followers": null,
        "date": "1d",
        "description": "In a recent PATHFINDER study published in Lancet Oncology, an analysis of patient-reported outcomes showed minimal patient distress associated with multi-cancer early detection (MCED) testing. \n\nEligible PATHFINDER study participants, with either a cancer signal detected or no cancer signal detected over a 12-month follow-up period, were assessed on their perspectives of general anxiety, distress and uncertainty after results disclosure, health-related quality of life, satisfaction with the test, and intent towards guideline-recommended screening and repeat MCED testing.\n\nLearn more: https://bit.ly/4gSlmui",
        "reactions_count": 58,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 887722897,
        "company_id": 3524741,
        "urn": "urn:li:activity:7282480614706950144",
        "followers": null,
        "date": "1w",
        "description": "Neil thought his #cancer was in the past, but he received a Cancer Signal Detected result from a multi-cancer early detection test. Neil explains how early cancer screening made a difference in his cancer journey.",
        "reactions_count": 61,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 887722899,
        "company_id": 3524741,
        "urn": "urn:li:activity:7274488541911392256",
        "followers": null,
        "date": "1mo",
        "description": "Cancer survivors often face a higher risk of new cancers due to the impact of prior cancer treatments, in addition to several other factors. On #TheCancerSignal, Dr. Eric Klein shares insights from the PATHFINDER study and other GRAIL data from 2024, revealing how multi-cancer early detection (MCED) testing can help survivors screen for recurrence and new cancers earlier. \n\nHear about these important findings on proactive cancer screening.\n\nApple Podcasts: https://apple.co/49vtDBR \nSpotify: https://spoti.fi/4io6YLz \nTranscripts and more: https://bit.ly/3Lx4g6t",
        "reactions_count": 49,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 887722901,
        "company_id": 3524741,
        "urn": "urn:li:activity:7273420360090292224",
        "followers": null,
        "date": "1mo",
        "description": "Reflecting on the potential impact of multi-cancer early detection (MCED) testing, Dr. Daniel Mackey says, \u201cIf we can diagnose our patients at an earlier stage, not only does it improve their quality of life, and improve the morbidity associated with the treatments, but we can also reduce health care costs.\u201d\n\nHear from Dr. Mackey and Dr. Tyler Kang with Adventis Health about their experiences using MCED testing for cancer screening in this video.",
        "reactions_count": 42,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 887722902,
        "company_id": 3524741,
        "urn": "urn:li:activity:7272695685878013953",
        "followers": null,
        "date": "1mo",
        "description": "Dak Prescott is on a mission to help people detect cancer early and through his foundation - Faith Fight, Finish - he is doing just that. Thank you Tad Carper of the Dallas Cowboys for sharing this impactful story of multi-cancer early detection. \n\nRx only. See Important Safety Information: https://lnkd.in/d_fp9JR5 \n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests.",
        "reactions_count": 201,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 887722903,
        "company_id": 3524741,
        "urn": "urn:li:activity:7272311319486201856",
        "followers": null,
        "date": "1mo",
        "description": "In 2024, health systems across the U.S. continued to make significant strides toward expanding early cancer detection screening. In fact, more than 11,000 health care providers have ordered the Galleri test to date. Hear from leading physicians on how the adoption of multi-cancer early detection (MCED) screening is helping address an urgent unmet need. \n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. The Galleri test should be used in addition to healthcare provider recommended screening tests. \n\nRx only. See Important Safety Information: http://bit.ly/33m8pFa\n\n#MCED #EarlyDetection #CancerScreening",
        "reactions_count": 95,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 887722904,
        "company_id": 3524741,
        "urn": "urn:li:activity:7271955167636254720",
        "followers": null,
        "date": "1mo",
        "description": "We\u2019re wrapping up 2024 with a research update with Dr. Eric Klein, Distinguished Scientist at GRAIL. In this episode of #TheCancerSignal, Dr. Klein shares GRAIL\u2019s highlights from ASCO, ESMO, AACR and more - findings on repeat multi-cancer early detection (MCED) testing, MCED use in cancer survivors, economic impacts of cancer screening, and even a couple case studies. Don\u2019t miss this episode! \n\nApple Podcasts: https://apple.co/49vtDBR \nSpotify: https://spoti.fi/4io6YLz \nTranscripts and more: https://bit.ly/3Lx4g6t",
        "reactions_count": 39,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 887722905,
        "company_id": 3524741,
        "urn": "urn:li:activity:7269740774135640064",
        "followers": null,
        "date": "1mo",
        "description": "After taking a multi-cancer early detection (MCED) test, Mercy informed Mike that the results showed a Cancer Signal Detected. Mercy quickly assembled a care team for Mike, who helped determine the necessary next steps. \n\nIn this video, Mike talks with oncologist Dr. Daniel Mackey about his care team\u2019s impact during his cancer experience: https://lnkd.in/d9qXVENh",
        "reactions_count": 72,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 887722906,
        "company_id": 3524741,
        "urn": "urn:li:activity:7267606859895738368",
        "followers": null,
        "date": "1mo",
        "description": "We\u2019re all wishing the Dallas Cowboys' Tad Carper a speedy recovery after learning about his recent cancer diagnosis. We are glad that Tad\u2019s cancer was caught early, using the Galleri\u00ae multi-cancer early detection test as a first step. \n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. The Galleri test should be used in addition to healthcare provider recommended screening tests.\n\nRx only. See Important Safety Information: https://lnkd.in/d_fp9JR5",
        "reactions_count": 263,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 887722907,
        "company_id": 3524741,
        "urn": "urn:li:activity:7267204719322771458",
        "followers": null,
        "date": "1mo",
        "description": "Rich believed he had low cancer risk based on his family health history. But after a recommendation from their doctor, Rich and his wife Staci decided to add multi-cancer early detection testing to their cancer screening routine.\n\nLearn more about his cancer experience.",
        "reactions_count": 55,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-03 14:04:34",
        "deleted": 1
      },
      {
        "id": 914964891,
        "company_id": 3524741,
        "urn": "urn:li:activity:7291179958540898307",
        "followers": null,
        "date": "2d",
        "description": "For Jack, taking a multi-cancer early detection (MCED) screening test at the recommendation of his family doctor helped open the door to critical next steps in his cancer journey.\n \nWatch his story to learn more about the powerful role that tools like MCED can have for patients like Jack.\n \n#CancerScreening #MCED #PatientStory",
        "reactions_count": 57,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 914964892,
        "company_id": 3524741,
        "urn": "urn:li:activity:7290793156902539265",
        "followers": null,
        "date": "3d",
        "description": "GRAIL celebrated Lunar New Year across sites with festive activities and delicious cuisine ?? Here's to prosperity, happiness, and good fortune in the Year of the Snake! ?? #LunarNewYear",
        "reactions_count": 42,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 914964893,
        "company_id": 3524741,
        "urn": "urn:li:activity:7290401330072870914",
        "followers": null,
        "date": "4d",
        "description": "Meet GRAIL\u2019s pharma and multi-cancer early detection (MCED) teams at #PMWC25! Join Eric A. Klein, MD at the MCED panel session to learn more about Galleri and the RWE demonstrating its utility. In addition to cancer screening, recent publications showcasing GRAIL's technology suggest that pre-surgical ctDNA analysis can enable precision medicine strategies in non-small cell lung cancer (NSCLC). Learn here: (https://lnkd.in/dpeWHprg).\n\nContact our team (biopharma@grailbio.com) to meet at #PMWC25 and learn more about how GRAIL can address your biopharma companion diagnostics research, development, and commercialization needs.\n\n#PrecisionMedicine #PersonalizedTreatment #LiquidBiopsy #TissueFree #Methylation #ctDNA #MCED",
        "reactions_count": 51,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 914964894,
        "company_id": 3524741,
        "urn": "urn:li:activity:7289697501371109376",
        "followers": null,
        "date": "6d",
        "description": "Dr. Ummat has dedicated her career to helping patients maintain optimal vitality, both inside and out, as they age. She joins the new episode of #TheCancerSignal podcast ? to share insights on longevity, cancer screening, and changing the approach to aging. \n\nApple Podcasts: https://apple.co/4h9UYw5 \nSpotify: https://spoti.fi/3WyDdOZ \nTranscripts and more: https://bit.ly/3CsREgH",
        "reactions_count": 28,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 914964895,
        "company_id": 3524741,
        "urn": "urn:li:activity:7287857856886845440",
        "followers": null,
        "date": "1w",
        "description": "Proactive #cancer screening can change the course of patient care. \n\nDr. Daniel Mackey at Mercy and Dr. Tyler Kang at Adventist Health discuss the impact of multi-cancer early detection (MCED) testing on early diagnosis and treatment: https://bit.ly/4eBJfEO",
        "reactions_count": 67,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 914964896,
        "company_id": 3524741,
        "urn": "urn:li:activity:7287114184226418688",
        "followers": null,
        "date": "1w",
        "description": "Today, we honor the life and legacy of Dr. Martin Luther King Jr., whose unwavering commitment to justice, equality, and inclusion continues to inspire us. His vision challenges us to reflect on how far we\u2019ve come and motivates us to keep building a brighter future\u2014for our workplaces, communities, and beyond.\n\nAt GRAIL, we believe that fostering a culture of diversity, equity, inclusion, and belonging strengthens us all. By embracing different perspectives, we spark innovation, deepen connection, and create an environment where everyone feels valued and empowered.\n\nLet\u2019s honor Dr. King\u2019s courage and commitment by continuing to foster spaces where everyone can thrive.\n\n#MLKDay #DiversityAndInclusion #Belonging",
        "reactions_count": 44,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 914964897,
        "company_id": 3524741,
        "urn": "urn:li:activity:7285720256029892612",
        "followers": null,
        "date": "2w",
        "description": "When Cindy received her cancer signal detected result, she was shocked; she felt fine and had no symptoms. But thanks to follow-up diagnostic testing, her cancer was caught early.\n\nWatch Cindy\u2019s full story to see how she\u2019s doing today: https://lnkd.in/gFMeN2c3",
        "reactions_count": 55,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 914964898,
        "company_id": 3524741,
        "urn": "urn:li:activity:7284719876319887360",
        "followers": null,
        "date": "2w",
        "description": "In a recent PATHFINDER study published in Lancet Oncology, an analysis of patient-reported outcomes showed minimal patient distress associated with multi-cancer early detection (MCED) testing. \n\nEligible PATHFINDER study participants, with either a cancer signal detected or no cancer signal detected over a 12-month follow-up period, were assessed on their perspectives of general anxiety, distress and uncertainty after results disclosure, health-related quality of life, satisfaction with the test, and intent towards guideline-recommended screening and repeat MCED testing.\n\nLearn more: https://bit.ly/4gSlmui",
        "reactions_count": 85,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 914964899,
        "company_id": 3524741,
        "urn": "urn:li:activity:7282480614706950144",
        "followers": null,
        "date": "3w",
        "description": "Neil thought his #cancer was in the past, but he received a Cancer Signal Detected result from a multi-cancer early detection test. Neil explains how early cancer screening made a difference in his cancer journey.",
        "reactions_count": 71,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-02-25 14:19:32",
        "deleted": 1
      },
      {
        "id": 951843271,
        "company_id": 3524741,
        "urn": "urn:li:activity:7298449342837792768",
        "followers": null,
        "date": "4d",
        "description": "Today GRAIL reported fourth quarter and full year 2024 financial results. Read more: https://bit.ly/3CXTOFm",
        "reactions_count": 69,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 951843272,
        "company_id": 3524741,
        "urn": "urn:li:activity:7298011468279545857",
        "followers": null,
        "date": "5d",
        "description": "Jack\u2019s path to a cancer diagnosis was anything but straightforward. See how two Cancer Signal Detected results from multi-cancer early detection (MCED) screening tests taken six months apart helped his care team determine the necessary diagnostics that confirmed an early stage cancer diagnosis.\n\nRx only. See Important Safety Information: https://bit.ly/3QHmPWo\n \n#CancerScreening #MCED #PatientStory",
        "reactions_count": 36,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 951843273,
        "company_id": 3524741,
        "urn": "urn:li:activity:7295877936379764736",
        "followers": null,
        "date": "1w",
        "description": "\u201cWhat if you caught cancer early enough to make a difference?\u201d\n\nGracie learned about multi-cancer early detection (MCED) testing through a workplace bulletin, offering it as a benefit. Though she had no symptoms of cancer, she took the test and was surprised to receive a Cancer Signal Detected result.\n\nWatch her story below. #CancerScreening #MCED #PatientStory\n\nRx only. See Important Safety Information: https://bit.ly/3QHmPWo",
        "reactions_count": 113,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 951843274,
        "company_id": 3524741,
        "urn": "urn:li:activity:7295828074506375168",
        "followers": null,
        "date": "1w",
        "description": "#BRCA1 promoter methylation is a cancer susceptibility marker with prognostic value in breast and ovarian cancer. Using GRAIL\u2019s tissue-free assay, we detected and quantified BRCA1 promoter hypermethylation in cell-free DNA from a large case-control study of cancer and non-cancer populations (https://lnkd.in/gwvngUji). \n\nMeet with our biopharma team (biopharma@grailbio.com) at the 9th Annual Liquid Biopsy for Precision Oncology Summit to learn more about how GRAIL\u2019s methylation platform can address your biopharma needs. \n\n#tissuefree #methylation #ctDNA #liquidbiopsy #PrecisionOncology",
        "reactions_count": 84,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 951843275,
        "company_id": 3524741,
        "urn": "urn:li:activity:7295549758645944320",
        "followers": null,
        "date": "1w",
        "description": "We will issue financial results for the fourth quarter 2024 on Thursday, February 20, 2025. Register for the live teleconference: https://bit.ly/4aVOej8 \n\nSee more details: https://bit.ly/42SiI3C",
        "reactions_count": 24,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 951843276,
        "company_id": 3524741,
        "urn": "urn:li:activity:7295446570513113088",
        "followers": null,
        "date": "1w",
        "description": "Today we announced that the Galleri Test is now available directly to physicians in the U.S. through a collaboration with  Quest Diagnostics, delivering a more streamlined provider and patient experience. Patients can now go directly to Quest without needing to bring a Galleri test kit or a test requisition form to the blood draw appointment. Learn more and see Important Safety Information: https://bit.ly/3QiiRpH Rx only.",
        "reactions_count": 542,
        "comments_count": 15,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 951843277,
        "company_id": 3524741,
        "urn": "urn:li:activity:7292929710286602240",
        "followers": null,
        "date": "2w",
        "description": "This #BlackHistoryMonth, we are honoring pioneers in cancer research, advocacy and medicine\u2014Black physicians, researchers, educators and others who have revolutionized how we prevent, screen, and treat cancer, particularly in Black and underserved communities. From renowned historical figures to individuals who are still actively working to improve the lives of those touched by cancer, these are just some of the Black leaders who have had a significant impact.",
        "reactions_count": 55,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 951843278,
        "company_id": 3524741,
        "urn": "urn:li:activity:7292589742875914241",
        "followers": null,
        "date": "2w",
        "description": "This #WorldCancerDay, the cancer community is recognizing that each and every experience with cancer is unique. At GRAIL, we know that the stage at which cancer is detected and diagnosed can play a significant role in one\u2019s cancer journey, which is why we are dedicated to detecting cancer early, when it can be cured. \n \nLearn more about World Cancer Day and share your story: https://lnkd.in/drnuZeE\n\n#UnitedByUnique",
        "reactions_count": 99,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 951843279,
        "company_id": 3524741,
        "urn": "urn:li:activity:7291179958540898307",
        "followers": null,
        "date": "3w",
        "description": "For Jack, taking a multi-cancer early detection (MCED) screening test at the recommendation of his family doctor helped open the door to critical next steps in his cancer journey.\n \nWatch his story to learn more about the powerful role that tools like MCED can have for patients like Jack.\n \n#CancerScreening #MCED #PatientStory",
        "reactions_count": 88,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 951843280,
        "company_id": 3524741,
        "urn": "urn:li:activity:7290793156902539265",
        "followers": null,
        "date": "3w",
        "description": "GRAIL celebrated Lunar New Year across sites with festive activities and delicious cuisine ?? Here's to prosperity, happiness, and good fortune in the Year of the Snake! ?? #LunarNewYear",
        "reactions_count": 48,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-03-12 01:09:23",
        "deleted": 1
      },
      {
        "id": 967619795,
        "company_id": 3524741,
        "urn": "urn:li:activity:7303792907788984320",
        "followers": 91453,
        "date": "4d",
        "description": "Throughout history, women have played a vital role in the field of cancer. This #InternationalWomensDay and throughout #WomensHistoryMonth, join us in celebrating the female physicians, researchers, and educators who have been trailblazers in cancer research, advocacy, and medicine.",
        "reactions_count": 50,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 967619796,
        "company_id": 3524741,
        "urn": "urn:li:activity:7303096492037201921",
        "followers": 91453,
        "date": "6d",
        "description": "Roger\u2019s story is a reminder of the impact of proactive cancer screening. \n\nHe is now cancer-free after undergoing treatment for pancreatic cancer, one of the deadliest types of cancer.\n\nListen to Roger's full story on The Cancer SIGNAL podcast: https://bit.ly/40n8bvC",
        "reactions_count": 49,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 967619797,
        "company_id": 3524741,
        "urn": "urn:li:activity:7300170695857053696",
        "followers": 91453,
        "date": "2w",
        "description": "Kate Walsh\u2019s personal connection to cancer, through both of her parents\u2019 diagnoses, highlights how their generation did not have the options we have today to screen for cancer. \n\nThat\u2019s why Kate is part of Generation Possible - the first generation with access to multi-cancer early detection (MCED) testing in addition to recommended single-cancer screenings. \n\nVisit GenPossible.com to hear Kate\u2019s story and see Important Safety Information.",
        "reactions_count": 516,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 967619798,
        "company_id": 3524741,
        "urn": "urn:li:activity:7298449342837792768",
        "followers": 91453,
        "date": "2w",
        "description": "Today GRAIL reported fourth quarter and full year 2024 financial results. Read more: https://bit.ly/3CXTOFm",
        "reactions_count": 79,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 967619799,
        "company_id": 3524741,
        "urn": "urn:li:activity:7298011468279545857",
        "followers": 91453,
        "date": "2w",
        "description": "Jack\u2019s path to a cancer diagnosis was anything but straightforward. See how two Cancer Signal Detected results from multi-cancer early detection (MCED) screening tests taken six months apart helped his care team determine the necessary diagnostics that confirmed an early stage cancer diagnosis.\n\nRx only. See Important Safety Information: https://bit.ly/3QHmPWo\n \n#CancerScreening #MCED #PatientStory",
        "reactions_count": 65,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 967619800,
        "company_id": 3524741,
        "urn": "urn:li:activity:7295877936379764736",
        "followers": 91453,
        "date": "3w",
        "description": "\u201cWhat if you caught cancer early enough to make a difference?\u201d\n\nGracie learned about multi-cancer early detection (MCED) testing through a workplace bulletin, offering it as a benefit. Though she had no symptoms of cancer, she took the test and was surprised to receive a Cancer Signal Detected result.\n\nWatch her story below. #CancerScreening #MCED #PatientStory\n\nRx only. See Important Safety Information: https://bit.ly/3QHmPWo",
        "reactions_count": 132,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 967619801,
        "company_id": 3524741,
        "urn": "urn:li:activity:7295828074506375168",
        "followers": 91453,
        "date": "3w",
        "description": "#BRCA1 promoter methylation is a cancer susceptibility marker with prognostic value in breast and ovarian cancer. Using GRAIL\u2019s tissue-free assay, we detected and quantified BRCA1 promoter hypermethylation in cell-free DNA from a large case-control study of cancer and non-cancer populations (https://lnkd.in/gwvngUji). \n\nMeet with our biopharma team (biopharma@grailbio.com) at the 9th Annual Liquid Biopsy for Precision Oncology Summit to learn more about how GRAIL\u2019s methylation platform can address your biopharma needs. \n\n#tissuefree #methylation #ctDNA #liquidbiopsy #PrecisionOncology",
        "reactions_count": 99,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 967619802,
        "company_id": 3524741,
        "urn": "urn:li:activity:7295549758645944320",
        "followers": 91453,
        "date": "3w",
        "description": "We will issue financial results for the fourth quarter 2024 on Thursday, February 20, 2025. Register for the live teleconference: https://bit.ly/4aVOej8 \n\nSee more details: https://bit.ly/42SiI3C",
        "reactions_count": 27,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 967619803,
        "company_id": 3524741,
        "urn": "urn:li:activity:7295446570513113088",
        "followers": 91453,
        "date": "3w",
        "description": "Today we announced that the Galleri Test is now available directly to physicians in the U.S. through a collaboration with  Quest Diagnostics, delivering a more streamlined provider and patient experience. Patients can now go directly to Quest without needing to bring a Galleri test kit or a test requisition form to the blood draw appointment. Learn more and see Important Safety Information: https://bit.ly/3QiiRpH Rx only.",
        "reactions_count": 594,
        "comments_count": 17,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 967619804,
        "company_id": 3524741,
        "urn": "urn:li:activity:7292929710286602240",
        "followers": 91453,
        "date": "1mo",
        "description": "This #BlackHistoryMonth, we are honoring pioneers in cancer research, advocacy and medicine\u2014Black physicians, researchers, educators and others who have revolutionized how we prevent, screen, and treat cancer, particularly in Black and underserved communities. From renowned historical figures to individuals who are still actively working to improve the lives of those touched by cancer, these are just some of the Black leaders who have had a significant impact.",
        "reactions_count": 56,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-04-13 03:45:33",
        "deleted": 1
      },
      {
        "id": 1005286373,
        "company_id": 3524741,
        "urn": "urn:li:activity:7315125978844827650",
        "followers": 92582,
        "date": "5d",
        "description": "According to the Prevent Cancer Foundation , \u201c7 in 10 Americans are behind on at least one routine cancer screening.\u201d This #WorldHealthDay, check out our discussion with PCF CEO Jody Hoyos on the importance of early cancer detection: https://bit.ly/4iZhpFd \n#EarlyCancerDetection",
        "reactions_count": 24,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1005286374,
        "company_id": 3524741,
        "urn": "urn:li:activity:7313656046676295681",
        "followers": 92582,
        "date": "1w",
        "description": "Today we had the pleasure of welcoming representatives from several cancer advocacy organizations to our North Carolina site to tour our state-of-the-art lab and meet with senior leaders at GRAIL. It was an incredible opportunity to convene this group and share the innovative work we are accomplishing both in and out of the lab, and explore the work needed to support those impacted by cancer. Together, we're forging a path towards the advancement of early cancer detection - a mission that unites us all. Thank you to everyone who joined us and for all the important work you do.\n\nAmerican Cancer Society Cancer Action Network (ACS CAN) \nAssociation of Cancer Care Centers \nCancer Support Community \nFight Colorectal Cancer \nGO2 for Lung Cancer \nNMQF Action Network\nOvarian Cancer Research Alliance  \nPrevent Cancer Foundation",
        "reactions_count": 328,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1005286375,
        "company_id": 3524741,
        "urn": "urn:li:activity:7313231271709536257",
        "followers": 92582,
        "date": "1w",
        "description": "Early detection is key to improving cancer outcomes. Adding multi-cancer early detection (MCED) testing to recommended screenings has the potential to shift the cancer detection paradigm.\n\nLearn more about the benefits of MCED: https://bit.ly/49eiZiN",
        "reactions_count": 82,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1005286376,
        "company_id": 3524741,
        "urn": "urn:li:activity:7311070494827442177",
        "followers": null,
        "date": "2w",
        "description": "As Women\u2019s History Month comes to a close, I\u2019ve been reflecting on the meaningful moments we\u2019ve shared at GRAIL over the past few months\u2014from honoring legacy and excellence during Black History Month, to celebrating Nowruz (Persian New Year) and the vibrant festival of Holi, to elevating the voices of women through intentional storytelling and community.\n\nWhat made these celebrations even more impactful? They were led by us.\n\nEach moment was brought to life by our Employee Resource Groups\u2014grassroots, authentic, and full of heart. These weren\u2019t top-down campaigns. They were real connection points, built by employees who care deeply about belonging and honoring one another.\n\nWe didn\u2019t just celebrate\u2014we gathered. Fireside chats, social hours, shared meals, and honest conversations created space for connection and learning. Because understanding culture requires more than acknowledgment\u2014it requires showing up curious. That\u2019s it.\n\nFor Women\u2019s History Month, we asked women across GRAIL to share the lessons they\u2019d want to pass down from generations before them. Their words have been powerful reminders of the strength, resilience, and quiet wisdom carried in our stories.\n\nMy own lesson? You can be soft and powerful. Tender and bold. You don\u2019t have to choose one to lead.\n\nI\u2019m grateful to walk alongside so many brilliant, thoughtful humans\u2014and to be part of a culture that values curiosity, connection, and community.\n\n#WomensHistoryMonth #EmployeeResourceGroups #Belonging #InclusionMatters #inusiveleadership #LeadershipWithHeart #AuthenticLeadership #WorkplaceCulture #PeopleFirst #CultureDriven",
        "reactions_count": 31,
        "comments_count": 6,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1005286377,
        "company_id": 3524741,
        "urn": "urn:li:activity:7311042860244443137",
        "followers": 92582,
        "date": "2w",
        "description": "GRAIL\u2018s recent exploratory research study (https://bit.ly/4i23i1A) demonstrated that methylation patterns of urine cell-free DNA can detect early-stage high-grade urothelial cancer with high sensitivity (100%) and specificity (93.9%), without the need for matched blood or tissue. \n\nConnect with our biopharma team (biopharma@grailbio.com) to learn more about GRAIL\u2019s urine workflow and potential applications. \n\n#Urine #TissueFree #Methylation #cfDNA #PrecisionOncology",
        "reactions_count": 86,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1005286378,
        "company_id": 3524741,
        "urn": "urn:li:activity:7309977100487180288",
        "followers": 92582,
        "date": "2w",
        "description": "The importance of screening for #ColorectalCancer cannot be understated. Screening can help detect colorectal cancer early, which can increase the chance of successful treatment. \n\nIn honor of #ColorectalCancerAwarenessMonth, tune in to an episode of The Cancer SIGNAL to hear experts discuss the role of screening for colorectal cancer: https://bit.ly/4htE4rQ\n\n#TheCancerSIGNAL #crcsm",
        "reactions_count": 29,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1005286379,
        "company_id": 3524741,
        "urn": "urn:li:activity:7308551773567229952",
        "followers": 92582,
        "date": "3w",
        "description": "Patrick McGill, MD MBA and his team at Community Health Network pride themselves on being early adopters, innovators, and leaders in oncology. He shares how his organization has continued its mission to be in the forefront of cancer detection in the latest episode of #TheCancerSignal podcast ?\n\nApple Podcasts: https://apple.co/4hkMMIQ \nSpotify: https://spoti.fi/4hkMNwo\nTranscripts and more: https://bit.ly/4hkMNMU",
        "reactions_count": 31,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1005286380,
        "company_id": 3524741,
        "urn": "urn:li:activity:7303792907788984320",
        "followers": 92582,
        "date": "1mo",
        "description": "Throughout history, women have played a vital role in the field of cancer. This #InternationalWomensDay and throughout #WomensHistoryMonth, join us in celebrating the female physicians, researchers, and educators who have been trailblazers in cancer research, advocacy, and medicine.",
        "reactions_count": 62,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1005286381,
        "company_id": 3524741,
        "urn": "urn:li:activity:7303096492037201921",
        "followers": 92582,
        "date": "1mo",
        "description": "Roger\u2019s story is a reminder of the impact of proactive cancer screening. \n\nHe is now cancer-free after undergoing treatment for pancreatic cancer, one of the deadliest types of cancer.\n\nListen to Roger's full story on The Cancer SIGNAL podcast: https://bit.ly/40n8bvC",
        "reactions_count": 65,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1005286382,
        "company_id": 3524741,
        "urn": "urn:li:activity:7300170695857053696",
        "followers": 92582,
        "date": "1mo",
        "description": "Kate Walsh\u2019s personal connection to cancer, through both of her parents\u2019 diagnoses, highlights how their generation did not have the options we have today to screen for cancer. \n\nThat\u2019s why Kate is part of Generation Possible - the first generation with access to multi-cancer early detection (MCED) testing in addition to recommended single-cancer screenings. \n\nVisit GenPossible.com to hear Kate\u2019s story and see Important Safety Information.",
        "reactions_count": 559,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-05-06 15:25:51",
        "deleted": 1
      },
      {
        "id": 1040509114,
        "company_id": 3524741,
        "urn": "urn:li:activity:7324887574920003584",
        "followers": 93543,
        "date": "1d",
        "description": "\u201cAs a result of their occupational risk, firefighters need this kind of support. They give so much to us. It\u2019s important that we give back to them.\u201d\n\nThis #InternationalFirefightersDay, see how Community Health Network is partnering with GRAIL to bring the benefits of multi-cancer early detection (MCED) testing to the brave individuals who put their lives on the line for their communities each day. \n\nRx only. See Important Safety Information: http://bit.ly/33m8pFa\n\n#IFFD #FirefightersDay #FightCancer #FirefighterCancer",
        "reactions_count": 44,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1040509115,
        "company_id": 3524741,
        "urn": "urn:li:activity:7323795885652410368",
        "followers": 93543,
        "date": "4d",
        "description": "Finding bladder cancer early improves the chance that treatment will be successful. But for people at average risk, there is currently no standard screening test for bladder cancer.\n\nThis Bladder Cancer Awareness Month, learn more about how multi-cancer early detection (MCED) testing can help screen for this and other types of cancer, potentially before symptoms appear: https://bit.ly/45wf8ux\n\nRx only. See Important Safety Information: https://bit.ly/45wf8ux \n#BladderCancer #BladderCancerAwarenessMonth",
        "reactions_count": 25,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1040509116,
        "company_id": 3524741,
        "urn": "urn:li:activity:7323392036454203394",
        "followers": 93543,
        "date": "5d",
        "description": "This National Oral, Head, and Neck Cancer Awareness Month, watch Jack\u2019s story about how multi-cancer early detection (MCED) testing led to his head and neck cancer (HNC) diagnosis: https://bit.ly/4jpU6UP\n\n#OralCancer #HeadAndNeckCancer",
        "reactions_count": 36,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1040509117,
        "company_id": 3524741,
        "urn": "urn:li:activity:7323075360399523840",
        "followers": 93543,
        "date": "6d",
        "description": "We will issue first quarter 2025 financial results on Tuesday, May 13, 2025. Register for the live teleconference: https://bit.ly/4cSEmI9\n\nSee more details: https://bit.ly/42RjYCn",
        "reactions_count": 9,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1040509118,
        "company_id": 3524741,
        "urn": "urn:li:activity:7322658693093670913",
        "followers": 93543,
        "date": "1w",
        "description": "April 25 is National DNA Day, which commemorates the discovery of DNA\u2019s double helix in 1953 and the completion of the Human Genome Project in 2003\u2014both of which led to major advancements in cancer research, detection, and treatment.\n\n#NationalDNADay",
        "reactions_count": 45,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1040509119,
        "company_id": 3524741,
        "urn": "urn:li:activity:7320539435232624643",
        "followers": 93543,
        "date": "1w",
        "description": "We\u2019re excited to attend the American Association for Cancer Research (AACR) Annual Meeting to present new data findings that highlight real-world evidence with the Galleri multi-cancer early detection (MCED) test. See when and where you can find our data presentations: https://bit.ly/3YD9NQz\n#AACR25",
        "reactions_count": 99,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1040509120,
        "company_id": 3524741,
        "urn": "urn:li:activity:7320112929461149698",
        "followers": 93543,
        "date": "2w",
        "description": "This Medical Laboratory Professionals Week, we are recognizing the important work our clinical laboratory personnel and professionals do in the fight against cancer. Thank you for your invaluable contribution to our mission. \n\n#MLPW #lab4life #labweek",
        "reactions_count": 166,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1040509121,
        "company_id": 3524741,
        "urn": "urn:li:activity:7315125978844827650",
        "followers": 93543,
        "date": "4w",
        "description": "According to the Prevent Cancer Foundation , \u201c7 in 10 Americans are behind on at least one routine cancer screening.\u201d This #WorldHealthDay, check out our discussion with PCF CEO Jody Hoyos on the importance of early cancer detection: https://bit.ly/4iZhpFd \n#EarlyCancerDetection",
        "reactions_count": 40,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1040509122,
        "company_id": 3524741,
        "urn": "urn:li:activity:7313656046676295681",
        "followers": 93543,
        "date": "1mo",
        "description": "Today we had the pleasure of welcoming representatives from several cancer advocacy organizations to our North Carolina site to tour our state-of-the-art lab and meet with senior leaders at GRAIL. It was an incredible opportunity to convene this group and share the innovative work we are accomplishing both in and out of the lab, and explore the work needed to support those impacted by cancer. Together, we're forging a path towards the advancement of early cancer detection - a mission that unites us all. Thank you to everyone who joined us and for all the important work you do.\n\nAmerican Cancer Society Cancer Action Network (ACS CAN) \nAssociation of Cancer Care Centers \nCancer Support Community \nFight Colorectal Cancer \nGO2 for Lung Cancer \nNMQF Action Network\nOvarian Cancer Research Alliance  \nPrevent Cancer Foundation",
        "reactions_count": 383,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1040509123,
        "company_id": 3524741,
        "urn": "urn:li:activity:7313231271709536257",
        "followers": 93543,
        "date": "1mo",
        "description": "Early detection is key to improving cancer outcomes. Adding multi-cancer early detection (MCED) testing to recommended screenings has the potential to shift the cancer detection paradigm.\n\nLearn more about the benefits of MCED: https://bit.ly/49eiZiN",
        "reactions_count": 107,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-06-04 10:36:15",
        "deleted": 1
      },
      {
        "id": 1079492106,
        "company_id": 3524741,
        "urn": "urn:li:activity:7335737939072610305",
        "followers": null,
        "date": "18h",
        "description": "I know it\u2019s already June\u2014but I didn\u2019t want to miss the chance to reflect on the incredible energy we brought to AAPI Heritage Month at GRAIL \n\nWe celebrated through meaningful moments that highlighted culture, community, and connection:\n? A lively AAPI-themed trivia session that had us learning and laughing\n? A powerful movie night that sparked conversation and reflection\n? A day of volunteering that reminded us how we show up for each other\n\nEach event was a reminder of the richness within the AAPI community and the strength that comes from honoring every voice and story.\n\nHuge thank you to everyone who participated and helped create space for celebration and learning. Let\u2019s carry this momentum forward all year long.\n\n#AAPIHeritageMonth #CultureAndConnection #InclusiveWorkplace #BelongingMatters",
        "reactions_count": 31,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1079492107,
        "company_id": 3524741,
        "urn": "urn:li:activity:7335037510068129794",
        "followers": 94610,
        "date": "2d",
        "description": "On National Cancer Survivors Day, we celebrate the estimated 18 million cancer survivors in the U.S. as of January 2022\u2014a number that is projected to increase to 21.6 million by 2030. Early cancer diagnosis can help improve treatment outcomes, leading to more survivors\u2014about 89% of people diagnosed early reach 5-year survival vs. approximately 21% diagnosed at a later stage.\n\n#EarlyCancerScreening #NationalCancerSurvivorsDay #NCSD2025",
        "reactions_count": 51,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1079492108,
        "company_id": 3524741,
        "urn": "urn:li:activity:7334248818864988160",
        "followers": 94610,
        "date": "4d",
        "description": "Lieutenant McFarland, an active and healthy firefighter of 30 years, was diagnosed with esophageal cancer after first taking a multi-cancer early detection (MCED) test. Because it was caught at stage one, he underwent a minimally invasive procedure to remove the tumor and avoided chemo and radiation. His surgeon, Dr. Robert E. Merritt, said \u201cThe impact of detecting it at an early stage opened the road for him to have a good chance at long-term survival.\u201d \n\n#EarlyCancerDetection #MCED #EsophagealCancer",
        "reactions_count": 159,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1079492109,
        "company_id": 3524741,
        "urn": "urn:li:activity:7332797772431052802",
        "followers": 94610,
        "date": "1w",
        "description": "All gave some, some gave all. This Memorial Day, our troops and veterans are at the forefront of our minds, especially those who made the ultimate sacrifice for our country on the battlefield and after due to cancer caused by exposure to toxins.\n\n#MemorialDay #SupportOurTroops #Veterans",
        "reactions_count": 85,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1079492110,
        "company_id": 3524741,
        "urn": "urn:li:activity:7330292454979502080",
        "followers": 94610,
        "date": "2w",
        "description": "Improvements in cancer screening, diagnosis, and treatment have led to longer survival\u2014about 70% of U.S. cancer survivors have lived 5 or more years since their diagnosis. But there is more work to be done. This National Cancer Research Month, our commitment to continuing to conduct more research to help detect cancer earlier when it can be cured has never been stronger.\n\n#NCRM25",
        "reactions_count": 64,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1079492111,
        "company_id": 3524741,
        "urn": "urn:li:activity:7328150811472023552",
        "followers": 94610,
        "date": "3w",
        "description": "Today GRAIL reported first quarter 2025 financial results. Learn more: https://bit.ly/3GV4t5b",
        "reactions_count": 55,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1079492112,
        "company_id": 3524741,
        "urn": "urn:li:activity:7327787164287623168",
        "followers": 94610,
        "date": "3w",
        "description": "Today we announced a new partnership with athenahealth, which will offer healthcare providers streamlined ordering of the Galleri multi-cancer early detection (MCED) test. Learn more: https://bit.ly/3SvxyGO",
        "reactions_count": 242,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1079492113,
        "company_id": 3524741,
        "urn": "urn:li:activity:7326637837041229825",
        "followers": 94610,
        "date": "3w",
        "description": "GRAIL has been recognized as the 2025 Best Overall MedTech Company in the 9th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough! The mission of this program is to honor excellence and recognize innovation, hard work, and success in a range of health and medical technology categories.",
        "reactions_count": 213,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1079492114,
        "company_id": 3524741,
        "urn": "urn:li:activity:7326270186162921472",
        "followers": 94610,
        "date": "3w",
        "description": "Currently, only ~20% of ovarian cancers are found at an early stage. And there are also no recommended ovarian cancer screening tests for people who are not exhibiting symptoms and are not at high risk of developing this cancer.\n\nThis World Ovarian Cancer Day, hear our podcast host Susanna Quinn\u2019s personal experience with ovarian cancer: https://bit.ly/4d476hi\n\n#WorldOvarianCancerDay #WOCD2025 #NoWomanLeftBehind #NoPersonLeftBehind #TheCancerSignal",
        "reactions_count": 86,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1079492115,
        "company_id": 3524741,
        "urn": "urn:li:activity:7324887574920003584",
        "followers": 94610,
        "date": "1mo",
        "description": "\u201cAs a result of their occupational risk, firefighters need this kind of support. They give so much to us. It\u2019s important that we give back to them.\u201d\n\nThis #InternationalFirefightersDay, see how Community Health Network is partnering with GRAIL to bring the benefits of multi-cancer early detection (MCED) testing to the brave individuals who put their lives on the line for their communities each day. \n\nRx only. See Important Safety Information: http://bit.ly/33m8pFa\n\n#IFFD #FirefightersDay #FightCancer #FirefighterCancer",
        "reactions_count": 74,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-04 10:30:43",
        "deleted": 1
      },
      {
        "id": 1113674708,
        "company_id": 3524741,
        "urn": "urn:li:activity:7344017893610733568",
        "followers": 95753,
        "date": "1w",
        "description": "Coming soon! Dallas Cowboys Senior VP of Communications, Tad Carper, recently joined The Cancer SIGNAL podcast host Susanna Quinn to share his recent experience with multi-cancer early detection (MCED) testing. Stay tuned for this new episode. ?\n\n#EarlyCancerDetection #TheCancerSignal",
        "reactions_count": 95,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 1113674710,
        "company_id": 3524741,
        "urn": "urn:li:activity:7341482449543024640",
        "followers": 95753,
        "date": "2w",
        "description": "This Juneteenth, we honor freedom and reflect on the ongoing fight for health equity. Black communities continue to face disparities in cancer detection and outcomes due to systemic barriers in healthcare access, trust, and screening availability.\n\nEarly detection can help save more lives when everyone has the opportunity to benefit from it. Addressing these gaps requires action, awareness, and inclusive solutions that serve all communities equitably.\n\n#Juneteenth #EarlyCancerDetection",
        "reactions_count": 48,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 1113674712,
        "company_id": 3524741,
        "urn": "urn:li:activity:7341089856804069376",
        "followers": 95753,
        "date": "2w",
        "description": "Today we announced positive top-line performance and safety results from our registrational PATHFINDER 2 study. In PATHFINDER 2, adding Galleri to standard of care screening demonstrated substantially greater additional cancer detection than in the previously published PATHFINDER study. \n\nLearn more: https://bit.ly/3SZU9M6",
        "reactions_count": 244,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 1113674715,
        "company_id": 3524741,
        "urn": "urn:li:activity:7337899063155036161",
        "followers": 95753,
        "date": "3w",
        "description": "This Pride Month, we\u2019re raising awareness about how members of the LGBTQ+ community face a greater risk of cancer and advanced-stage diagnoses. The LGBTQ+ community often faces unique barriers to cancer screening, including access to health care or fear of discrimination.\n\nHear Dr. Scout on The Cancer SIGNAL podcast discuss cancer screening barriers in the LGBTQ+ community and why inclusive care matters: https://bit.ly/45bUra5\n\n#PrideMonth #CancerDetection #TheCancerSignal",
        "reactions_count": 27,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 1113674717,
        "company_id": 3524741,
        "urn": "urn:li:activity:7336781273421500416",
        "followers": 95753,
        "date": "3w",
        "description": "Jack was enjoying retirement and became interested in taking a multi-cancer early detection (MCED) test when his doctor told him about the test. In Episode 28 of The Cancer SIGNAL podcast, Jack shares with host Susanna Quinn how he felt when a Cancer Signal was detected, eventually leading to a head and neck cancer diagnosis before ever experiencing any symptoms. \n\nCheck out the latest episode of The Cancer SIGNAL to hear their in-depth conversation. ?\n\nApple Podcasts: https://apple.co/4n7zwvt\nSpotify: https://spoti.fi/43Liudw\nTranscripts and more: https://bit.ly/4mQHuZE",
        "reactions_count": 51,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 1113674719,
        "company_id": 3524741,
        "urn": "urn:li:activity:7335737939072610305",
        "followers": null,
        "date": "1mo",
        "description": "I know it\u2019s already June\u2014but I didn\u2019t want to miss the chance to reflect on the incredible energy we brought to AAPI Heritage Month at GRAIL \n\nWe celebrated through meaningful moments that highlighted culture, community, and connection:\n? A lively AAPI-themed trivia session that had us learning and laughing\n? A powerful movie night that sparked conversation and reflection\n? A day of volunteering that reminded us how we show up for each other\n\nEach event was a reminder of the richness within the AAPI community and the strength that comes from honoring every voice and story.\n\nHuge thank you to everyone who participated and helped create space for celebration and learning. Let\u2019s carry this momentum forward all year long.\n\n#AAPIHeritageMonth #CultureAndConnection #InclusiveWorkplace #BelongingMatters",
        "reactions_count": 48,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1113674721,
        "company_id": 3524741,
        "urn": "urn:li:activity:7335037510068129794",
        "followers": 95753,
        "date": "1mo",
        "description": "On National Cancer Survivors Day, we celebrate the estimated 18 million cancer survivors in the U.S. as of January 2022\u2014a number that is projected to increase to 21.6 million by 2030. Early cancer diagnosis can help improve treatment outcomes, leading to more survivors\u2014about 89% of people diagnosed early reach 5-year survival vs. approximately 21% diagnosed at a later stage.\n\n#EarlyCancerScreening #NationalCancerSurvivorsDay #NCSD2025",
        "reactions_count": 71,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 1113674722,
        "company_id": 3524741,
        "urn": "urn:li:activity:7334248818864988160",
        "followers": 95753,
        "date": "1mo",
        "description": "Lieutenant McFarland, an active and healthy firefighter of 30 years, was diagnosed with esophageal cancer after first taking a multi-cancer early detection (MCED) test. Because it was caught at stage one, he underwent a minimally invasive procedure to remove the tumor and avoided chemo and radiation. His surgeon, Dr. Robert E. Merritt, said \u201cThe impact of detecting it at an early stage opened the road for him to have a good chance at long-term survival.\u201d \n\n#EarlyCancerDetection #MCED #EsophagealCancer",
        "reactions_count": 204,
        "comments_count": 7,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 1113674723,
        "company_id": 3524741,
        "urn": "urn:li:activity:7332797772431052802",
        "followers": 95753,
        "date": "1mo",
        "description": "All gave some, some gave all. This Memorial Day, our troops and veterans are at the forefront of our minds, especially those who made the ultimate sacrifice for our country on the battlefield and after due to cancer caused by exposure to toxins.\n\n#MemorialDay #SupportOurTroops #Veterans",
        "reactions_count": 96,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 1113674724,
        "company_id": 3524741,
        "urn": "urn:li:activity:7330292454979502080",
        "followers": 95753,
        "date": "1mo",
        "description": "Improvements in cancer screening, diagnosis, and treatment have led to longer survival\u2014about 70% of U.S. cancer survivors have lived 5 or more years since their diagnosis. But there is more work to be done. This National Cancer Research Month, our commitment to continuing to conduct more research to help detect cancer earlier when it can be cured has never been stronger.\n\n#NCRM25",
        "reactions_count": 75,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-07-17 06:31:25",
        "deleted": 1
      },
      {
        "id": 1151464696,
        "company_id": 3524741,
        "urn": "urn:li:activity:7336781273421500416",
        "followers": 97160,
        "date": "1mo",
        "description": "Jack was enjoying retirement and became interested in taking a multi-cancer early detection (MCED) test when his doctor told him about the test. In Episode 28 of The Cancer SIGNAL podcast, Jack shares with host Susanna Quinn how he felt when a Cancer Signal was detected, eventually leading to a head and neck cancer diagnosis before ever experiencing any symptoms. \n\nCheck out the latest episode of The Cancer SIGNAL to hear their in-depth conversation. ?\n\nApple Podcasts: https://apple.co/4n7zwvt\nSpotify: https://spoti.fi/43Liudw\nTranscripts and more: https://bit.ly/4mQHuZE",
        "reactions_count": 55,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1151464697,
        "company_id": 3524741,
        "urn": "urn:li:activity:7351242784189652994",
        "followers": 97160,
        "date": "16h",
        "description": "Everlywell recently announced they are collaborating with GRAIL to offer the Galleri test, which is now available for request directly on everlywell.com via prescription only. \n\nLearn more below. See Important Safety Information: https://lnkd.in/d_fp9JR5",
        "reactions_count": 76,
        "comments_count": 1,
        "reshared_post_author": "Everlywell",
        "reshared_post_author_url": "https://www.linkedin.com/company/everlywell",
        "reshared_post_author_headline": null,
        "reshared_post_description": "We\u2019re proud to partner with GRAIL to expand access to the Galleri Multi-Cancer Early Detection Test, which is now available through Everlywell.\n\nThe Galleri test screens for a signal shared by 50+ types of cancer, many of which do not have standard recommended screenings today. Early detection saves lives\u2014and together, we\u2019re making it more accessible than ever. Hear from Gabe Gaviola, MD, MPH, Senior Medical Director, Everlywell. ?\n\n\u201cAs a company that has transformed how people access care for nearly a decade, we know innovation only matters when it\u2019s accessible\u2014and access is what changes lives. We\u2019re empowering people with answers when it matters most.\u201d\n\nLearn more: https://lnkd.in/gwBzMBm6\n\nSee the test: https://lnkd.in/gna69jnz\n\n#EarlyDetection #Cancer #DigitalHealth #Diagnostics",
        "reshared_post_followers": null,
        "reshared_post_date": "2w",
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1151464698,
        "company_id": 3524741,
        "urn": "urn:li:activity:7350588158348062721",
        "followers": 97160,
        "date": "2d",
        "description": "Jack was surprised when a multi-cancer early detection (MCED) test yielded a Cancer Signal Detected result. Hear more about Jack\u2019s experience as he shares his journey from his first MCED test, through to diagnosis, treatment, and recovery with The Cancer SIGNAL host Susanna Quinn.\n\nApple Podcasts: https://apple.co/4eFEL1x\nSpotify: https://bit.ly/4ePbce0\nTranscripts and more:  https://bit.ly/4nKUX5Q\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 28,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1151464699,
        "company_id": 3524741,
        "urn": "urn:li:activity:7349477585791184899",
        "followers": 97160,
        "date": "5d",
        "description": "As an adult in good health with no symptoms, Neil was surprised when he received a Cancer Signal Detected result from a multi-cancer early detection (MCED) test.\n\nWatch as this cancer survivor shares his inspiring story: https://bit.ly/3TsdPsl\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 74,
        "comments_count": 4,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1151464700,
        "company_id": 3524741,
        "urn": "urn:li:activity:7348395508589109248",
        "followers": 97160,
        "date": "1w",
        "description": "July is Sarcoma Awareness Month\u2014a critical time to highlight the importance of early detection in rare cancers. Increased awareness and cancer screenings can lead to earlier diagnoses and better treatment outcomes.\n\n#EarlyCancerDetection #Sarcoma #SarcomaAwarenessMonth",
        "reactions_count": 43,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1151464701,
        "company_id": 3524741,
        "urn": "urn:li:activity:7344017893610733568",
        "followers": 97160,
        "date": "2w",
        "description": "Coming soon! Dallas Cowboys Senior VP of Communications, Tad Carper, recently joined The Cancer SIGNAL podcast host Susanna Quinn to share his recent experience with multi-cancer early detection (MCED) testing. Stay tuned for this new episode. ?\n\n#EarlyCancerDetection #TheCancerSignal",
        "reactions_count": 113,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1151464702,
        "company_id": 3524741,
        "urn": "urn:li:activity:7341482449543024640",
        "followers": 97160,
        "date": "3w",
        "description": "This Juneteenth, we honor freedom and reflect on the ongoing fight for health equity. Black communities continue to face disparities in cancer detection and outcomes due to systemic barriers in healthcare access, trust, and screening availability.\n\nEarly detection can help save more lives when everyone has the opportunity to benefit from it. Addressing these gaps requires action, awareness, and inclusive solutions that serve all communities equitably.\n\n#Juneteenth #EarlyCancerDetection",
        "reactions_count": 52,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1151464703,
        "company_id": 3524741,
        "urn": "urn:li:activity:7341089856804069376",
        "followers": 97160,
        "date": "4w",
        "description": "Today we announced positive top-line performance and safety results from our registrational PATHFINDER 2 study. In PATHFINDER 2, adding Galleri to standard of care screening demonstrated substantially greater additional cancer detection than in the previously published PATHFINDER study. \n\nLearn more: https://bit.ly/3SZU9M6",
        "reactions_count": 259,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1151464704,
        "company_id": 3524741,
        "urn": "urn:li:activity:7337899063155036161",
        "followers": 97160,
        "date": "1mo",
        "description": "This Pride Month, we\u2019re raising awareness about how members of the LGBTQ+ community face a greater risk of cancer and advanced-stage diagnoses. The LGBTQ+ community often faces unique barriers to cancer screening, including access to health care or fear of discrimination.\n\nHear Dr. Scout on The Cancer SIGNAL podcast discuss cancer screening barriers in the LGBTQ+ community and why inclusive care matters: https://bit.ly/45bUra5\n\n#PrideMonth #CancerDetection #TheCancerSignal",
        "reactions_count": 27,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-03 19:36:27",
        "deleted": 1
      },
      {
        "id": 1191926571,
        "company_id": 3524741,
        "urn": "urn:li:activity:7336781273421500416",
        "followers": 97746,
        "date": "1mo",
        "description": "Jack was enjoying retirement and became interested in taking a multi-cancer early detection (MCED) test when his doctor told him about the test. In Episode 28 of The Cancer SIGNAL podcast, Jack shares with host Susanna Quinn how he felt when a Cancer Signal was detected, eventually leading to a head and neck cancer diagnosis before ever experiencing any symptoms. \n\nCheck out the latest episode of The Cancer SIGNAL to hear their in-depth conversation. ?\n\nApple Podcasts: https://apple.co/4n7zwvt\nSpotify: https://spoti.fi/43Liudw\nTranscripts and more: https://bit.ly/4mQHuZE",
        "reactions_count": 58,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1191926572,
        "company_id": 3524741,
        "urn": "urn:li:activity:7357092915132715010",
        "followers": 97746,
        "date": "2d",
        "description": "On World Lung Cancer Day, we can celebrate some positive news: Deaths from lung cancer continue to decline largely thanks to advances in early detection and treatment.\n\nHear from oncologist Daniel Mackey, MD, who reminds us of the importance of early cancer detection.\n\n#EarlyCancerDetection #WorldLungCancerDay #LungCancerAwareness",
        "reactions_count": 12,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1191926573,
        "company_id": 3524741,
        "urn": "urn:li:activity:7356054685457244161",
        "followers": 97746,
        "date": "4d",
        "description": "We will issue second quarter 2025 financial results on Tuesday, August 12, 2025. Register for the live teleconference: https://bit.ly/46ySmWq\n\nSee more details: https://bit.ly/3IRix0H",
        "reactions_count": 19,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1191926574,
        "company_id": 3524741,
        "urn": "urn:li:activity:7355268747252678656",
        "followers": 97746,
        "date": "1w",
        "description": "Today is World Head and Neck Cancer Day\u2014a reminder of the importance of early detection. These cancers are increasingly being diagnosed at later stages when treatment is more difficult. Early detection can potentially uncover these cancers at earlier stages when they may respond better to treatment.\n\n#WorldHeadAndNeckCancerDay #HeadAndNeckCancer #EarlyCancerDetection",
        "reactions_count": 77,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1191926575,
        "company_id": 3524741,
        "urn": "urn:li:activity:7351623484604579840",
        "followers": 97746,
        "date": "2w",
        "description": "Cindy\u2019s OB-GYN, Dr. Candace Westgate, knew that she had a BRCA1 gene mutation and a family history of cancer. She recommended Cindy take a multi-cancer early detection (MCED) test, which yielded a Cancer Signal Detected result.\n\nWatch Cindy\u2019s story to see how this test detected a cancer signal while she was still asymptomatic: https://bit.ly/3YYaxPB\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 76,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1191926576,
        "company_id": 3524741,
        "urn": "urn:li:activity:7351242784189652994",
        "followers": 97746,
        "date": "2w",
        "description": "Everlywell recently announced they are collaborating with GRAIL to offer the Galleri test, which is now available for request directly on everlywell.com via prescription only. \n\nLearn more below. See Important Safety Information: https://lnkd.in/d_fp9JR5",
        "reactions_count": 120,
        "comments_count": 1,
        "reshared_post_author": "Everlywell",
        "reshared_post_author_url": "https://www.linkedin.com/company/everlywell",
        "reshared_post_author_headline": null,
        "reshared_post_description": "We\u2019re proud to partner with GRAIL to expand access to the Galleri Multi-Cancer Early Detection Test, which is now available through Everlywell.\n\nThe Galleri test screens for a signal shared by 50+ types of cancer, many of which do not have standard recommended screenings today. Early detection saves lives\u2014and together, we\u2019re making it more accessible than ever. Hear from Gabe Gaviola, MD, MPH, Senior Medical Director, Everlywell. ?\n\n\u201cAs a company that has transformed how people access care for nearly a decade, we know innovation only matters when it\u2019s accessible\u2014and access is what changes lives. We\u2019re empowering people with answers when it matters most.\u201d\n\nLearn more: https://lnkd.in/gwBzMBm6\n\nSee the test: https://lnkd.in/gna69jnz\n\n#EarlyDetection #Cancer #DigitalHealth #Diagnostics",
        "reshared_post_followers": null,
        "reshared_post_date": "1mo",
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1191926577,
        "company_id": 3524741,
        "urn": "urn:li:activity:7350588158348062721",
        "followers": 97746,
        "date": "2w",
        "description": "Jack was surprised when a multi-cancer early detection (MCED) test yielded a Cancer Signal Detected result. Hear more about Jack\u2019s experience as he shares his journey from his first MCED test, through to diagnosis, treatment, and recovery with The Cancer SIGNAL host Susanna Quinn.\n\nApple Podcasts: https://apple.co/4eFEL1x\nSpotify: https://bit.ly/4ePbce0\nTranscripts and more:  https://bit.ly/4nKUX5Q\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 65,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1191926578,
        "company_id": 3524741,
        "urn": "urn:li:activity:7349477585791184899",
        "followers": 97746,
        "date": "3w",
        "description": "As an adult in good health with no symptoms, Neil was surprised when he received a Cancer Signal Detected result from a multi-cancer early detection (MCED) test.\n\nWatch as this cancer survivor shares his inspiring story: https://bit.ly/3TsdPsl\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 105,
        "comments_count": 10,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1191926579,
        "company_id": 3524741,
        "urn": "urn:li:activity:7348395508589109248",
        "followers": 97746,
        "date": "3w",
        "description": "July is Sarcoma Awareness Month\u2014a critical time to highlight the importance of early detection in rare cancers. Increased awareness and cancer screenings can lead to earlier diagnoses and better treatment outcomes.\n\n#EarlyCancerDetection #Sarcoma #SarcomaAwarenessMonth",
        "reactions_count": 51,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1191926580,
        "company_id": 3524741,
        "urn": "urn:li:activity:7344017893610733568",
        "followers": 97746,
        "date": "1mo",
        "description": "Coming soon! Dallas Cowboys Senior VP of Communications, Tad Carper, recently joined The Cancer SIGNAL podcast host Susanna Quinn to share his recent experience with multi-cancer early detection (MCED) testing. Stay tuned for this new episode. ?\n\n#EarlyCancerDetection #TheCancerSignal",
        "reactions_count": 122,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-08 22:57:13",
        "deleted": 1
      },
      {
        "id": 1214918800,
        "company_id": 3524741,
        "urn": "urn:li:activity:7336781273421500416",
        "followers": 97905,
        "date": "2mo",
        "description": "Jack was enjoying retirement and became interested in taking a multi-cancer early detection (MCED) test when his doctor told him about the test. In Episode 28 of The Cancer SIGNAL podcast, Jack shares with host Susanna Quinn how he felt when a Cancer Signal was detected, eventually leading to a head and neck cancer diagnosis before ever experiencing any symptoms. \n\nCheck out the latest episode of The Cancer SIGNAL to hear their in-depth conversation. ?\n\nApple Podcasts: https://apple.co/4n7zwvt\nSpotify: https://spoti.fi/43Liudw\nTranscripts and more: https://bit.ly/4mQHuZE",
        "reactions_count": 59,
        "comments_count": 3,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1214918801,
        "company_id": 3524741,
        "urn": "urn:li:activity:7359623219470872577",
        "followers": 97905,
        "date": "6h",
        "description": "Firefighters across the country choose to lead by example by proactively managing their health, specifically by taking a multi-cancer early detection (MCED) test.\n\nWatch as they share what fueled their decisions to take a test that could detect a cancer signal despite having no symptoms: https://bit.ly/3Tv7JHy\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.",
        "reactions_count": 18,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1214918802,
        "company_id": 3524741,
        "urn": "urn:li:activity:7357092915132715010",
        "followers": 97905,
        "date": "1w",
        "description": "On World Lung Cancer Day, we can celebrate some positive news: Deaths from lung cancer continue to decline largely thanks to advances in early detection and treatment.\n\nHear from oncologist Daniel Mackey, MD, who reminds us of the importance of early cancer detection.\n\n#EarlyCancerDetection #WorldLungCancerDay #LungCancerAwareness",
        "reactions_count": 25,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1214918803,
        "company_id": 3524741,
        "urn": "urn:li:activity:7356054685457244161",
        "followers": 97905,
        "date": "1w",
        "description": "We will issue second quarter 2025 financial results on Tuesday, August 12, 2025. Register for the live teleconference: https://bit.ly/46ySmWq\n\nSee more details: https://bit.ly/3IRix0H",
        "reactions_count": 25,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1214918804,
        "company_id": 3524741,
        "urn": "urn:li:activity:7355268747252678656",
        "followers": 97905,
        "date": "1w",
        "description": "Today is World Head and Neck Cancer Day\u2014a reminder of the importance of early detection. These cancers are increasingly being diagnosed at later stages when treatment is more difficult. Early detection can potentially uncover these cancers at earlier stages when they may respond better to treatment.\n\n#WorldHeadAndNeckCancerDay #HeadAndNeckCancer #EarlyCancerDetection",
        "reactions_count": 84,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1214918805,
        "company_id": 3524741,
        "urn": "urn:li:activity:7351623484604579840",
        "followers": 97905,
        "date": "3w",
        "description": "Cindy\u2019s OB-GYN, Dr. Candace Westgate, knew that she had a BRCA1 gene mutation and a family history of cancer. She recommended Cindy take a multi-cancer early detection (MCED) test, which yielded a Cancer Signal Detected result.\n\nWatch Cindy\u2019s story to see how this test detected a cancer signal while she was still asymptomatic: https://bit.ly/3YYaxPB\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 83,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1214918806,
        "company_id": 3524741,
        "urn": "urn:li:activity:7351242784189652994",
        "followers": 97905,
        "date": "3w",
        "description": "Everlywell recently announced they are collaborating with GRAIL to offer the Galleri test, which is now available for request directly on everlywell.com via prescription only. \n\nLearn more below. See Important Safety Information: https://lnkd.in/d_fp9JR5",
        "reactions_count": 123,
        "comments_count": 1,
        "reshared_post_author": "Everlywell",
        "reshared_post_author_url": "https://www.linkedin.com/company/everlywell",
        "reshared_post_author_headline": null,
        "reshared_post_description": "We\u2019re proud to partner with GRAIL to expand access to the Galleri Multi-Cancer Early Detection Test, which is now available through Everlywell.\n\nThe Galleri test screens for a signal shared by 50+ types of cancer, many of which do not have standard recommended screenings today. Early detection saves lives\u2014and together, we\u2019re making it more accessible than ever. Hear from Gabe Gaviola, MD, MPH, Senior Medical Director, Everlywell. ?\n\n\u201cAs a company that has transformed how people access care for nearly a decade, we know innovation only matters when it\u2019s accessible\u2014and access is what changes lives. We\u2019re empowering people with answers when it matters most.\u201d\n\nLearn more: https://lnkd.in/gwBzMBm6\n\nSee the test: https://lnkd.in/gna69jnz\n\n#EarlyDetection #Cancer #DigitalHealth #Diagnostics",
        "reshared_post_followers": null,
        "reshared_post_date": "1mo",
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1214918807,
        "company_id": 3524741,
        "urn": "urn:li:activity:7350588158348062721",
        "followers": 97905,
        "date": "3w",
        "description": "Jack was surprised when a multi-cancer early detection (MCED) test yielded a Cancer Signal Detected result. Hear more about Jack\u2019s experience as he shares his journey from his first MCED test, through to diagnosis, treatment, and recovery with The Cancer SIGNAL host Susanna Quinn.\n\nApple Podcasts: https://apple.co/4eFEL1x\nSpotify: https://bit.ly/4ePbce0\nTranscripts and more:  https://bit.ly/4nKUX5Q\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 67,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1214918808,
        "company_id": 3524741,
        "urn": "urn:li:activity:7349477585791184899",
        "followers": 97905,
        "date": "4w",
        "description": "As an adult in good health with no symptoms, Neil was surprised when he received a Cancer Signal Detected result from a multi-cancer early detection (MCED) test.\n\nWatch as this cancer survivor shares his inspiring story: https://bit.ly/3TsdPsl\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 112,
        "comments_count": 10,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1214918809,
        "company_id": 3524741,
        "urn": "urn:li:activity:7348395508589109248",
        "followers": 97905,
        "date": "1mo",
        "description": "July is Sarcoma Awareness Month\u2014a critical time to highlight the importance of early detection in rare cancers. Increased awareness and cancer screenings can lead to earlier diagnoses and better treatment outcomes.\n\n#EarlyCancerDetection #Sarcoma #SarcomaAwarenessMonth",
        "reactions_count": 54,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-08-25 06:33:58",
        "deleted": 1
      },
      {
        "id": 1261803447,
        "company_id": 3524741,
        "urn": "urn:li:activity:7361134770434576384",
        "followers": 98445,
        "date": "1w",
        "description": "Today GRAIL reported second quarter 2025 financial results.\n\nLearn more: https://bit.ly/3JtBmXQ",
        "reactions_count": 31,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1261803448,
        "company_id": 3524741,
        "urn": "urn:li:activity:7360728065355771904",
        "followers": 98445,
        "date": "1w",
        "description": "As an adult in good health with no symptoms, Neil was surprised when he received a Cancer Signal Detected result from a multi-cancer early detection (MCED) test.\n\nWatch as this cancer survivor shares his inspiring story: https://bit.ly/3TsdPsl\n\n#EarlyCancerDetection \n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 43,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1261803449,
        "company_id": 3524741,
        "urn": "urn:li:activity:7359623219470872577",
        "followers": 98445,
        "date": "2w",
        "description": "Firefighters across the country choose to lead by example by proactively managing their health, specifically by taking a multi-cancer early detection (MCED) test.\n\nWatch as they share what fueled their decisions to take a test that could detect a cancer signal despite having no symptoms: https://bit.ly/3Tv7JHy\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.",
        "reactions_count": 73,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1261803450,
        "company_id": 3524741,
        "urn": "urn:li:activity:7357092915132715010",
        "followers": 98445,
        "date": "3w",
        "description": "On World Lung Cancer Day, we can celebrate some positive news: Deaths from lung cancer continue to decline largely thanks to advances in early detection and treatment.\n\nHear from oncologist Daniel Mackey, MD, who reminds us of the importance of early cancer detection.\n\n#EarlyCancerDetection #WorldLungCancerDay #LungCancerAwareness",
        "reactions_count": 37,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1261803451,
        "company_id": 3524741,
        "urn": "urn:li:activity:7356054685457244161",
        "followers": 98445,
        "date": "3w",
        "description": "We will issue second quarter 2025 financial results on Tuesday, August 12, 2025. Register for the live teleconference: https://bit.ly/46ySmWq\n\nSee more details: https://bit.ly/3IRix0H",
        "reactions_count": 30,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1261803452,
        "company_id": 3524741,
        "urn": "urn:li:activity:7355268747252678656",
        "followers": 98445,
        "date": "4w",
        "description": "Today is World Head and Neck Cancer Day\u2014a reminder of the importance of early detection. These cancers are increasingly being diagnosed at later stages when treatment is more difficult. Early detection can potentially uncover these cancers at earlier stages when they may respond better to treatment.\n\n#WorldHeadAndNeckCancerDay #HeadAndNeckCancer #EarlyCancerDetection",
        "reactions_count": 96,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1261803453,
        "company_id": 3524741,
        "urn": "urn:li:activity:7351623484604579840",
        "followers": 98445,
        "date": "1mo",
        "description": "Cindy\u2019s OB-GYN, Dr. Candace Westgate, knew that she had a BRCA1 gene mutation and a family history of cancer. She recommended Cindy take a multi-cancer early detection (MCED) test, which yielded a Cancer Signal Detected result.\n\nWatch Cindy\u2019s story to see how this test detected a cancer signal while she was still asymptomatic: https://bit.ly/3YYaxPB\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 89,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1261803454,
        "company_id": 3524741,
        "urn": "urn:li:activity:7351242784189652994",
        "followers": 98445,
        "date": "1mo",
        "description": "Everlywell recently announced they are collaborating with GRAIL to offer the Galleri test, which is now available for request directly on everlywell.com via prescription only. \n\nLearn more below. See Important Safety Information: https://lnkd.in/d_fp9JR5",
        "reactions_count": 127,
        "comments_count": 1,
        "reshared_post_author": "Everlywell",
        "reshared_post_author_url": "https://www.linkedin.com/company/everlywell",
        "reshared_post_author_headline": null,
        "reshared_post_description": "We\u2019re proud to partner with GRAIL to expand access to the Galleri Multi-Cancer Early Detection Test, which is now available through Everlywell.\n\nThe Galleri test screens for a signal shared by 50+ types of cancer, many of which do not have standard recommended screenings today. Early detection saves lives\u2014and together, we\u2019re making it more accessible than ever. Hear from Gabe Gaviola, MD, MPH, Senior Medical Director, Everlywell. ?\n\n\u201cAs a company that has transformed how people access care for nearly a decade, we know innovation only matters when it\u2019s accessible\u2014and access is what changes lives. We\u2019re empowering people with answers when it matters most.\u201d\n\nLearn more: https://lnkd.in/gwBzMBm6\n\nSee the test: https://lnkd.in/gna69jnz\n\n#EarlyDetection #Cancer #DigitalHealth #Diagnostics",
        "reshared_post_followers": null,
        "reshared_post_date": "1mo",
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1261803455,
        "company_id": 3524741,
        "urn": "urn:li:activity:7350588158348062721",
        "followers": 98445,
        "date": "1mo",
        "description": "Jack was surprised when a multi-cancer early detection (MCED) test yielded a Cancer Signal Detected result. Hear more about Jack\u2019s experience as he shares his journey from his first MCED test, through to diagnosis, treatment, and recovery with The Cancer SIGNAL host Susanna Quinn.\n\nApple Podcasts: https://apple.co/4eFEL1x\nSpotify: https://bit.ly/4ePbce0\nTranscripts and more:  https://bit.ly/4nKUX5Q\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 67,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1261803456,
        "company_id": 3524741,
        "urn": "urn:li:activity:7349477585791184899",
        "followers": 98445,
        "date": "1mo",
        "description": "As an adult in good health with no symptoms, Neil was surprised when he received a Cancer Signal Detected result from a multi-cancer early detection (MCED) test.\n\nWatch as this cancer survivor shares his inspiring story: https://bit.ly/3TsdPsl\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 114,
        "comments_count": 10,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-09-04 16:57:20",
        "deleted": 1
      },
      {
        "id": 1290270947,
        "company_id": 3524741,
        "urn": "urn:li:activity:7369393569519849473",
        "followers": 98739,
        "date": "1h",
        "description": "September is Blood Cancer Awareness Month, and it\u2019s worth noting that while the overall cancer death rate decreased by 34% from 1991 to 2022, the leukemia incidence rate has increased, underscoring the importance of early detection.\n\n#BloodCancerAwareness #Leukemia",
        "reactions_count": 9,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1290270948,
        "company_id": 3524741,
        "urn": "urn:li:activity:7368660321785249792",
        "followers": 98739,
        "date": "2d",
        "description": "WATCH: Dr. Daniel Mackey and cancer survivor, Mike, share their experiences with multi-cancer early detection (MCED) testing, as well as care coordination and precision medicine in the Mercy Health system for people like Mike: https://bit.ly/4eDH9oB\n\n#EarlyCancerDetection #PrecisionMedicine",
        "reactions_count": 37,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1290270949,
        "company_id": 3524741,
        "urn": "urn:li:activity:7366443226624446464",
        "followers": 98739,
        "date": "1w",
        "description": "All of us at GRAIL are saddened to learn about the passing of\u00a0Bonnie J. Addario, a fierce advocate who made an indelible impact on countless people impacted by lung cancer. Our thoughts are with her family, friends, and all who knew her.",
        "reactions_count": 49,
        "comments_count": 2,
        "reshared_post_author": "GO2 for Lung Cancer",
        "reshared_post_author_url": "https://www.linkedin.com/company/go2forlungcancer",
        "reshared_post_author_headline": null,
        "reshared_post_description": "With heavy hearts, we share the passing of our beloved co-founder and leader of GO2 for Lung Cancer, founder of the Bonnie J. Addario Lung Cancer Foundation, and founder of Addario Lung Cancer Medical Institute, Bonnie J. Addario. \n\nBonnie was an extraordinary woman whose vision, strength, and generosity transformed the lung cancer space forever. Following her own diagnosis, she turned adversity into action\u2014channeling her experience into a movement that put patients first. From patient to powerhouse, Bonnie became a fierce and tireless advocate, giving voice and hope to countless individuals and families impacted by lung cancer. \n\nShe united survivors, caregivers, health care providers, researchers, industry leaders, and policymakers to confront this disease with compassion, innovation, and urgency. \n\nWhile her loss is deeply felt, Bonnie\u2019s legacy lives on\u2014in the lives she touched, the progress she inspired, and the unwavering belief she held: that every person affected by lung cancer matters. \n \nWe honor her by continuing the mission she so passionately led\u2014with courage, love, and hope.",
        "reshared_post_followers": null,
        "reshared_post_date": "1w",
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1290270950,
        "company_id": 3524741,
        "urn": "urn:li:activity:7361134770434576384",
        "followers": 98739,
        "date": "3w",
        "description": "Today GRAIL reported second quarter 2025 financial results.\n\nLearn more: https://bit.ly/3JtBmXQ",
        "reactions_count": 36,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1290270951,
        "company_id": 3524741,
        "urn": "urn:li:activity:7360728065355771904",
        "followers": 98739,
        "date": "3w",
        "description": "As an adult in good health with no symptoms, Neil was surprised when he received a Cancer Signal Detected result from a multi-cancer early detection (MCED) test.\n\nWatch as this cancer survivor shares his inspiring story: https://bit.ly/3TsdPsl\n\n#EarlyCancerDetection \n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 47,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1290270952,
        "company_id": 3524741,
        "urn": "urn:li:activity:7359623219470872577",
        "followers": 98739,
        "date": "3w",
        "description": "Firefighters across the country choose to lead by example by proactively managing their health, specifically by taking a multi-cancer early detection (MCED) test.\n\nWatch as they share what fueled their decisions to take a test that could detect a cancer signal despite having no symptoms: https://bit.ly/3Tv7JHy\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur.",
        "reactions_count": 79,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1290270953,
        "company_id": 3524741,
        "urn": "urn:li:activity:7357092915132715010",
        "followers": 98739,
        "date": "1mo",
        "description": "On World Lung Cancer Day, we can celebrate some positive news: Deaths from lung cancer continue to decline largely thanks to advances in early detection and treatment.\n\nHear from oncologist Daniel Mackey, MD, who reminds us of the importance of early cancer detection.\n\n#EarlyCancerDetection #WorldLungCancerDay #LungCancerAwareness",
        "reactions_count": 40,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1290270954,
        "company_id": 3524741,
        "urn": "urn:li:activity:7356054685457244161",
        "followers": 98739,
        "date": "1mo",
        "description": "We will issue second quarter 2025 financial results on Tuesday, August 12, 2025. Register for the live teleconference: https://bit.ly/46ySmWq\n\nSee more details: https://bit.ly/3IRix0H",
        "reactions_count": 29,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1290270955,
        "company_id": 3524741,
        "urn": "urn:li:activity:7355268747252678656",
        "followers": 98739,
        "date": "1mo",
        "description": "Today is World Head and Neck Cancer Day\u2014a reminder of the importance of early detection. These cancers are increasingly being diagnosed at later stages when treatment is more difficult. Early detection can potentially uncover these cancers at earlier stages when they may respond better to treatment.\n\n#WorldHeadAndNeckCancerDay #HeadAndNeckCancer #EarlyCancerDetection",
        "reactions_count": 95,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1290270956,
        "company_id": 3524741,
        "urn": "urn:li:activity:7351623484604579840",
        "followers": 98739,
        "date": "1mo",
        "description": "Cindy\u2019s OB-GYN, Dr. Candace Westgate, knew that she had a BRCA1 gene mutation and a family history of cancer. She recommended Cindy take a multi-cancer early detection (MCED) test, which yielded a Cancer Signal Detected result.\n\nWatch Cindy\u2019s story to see how this test detected a cancer signal while she was still asymptomatic: https://bit.ly/3YYaxPB\n\n#EarlyCancerDetection\n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 89,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-04 03:51:04",
        "deleted": 1
      },
      {
        "id": 1321220622,
        "company_id": 3524741,
        "urn": "urn:li:activity:7376635398187552768",
        "followers": 99265,
        "date": "1w",
        "description": "Senior VP of Communications for the Dallas Cowboys, Tad Carper, took a multi-cancer early detection (MCED) test during the team\u2019s 2024 training camp\u2014and that sent him on a cancer journey he had never expected. Hear his story about early cancer detection, positive thinking, and paying it forward in the latest episode of The Cancer SIGNAL podcast. ?\n\nApple Podcasts: https://apple.co/4mI2WPm \nSpotify: https://bit.ly/46zh9b5 \nTranscripts and more: https://bit.ly/4mtqnvp \n\n#EarlyCancerDetection #MCED",
        "reactions_count": 78,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1321220624,
        "company_id": 3524741,
        "urn": "urn:li:activity:7379165495687581698",
        "followers": 99265,
        "date": "2d",
        "description": "For Breast Cancer Awareness Month, we\u2019re calling attention to the importance of early detection\u2014especially if you have or are at risk of having the BRCA gene mutation\u2014which can increase your risk for breast cancer. Our podcast, The Cancer SIGNAL, delves into this important topic and is available wherever you listen to podcasts: https://bit.ly/3KrMLbk\n\n#BreastCancerAwarenessMonth #EarlyDetection",
        "reactions_count": 44,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1321220625,
        "company_id": 3524741,
        "urn": "urn:li:activity:7378815678230945792",
        "followers": 99265,
        "date": "3d",
        "description": "Happy International Podcast Day! If you\u2019re looking for something new, check out The Cancer SIGNAL podcast available through GRAIL and hosted by cancer survivor Susanna Quinn. On this podcast, we dive into the stories behind multi-cancer early detection (MCED)\u2014from patients to doctors, advocates to researchers, and more. \n\nThe Cancer SIGNAL is available wherever you listen to podcasts: https://bit.ly/463jhaS\n\n#InternationalPodcastDay #PodcastCommunity #EarlyCancerDetection",
        "reactions_count": 19,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1321220627,
        "company_id": 3524741,
        "urn": "urn:li:activity:7377358554741039104",
        "followers": 99265,
        "date": "1w",
        "description": "Regular screenings are key to detecting cervical cancer early. This Gynecologic Cancer Awareness Month, we\u2019re reminding everyone that early detection improves a person\u2019s prognosis and chances of being successfully treated.\n\n#GynecologicCancerAwarenessMonth #GCAM",
        "reactions_count": 28,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1321220628,
        "company_id": 3524741,
        "urn": "urn:li:activity:7376388666203697152",
        "followers": 99265,
        "date": "1w",
        "description": "We are pleased to present new data from our registrational PATHFINDER 2 study at the upcoming ESMO - European Society for Medical Oncology\u202fCongress in Berlin.\n\nWe also look forward to sharing data from our prospective observational study, SYMPLIFY, and real-world experience of veterans from the REFLECTION study at the Early Detection of Cancer Conference (EDCC) 2025 in Portland.\n\nRead more in our latest press release: https://bit.ly/4nc39Lu\n#ESMO25",
        "reactions_count": 187,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1321220630,
        "company_id": 3524741,
        "urn": "urn:li:activity:7375955880263127041",
        "followers": 99265,
        "date": "1w",
        "description": "According to the CDC, cancer is a leading cause of death among firefighters. These firefighter leaders know the importance of being proactive about their health for themselves, their families, and their teammates.\n\nHear how this led to many of these first responders taking multi-cancer early detection (MCED) tests: https://bit.ly/4lRh9JL",
        "reactions_count": 45,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1321220631,
        "company_id": 3524741,
        "urn": "urn:li:activity:7373418849775386625",
        "followers": 99265,
        "date": "2w",
        "description": "Today is World Lymphoma Awareness Day, an ideal time for a reminder to pay attention to unusual signs and symptoms and to get regular medical checkups, especially if you\u2019re considered high risk for lymphoma.\n\nKeep in mind that catching it early will likely allow for more treatment options.\n\n#WorldLymphomaAwarenessDay #WLAD",
        "reactions_count": 32,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1321220632,
        "company_id": 3524741,
        "urn": "urn:li:activity:7371983976678424576",
        "followers": 99265,
        "date": "3w",
        "description": "Cindy\u2019s OB-GYN, Dr. Candace Westgate, knew that she had a BRCA1 gene mutation and a family history of cancer. She recommended Cindy take a multi-cancer early detection (MCED) test, which yielded a Cancer Signal Detected result.\n\nWatch Cindy\u2019s story to see how this test detected a cancer signal while she was still asymptomatic: https://bit.ly/3YYaxPB\n\n#EarlyCancerDetection \n\nThe Galleri test does not detect a signal for all cancers and not all cancers can be detected in the blood. False positive and false negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer.",
        "reactions_count": 43,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1321220634,
        "company_id": 3524741,
        "urn": "urn:li:activity:7371192939001122816",
        "followers": 99265,
        "date": "3w",
        "description": "In observance of Ovarian Cancer Awareness Month, we\u2019re spotlighting a few compelling statistics: While stage I ovarian cancer can be cured in up to 90% of patients, and stage II has a 5-year survival rate of 70%, only 20% of cases are diagnosed at stage I or II, underscoring the importance of early detection.\n\n#OvarianCancer #OCAM",
        "reactions_count": 51,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1321220635,
        "company_id": 3524741,
        "urn": "urn:li:activity:7370876851302432768",
        "followers": 99265,
        "date": "3w",
        "description": "Eric Fung, MD, PhD, SVP of Clinical Development at GRAIL, will join fellow experts in ctDNA to explore how innovations in liquid biopsy are transforming patient monitoring at #WorldCDx on September 24. Be part of the conversation driving the future of precision oncology\u2014join us at #WorldCDx!\n\nContact us at PharmaBD@grailbio.com to learn about partnership opportunities.\n\n#PrecisionMedicine #liquidbiopsy #tissueFree #methylation #ctDNA",
        "reactions_count": 78,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 1
      },
      {
        "id": 1360343383,
        "company_id": 3524741,
        "urn": "urn:li:activity:7383887328844500992",
        "followers": 99497,
        "date": "7h",
        "description": "While rare, men are at risk for breast cancer and should not ignore any unusual symptoms\u2014like a painless lump, skin dimpling, nipple inversion, redness or scaling, or nipple discharge.\n\nFor Men\u2019s Breast Cancer Awareness Week, we\u2019re urging men to take these warning signs seriously and see their doctor. Early detection can help ensure their treatment success.\n\n#MensBreastCancerAwareness #MenGetBreastCancerToo #EarlyDetection",
        "reactions_count": 18,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1360343384,
        "company_id": 3524741,
        "urn": "urn:li:activity:7383559174086934528",
        "followers": 99497,
        "date": "1d",
        "description": "We were honored to welcome leadership from the American Cancer Society Cancer Action Network (ACS CAN) to the GRAIL lab in North Carolina last week.\n\nTheir tireless commitment to improving the status quo and advancing the fight against cancer continues to inspire all of us. Together, we share a vision of a future where early detection is possible for everyone \u2014 saving more lives and changing outcomes for patients and families everywhere.\n\nThank you to the ACS team for your partnership, leadership, and unwavering dedication to making that vision a reality.",
        "reactions_count": 200,
        "comments_count": 1,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1360343385,
        "company_id": 3524741,
        "urn": "urn:li:activity:7382466740779352064",
        "followers": 99497,
        "date": "4d",
        "description": "Primary liver cancer is the fourth most common cause of cancer death worldwide, and hepatocellular carcinoma (HCC) accounts for nearly 75% of all cases. Because HCC is often diagnosed in advanced stages, deaths have doubled since 1999, and effective treatments remain limited. For Liver Cancer Awareness Month, we\u2019re raising awareness and promoting early detection.\n\n#OctoberIs4Livers #LiverCancerAwarenessMonth #EarlyDetection",
        "reactions_count": 48,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1360343386,
        "company_id": 3524741,
        "urn": "urn:li:activity:7381355741753925632",
        "followers": 99497,
        "date": "1w",
        "description": "Darla, a community service officer serving her local police department for 20 years, took her insurance company up on an offer to take a multi-cancer early detection test (MCED). She was ultimately grateful that this test detected a cancer signal while she was still asymptomatic, enabling swift action, and likely the reason she is cancer free today. https://bit.ly/47aCE3o",
        "reactions_count": 83,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1360343387,
        "company_id": 3524741,
        "urn": "urn:li:activity:7381051132640546816",
        "followers": 99497,
        "date": "1w",
        "description": "PATHFINDER 2 is the largest U.S. interventional study of a multi-cancer early detection (MCED) screening test to date, enrolling more than 35,000 participants. Our president, Joshua Ofman MD, MSHS, shares why this study marks an important milestone for MCED and what to expect as results are presented at the upcoming #ESMO25 congress.\n\nRead more: https://bit.ly/46EECck\n#MCED #EarlyDetection #ClinicalTrial",
        "reactions_count": 179,
        "comments_count": 5,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1360343388,
        "company_id": 3524741,
        "urn": "urn:li:activity:7379165495687581698",
        "followers": 99497,
        "date": "1w",
        "description": "For Breast Cancer Awareness Month, we\u2019re calling attention to the importance of early detection\u2014especially if you have or are at risk of having the BRCA gene mutation\u2014which can increase your risk for breast cancer. Our podcast, The Cancer SIGNAL, delves into this important topic and is available wherever you listen to podcasts: https://bit.ly/3KrMLbk\n\n#BreastCancerAwarenessMonth #EarlyDetection",
        "reactions_count": 58,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1360343389,
        "company_id": 3524741,
        "urn": "urn:li:activity:7378815678230945792",
        "followers": 99497,
        "date": "2w",
        "description": "Happy International Podcast Day! If you\u2019re looking for something new, check out The Cancer SIGNAL podcast available through GRAIL and hosted by cancer survivor Susanna Quinn. On this podcast, we dive into the stories behind multi-cancer early detection (MCED)\u2014from patients to doctors, advocates to researchers, and more. \n\nThe Cancer SIGNAL is available wherever you listen to podcasts: https://bit.ly/463jhaS\n\n#InternationalPodcastDay #PodcastCommunity #EarlyCancerDetection",
        "reactions_count": 33,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1360343390,
        "company_id": 3524741,
        "urn": "urn:li:activity:7377358554741039104",
        "followers": 99497,
        "date": "2w",
        "description": "Regular screenings are key to detecting cervical cancer early. This Gynecologic Cancer Awareness Month, we\u2019re reminding everyone that early detection improves a person\u2019s prognosis and chances of being successfully treated.\n\n#GynecologicCancerAwarenessMonth #GCAM",
        "reactions_count": 40,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1360343391,
        "company_id": 3524741,
        "urn": "urn:li:activity:7376635398187552768",
        "followers": 99497,
        "date": "2w",
        "description": "Senior VP of Communications for the Dallas Cowboys, Tad Carper, took a multi-cancer early detection (MCED) test during the team\u2019s 2024 training camp\u2014and that sent him on a cancer journey he had never expected. Hear his story about early cancer detection, positive thinking, and paying it forward in the latest episode of The Cancer SIGNAL podcast. ?\n\nApple Podcasts: https://apple.co/4mI2WPm \nSpotify: https://bit.ly/46zh9b5 \nTranscripts and more: https://bit.ly/4mtqnvp \n\n#EarlyCancerDetection #MCED",
        "reactions_count": 101,
        "comments_count": null,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      },
      {
        "id": 1360343392,
        "company_id": 3524741,
        "urn": "urn:li:activity:7376388666203697152",
        "followers": 99497,
        "date": "2w",
        "description": "We are pleased to present new data from our registrational PATHFINDER 2 study at the upcoming ESMO - European Society for Medical Oncology\u202fCongress in Berlin.\n\nWe also look forward to sharing data from our prospective observational study, SYMPLIFY, and real-world experience of veterans from the REFLECTION study at the Early Detection of Cancer Conference (EDCC) 2025 in Portland.\n\nRead more in our latest press release: https://bit.ly/4nc39Lu\n#ESMO25",
        "reactions_count": 203,
        "comments_count": 2,
        "reshared_post_author": null,
        "reshared_post_author_url": null,
        "reshared_post_author_headline": null,
        "reshared_post_description": null,
        "reshared_post_followers": null,
        "reshared_post_date": null,
        "last_updated": "2025-10-14 22:38:01",
        "deleted": 0
      }
    ]
  },
  "status_code": 200
}